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ABSTRACT 
Previous studies have shown that lymphocytes carry cell surface 
receptors for SPS and SPS recognition may play a role in 
lymphocyte migration and positioning in vivo. This thesis 
describes attempts to isolate and characterise endogenous GAGs 
and GAG-binding molecules of murine spleen and determine if 
these molecules are involved in lymphocyte migration. 
In Chapter 3 a procedure was devised for isolating GAGs from 
murine spleen in good yield and high purity and the GAG 
preparation was then radiolabelled for subsequent binding 
studies. It was found that endogenous heparan sulfate/heparin-
like molecules (MW approx. 50 kDa) bound to murine splenocytes 
in a saturable, rapid and reversible manner with a binding 
affinity of approx. 5 x 10-8 M. Using immunofluorescent flow 
cytometry studies it was demonstrated that the majority of spleen 
cells have receptors for these GAGs. 
Subsequent, binding studies with radiolabelled GAGs (Chapter 4) 
demonstrated that bovine lung heparin has a binding affinity. to 
splenocytes of approx. 1.1 x 1 o-6 M, which is approx. a 20 fold 
lower affinity than that observed with the endogenous splenic 
heparin/heparan sulfate molecules. However, due to the large 
amount of non-specific binding incurred in this assay the binding 
affinities for other GAG molecules could not be calculated. 
Rosetting studies with GAG-coupled red cells demonstrated that 
between 20% and 90% of lymphocytes express receptors for all 
the GAGs tested. Analysis of the binding of solubilised 
radiolabelled cell surface molecules to immobilised GAGs revealed 
that murine lymphocytes express at least 12 distinct cell surface 
receptors for GAGs (molecular masses of 10-250 kDa). Each GAG 
bound to a unique profile of cell surface molecules, although 
splenocytes exhibited a much more heterogeneous binding pattern 
than thymocytes. Immunoprecipitation studies demonstrated that 
the GAG-binding molecules on splenocytes did not correspond to 
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any of the cell surface antigens tested, namely MEL-14, FcR, CD3 , 
ThB, Ly-5, Ly-15, Pgp-1 and Thy-I, although some data suggested 
that Ly-2 may bind weakly to heparin ,(Chapter 4). 
Characterisation of a very prominent 90 kDa GAG-binding 
molecule (Chapter 5) on lymphocytes revealed that it is a 
peripheral membrane glycoprotein with a pl of 6.16. High 1on1c 
strength (2 M KCl) treatment released the molecule from cells 
although RGDS (1 mg/mL) treatment did not, suggesting an 
integrin binding sequence was not involved. Subsequent studies 
suggested that the molecule is bound to the lymphocyte surf ace 
via a PI receptor as (i) inositol hexaphosphate displaced the 90 
kDa protein from the splenocyte surf ace and other inositol 
derivatives were either ineffective or much less effective at 
displacing the molecule and (ii) reassociation experiments 
demonstrated that the soluble 90 kDa protein reassociated with 
lymphocytes in an inositol hexaphosphate inhibitable manner. 
Additional studies are required to unequivocally demonstrate the 
existence of a PI receptor on lymphocytes. Such a receptor has 
important implications for GPI-anchored cell surface molecules. 
Attempts were made to relate the expression of GAG-binding 
molecules to the splenic and lymph node homing capacity of 
lymphomyeloid cell lines. It was found that certain cell lines 
failed to enter the spleen (EL-4, BL/VL3, MBL-2, RK4.7, C6VL/1, 
P815 and LSTRA) while others gained access (BCL.1, RD10s, Rl+, 
R 1 - and CL2-FT2). Positioning of fluorescently-labelled cell lines 
in the spleen was visualised by fluorescence microscopy and 
revealed that certain cell lines (Rl +, BCL.1 and RD10s) migrated 
into the red pulp and marginal zones of the spleen. Entry of the 
cell lines into other lymphoid organs and the liver and lungs, was 
found to be unrelated to splenic entry. 
SDS-PAGE analysis of 1251-Iabelled cell surface molecules 
indicates that each cell line examined (EL-4, R 1 +, BCL.1 and RD 1 Os) 
expressed distinct GAG-binding molecules with a wide range of 
molecular masses. Interestingly the 90 kDa GAG-binding molecule 
on lymphocytes is expressed strongly by both R 1 + and BCL.1, but 
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not by RD 1 Os indicating that this protein IS not necessary for 
splenic entry. However, an approx. 35 kDa GAG-binding protein IS 
present on all three cell lines which migrated to the spleen (Rl +, 
BCL.1 and RD 1 Os) but is absent from EL-4, a cell line which did not 
enter spleen. Further experiments are required to prove that this 
molecule is involved in splenic-homing. 
In conclusion, data are presented in this thesis which are 
consistent with the view that GAG recognition by lymphocytes 
may control the entry and positioning of lymphocytes within 
lymphoid organs. However, further work is required to 
conclusively demonstrate the role of the various GAG receptors 
identified in lymphocyte migration. 
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CHAPTER 1 : INTRODUCTION 
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1.1 INTRODUCTION 
Lymphocytes are in a constant state of flux, recirculating between. the 
bloodstream and lymphoid tissue (Gowans and Knight, 1964 ), a 
process which allows maximal exposure of a captured antigen in a 
particular lymphoid organ to migrating lymphocytes (reviewed by 
Kieran et al ., 1989; Yednock and Rosen, 1989). A major entry point of 
blood-borne lymphocytes into lymphoid organs is through specialised 
postcapillary venules, termed high endothelial venules (HEV). This 
process of lymphocyte extravasation is mediated by the highly 
selective interaction of cell surface molecules on the lymphocyte and 
HEV. Alternatively lymphocytes may gain access to a secondary 
lymphoid organ, such as the spleen, directly via the bloodstream 
without HEV binding. Neither of these processes are well understood. 
However, the recent upsurge in molecular technology has led to an 
increasing awareness of the important role of. specific cell surface 
molecules 1n these interactions. 
The positioning of lymphocytes within lymphoid organs is also highly 
selective, \Vith subsets of lymphocytes migrating to discrete 
anatomical locations within the lymphoid organ. Indeed lymphocyte 
recirculation and positioning within organs is a highly specialised 
process as implied by the term "homing" (Gowans and Knight, 1964), 
used to describe the migratory preference of a lymphocyte for a 
particular lymph node site. The vital role that carbohydrate 
recognition plays in this system has only recently been realised and 
represents a major research theme of this thesis. 
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1.2 STRUCTURE OF THE LYMPHOID SYSTEM 
The lymphoid system is composed of usually mobile lymphocytes and 
sessile epithelial and stromal cells arranged either as discrete organs 
or accumulations of diffuse tissue. Lymphoid organs may be classified 
as either primary or secondary organs depending on certain criteria as 
outlined below. 
1.2.1 PRIMARY LYMPHOID ORGANS 
Primary lymphoid organs are the major sites of lymphopoiesis in the 
body, consisting of the thymus for T cells and the bone marrow 
(mammals) or the bursa of Fabricus (avian species) for B cells. Here 
lymphocytes acquire specific antigen receptors with the ability to 
discriminate between self and non-self antigens. 
The bone marrow which constitutes 4.5% of the body weight has a 
large pool of haemopoietic stem cells which are capable of 
differentiating into various blood cell components such as 
lymphocytes, mononuclear phagocytes, granulocytes, platelets and 
erythrocytes. It can be divided into the active, haemopoietic material 
and the inactive, fatty marrow which consists of a framework of 
stroma intimately connected with ·the blood vessels. The stroma 
consists of pri1nitive and phagocytic reticular cells attached to 
argyrophilic fibres. Stromal cells produce regulatory substances 
including CSF ( colony stimulating factor), IL-6 (interleukin-6), IL-7 
and TGF-P (transforming growth factors p) and can generate fat cells. 
Although their precise location in the bone marrow is not known it is 
thought that they may be located in the subendosteal area of the bone 
(reviewed by Kincade, 1990). The free, immature myeloid cells of the 
bone marrow include haemocytoblasts, erythroblasts, myeloblasts and 
megakaryocytes. 
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Circulation in the bone marrow is by means of sinusoids through 
which haemopoietic precursors pass into the bloodstream. The bone 
marrow is the chief source of multipotential stem cells for the 
repopulation of the spleen and thymus (McCulloch and Till, 1961; 
Micklem et al., 1966) containing progenitors for various cell types 
including lymphoid cells, macrophages (Goodman, 1964) and dendritic 
cells (Steinman et al., 197 4 ). T cells derived from bone marrow 
precursors migrate to the thymus where they proliferate and 
differentiate into mature cells. 
The thymus is very important in T cell development. As shown by 
the experiments of Miller ( 1961) neonatal thymectomy of mice 
produced immunologically-defective mature animals which had 
increased susceptibility to infections, a deficiency of cells in the lymph 
nodes and spleen, and an inability to reject unmatched skin grafts. In 
recent years, many studies have been published on the 
characterisation of cells in the thymus and the events necessary to 
produce immunocompetent T cells. 
Immature T cells which enter the thymus (prothymocytes) undergo 
an ordered sequence of differentiation events producing mature T 
cells which migrate to peripheral lymphoid organs. These 
differentiation events include changes in cell surface antigens such as 
CD4, CD8 and the TcR (T cell receptor) with the formation of a 
thymocyte which is self-MHC (major histocompatibility complex) 
restricted but still self-tolerant. The mechanism of self-tolerance 
probably occurs through a clonal deletion process where self-reactive 
clones, during a critical stage in development, are eliminated from the 
population by certain thymic cells (reviewed by Sprent et al., 1988). 
The prothmocyte which is phenotypically Thy-1 + /CD4-CD 8 - has been 
poorly characterised but is thought to contain TcR chains in germline 
configuration ( a and p antigen receptor genes before rearrangement) 
but does not express CD3 mRNA (Palacios et al., 1987; Palacios and 
Pelkonen, 1988). 
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Thymocytes can be divided into three populations on the basis of 
CD4/CD8 expression. These are thymocytes that 1) express neither 
antigen (CD4-CD 8 -) from which is generated all CD4/CD8 phenotypes 
(Kingston et al., 1985) and constitutes 3-5% of adult thymocytes 
(Ceredig et al., 1983 ), 2) single positive populations with either the 
CD4 or CD8 antigen (CD4-CD8+, CD4+CD8-) which constitute 5-10% of 
adult thymocytes, and 3) a double positive population (CD4+Cn8+) 
which constitutes 75-85% of adult thymocytes and is located in the 
cortical region of the thymus (Scollay et al., 1984 ). Recent data 
(Kisielow et al., 1988) has suggested that CD4+CD8+ thymocytes are the 
precursors of CD4-CD8+ and CD4+CD8- thymocytes, however 
mechanisms involved in the regulation of expression of CD4 and CD8 
are still unknown. Another interesting aspect of T cell development is 
the sequential assembly and expression of the antigen receptor 
complex (TcR and CD3) in the thymus (Snodgrass et al., 1985a, 1985b). 
The thymus is arranged into four distinct regions: 1) the outermost 
subcapsular cortex which is the major site of lymphopoiesis where 
large lymphocytes proliferate to .  produce thymocytes; 2) the inner 
cortex into which thymocytes migrate; 3) the medulla within the 
thymic parenchyrna which contains mature cells; and 4) the 
perivascular connective tissue space surrounding larger medullary 
blood vessels. Besides lymphocytes, dendritic cells, macrophages and 
epithelial cells are also present in the thymus (Beller and U nanue, 
1980; van Ewijk, 1988). 
The thymus contains a highly organised system of blood vessels and a 
lymphatic drainage system which lies in the perivascular connective 
tissue space. Studies have shown that lymphocytes can leave this 
organ via the lymphatic route (Kotani et al., 1966) or the venous route 
(Ernstrom et al., 1965) It has been suggested that only a small 
percentage of lymphocytes migrate from the thymus, the rest dying 
within that organ (Matsuyama et al., 1966; Metcalf and Wiadrowski, 
1966). 
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Based on the brief outline presented above, it is clear that both the 
bone marrow and thymus represent highly organised and complex 
organs in which well defined patterns of cell migration and positioning 
occur. Virtually nothing is known about the molecular basis of this 
migration process. 
1.2.2 SECONDARY LYMPHOID ORGANS 
Secondary lymphoid organs include the spleen, lymph nodes and 
mucosal associated lymphoid tissue (MALT) which encompasses the 
Peyer' s patches (PP) of the gut and the tonsils. The secondary 
lymphoid organs provide the appropriate microenvironment for the 
interaction of immunologically mature lymphocytes with foreign 
antigen and the subsequent development of an immune response. 
The spleen (Figure 1.1 a), although little studied, is a vital organ in 
lymphocyte recirculation and, presumably, presentation of foreign 
antigen to the immune system. More lymphocytes pass through the 
spleen than recirculate through all lymph nodes (Ford, 1968). 
The spleen is made up of two main tissue types, the red and the white 
pulp. The red pulp is mainly concerned with destruction of effete 
erythrocytes and consists of sinuses lined by macrophages, 
lymphocytes and plasma cells. The white pulp or periarteriolar 
lymphoid sheath (PALS) is the main lymphocyte containing area and 
is arranged around a central arteriole. B and T cells are segregated in 
the PALS with the B cells predominantly found in germinal centres 
and the marginal zones, and the T cells being found around the central 
arteriole. The reticulum cells present in the PALS include dendritic 
cells in the B cell region, interdigitating cells in the T cell region and 
fibroblasts (reviewed by De Sousa, 1981). The marginal zones also 
contain macrophages which are distinct from the red pulp 
macrophages (Humphrey, 1980) and circulating granulocytes. 
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Figure 1.1 Structure of Lymphoid Tissue 
a) Spleen and b) Lymph Node 
Modified from Raitt et al., 1989 
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The spleen is an unusual secondary lymphoid organ 1n that it does not 
contain HEY for lymphocyte entry, as is the case for lymph nodes. 
Instead the marginal zone is the primary entry point for lymphocytes 
into the white pulp where they segregate into T and B-dependent 
areas as mentioned. The exit point of lymphocytes from the spleen is 
basically unknown although one theory is that lymphocytes leave the 
white pulp by a lymphatic drainage system, originating in large 
lymphatic channels surrounding the central artery (Figure 1.2). These 
drain eventually into the splenic vein although as yet there 1s no 
evidence for this exit point (reviewed by De Sousa, 1981 ). 
Lymph nodes (Figure 1.1 b ), like the spleen are made up of discrete 
cellular areas, namely the cortex, paracortex and medulla. The cortex 
conta1ns aggregates of B cells either as primary or secondary follicles 
whereas the paracortex mainly consists . of T cells and interdigitating 
cells. The medulla contains a combination of both T and B cells and 
phagocytes with_ plasma cells organised into medullary cords that run 
into the trabeculae and sinuses. Lymph enters and leaves the node at 
the hilus through the afferent and efferent lymphatics, respectively. 
Antigen which is filtered into these organs comes into contact with 
lymphocytes which have either traversed from the afferent 
lymphatics into the paracortex or have passed between the high 
endothelial cells (HEC) of the HEV (Section 1.2.3 ). After leaving the 
lymph node via the efferent lymphatics, the lymphocytes pass into 
the thoracic duct and the left subclavian vein and hence back into the 
circulation. Normally there is a continuous flow of lymphocytes 
through the nodes but in a sensitised animal stimulated by antigen, 
there is a temporary shutdown in lymphocyte traffic for 
approximately 24 hours following antigenic stimulation (Roitt et al., 
1985). 
MALT consists of aggregates of lymphoid tissue which are not 
encapsulated as is the case with spleen and lymph nodes. They occur 
primarily in the gastrointestinal (PP), urogenital and respiratory tracts 
and are the main entry point for foreign organisms into the body. 
ms 
LL 
Figure 1.2 Diagrammatic Representation of the 
White Pulp Microcirculation 
ca = central artery; ms = marginal sinus, close anastomosing irregular 
channels filling from capillaries branching off the ca; ve = veins of the red 
pulp; LL= lymphatic channels around the ca; pa= penicillae arteries 
originating at the ca (De Sousa, 1981 ). 
ve 
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Similar to other secondary lymphoid organs the PP can be divided into 
three regions. These are a nodular area occupied mainly by B cells , 
the interf ollicular area which contains T cells and the dome area (De 
Sousa, 1981 ). Similar to lymph nodes, lymphocytes enter the tonsils 
and PP via HEY. Drainage of the lymphoid tissue again takes place via 
the efferent lymphatics to the thoracic duct and back into the 
circulation. 
1.2.3 HIGH ENDOTHELIAL VENULES 
As has been previously mentioned, the passage of lymphocytes into 
lymphoid organs and non-lymphoid sites of inflammation requires 
recognition and adhesion to HEY. These specialised postcapillary 
venules are characterised by a cuboidal, rather than the typically flat, 
endothelium (Gowans and Knight, 1964 ), hence their name "high" 
endothelial venule, and are readily distinguishable from other vessels 
in the vascular tree (Claesson et al., 1971; Smith and Henon, 1959; 
Thome, 1898). Most mammalian species from the primitive 
monotremes to the human have HEY (Miller, 1969; Shulze, 1925). The 
exceptions are certain mammals such as sheep and other species 
including plaice and duck which are devoid of HEY (Bell and Lafferty, 
1972; Ellis and De Sousa, 197 4; Morris and Courtice, 1977; Schoefl, 
1981 ), the functional significance of which is unknown. 
HEY are found in all secondary lymphoid organs ( with the exception 
of the spleen) including lymph nodes, PP, tonsils, adenoids, appendix, 
and small lymphoid aggregates associated with the mucosa! surf aces 
of the respiratory, gastrointestinal, and urogenital tracts (Butcher and 
Weissman, 1984; Miller, 1969). However, they are absent from the 
primary lymphoid organs, although, they may be present in non-
lymphoid tissues under certain circumstances such as during 
inflammation in mammals (Freemont, 1983; Freemont and Jones , 
1983) and birds (Miller, 1969). 
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Histologically, HEC of the HEV are characterised by a number a 
interesting features. The HEC are cuboidal, 10-20 µm in diameter and 
linked by discontinuous junctions. This single layer of endothelium 
rests on a basement membrane which together with the associated 
sheath of reticular fibres appears to regulate the rate of lymphocyte 
migration into the lymphoid organ (Anderson and Anderson, 1975, 
1976; Wenk et al., 1974). 
The ultrastructure of the HEC are also unusual, exhibiting the 
characteristics of metabolically active cells. Features include a 
prominent Golgi apparatus, numerous mitochondria, ribosomes and 
vesicles typical of active secretory cells, and a large nucleus with one 
or two nucleoli (Anderson and Anderson, 1975; Wenk et al., 1974). 
Furthermore HEC can synthesise and secrete a sulfated glycolipid 
(Andrews et al., 1982, 1983; Section 1.7.3), and have elevated levels 
of the enzymes, acid phosphatase, J3-glucuronidase (Anderson et al., 
1976) and certain esterases (Smith and Henon, 1959). 
Recently, monoclonal antibodies (mAbs) have been produced which 
are specific for HEV. These mAbs define the MECA series of HEV 
antigens which are thought to play a role in the binding of 
lymphocytes to HEV and have been termed "vascular addressins" 
(Streeter et al., 1988a; Section 1.6.1). 
1.3 RECIRCULATION OF LYMPHOCYTES THROUGH 
LYMPHOID ORGANS 
Studies of lymphocyte recirculation revealed that the large numbers 
of cells leaving the thoracic duct and entering the circulation were 
sufficient to replenish the lymphocyte content of the blood several 
times daily (Sanders et al., 1940; Yoffey, 1936). Since lymphocyte 
numbers in the blood remained constant, it was postulated that 
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lymphocytes were destroyed in the periphery (Hughes et al., 1956; 
Y of fey, 1936) with associated, rapid lymphocyte proliferation 
elsewhere. 
The concept that lymphocytes recirculate from blood to lymph \Vas 
first suggested by Gowans ( 1957, 1959a, 1959b) who reinfused rats 
intravenously with their own lymphocytes taken from a previous 
thoracic duct drainage, and demonstrated that lymphocyte depletion 
could be prevented. Also, radiolabelled thoracic duct lymphocytes 
taken from donor animals and intravenously injected into recipient 
animals, reappeared in the lymph (Gowans, 1959a). 
In 1964 Gowans and Knight finally demonstrated lymphocyte 
"homing" whereby lymphocytes left the blood and entered lymph 
nodes via postcapillary ven ules, returning to the bloodstream by way 
of the thoracic duct. The term "homing" was used to describe the 
migratory preference of lymphocytes for specific lymphoid organs. 
However, this term has some limitations for it implies previous 
familiarisation of the lymphocyte with the target lymphoid tissue. 
Other more generalised terms such as "migration" and "topographical 
memory" (Hamann and Thiele, 1989) may be more appropriate 
alternatives when the mechanism of lymphocyte recirculation is not 
inferred. 
In studying lymphocyte recirculation the question arises as to why 
lymphocytes need to recirculate. Although this appears to be a purely 
philosophical question, the answer may lie in practicalities. For 
example, Kieran et al. (1989) have suggested that to maintain a 
generalised immunological surveillance of all body tissues is very 
costly. Discrete localisation of antigens in concentrated areas such as 
lymph nodes where the greatest number of antigen specific effector 
cells could see antigen, and specialised antigen presenting cells are 
localised, would minimise this cost to the body while affording 
maximum protection to the individual. 
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Thus lymphocyte recirculation max1m1ses the probability of an 
interaction between an antigen trapped in a particular lymphoid 
organ interacting with the relatively small number of specific 
lymphocytes which can respond to it. The efficiency of this process is 
dependent on a continual and rapid recirculation of lymphocytes from 
the blood, into lymphoid tissue. For example in the rat 4 x 10 7 
lymphocytes are returned to the blood via the thoracic duct per hour 
(Yednock and Rosen, 1989), which is sufficient to replace the blood 
content of lymphocytes 10-20 times per day (Ford, 1969; Gowans, 
1959a). Also immunological tolerance to self antigens may be 
maintained during the process of lymphocyte recirculation, a topic on 
which little is known outside the primary lymphoid organs. 
There are however, a number of normal physiological factors which 
can influence lymphocyte recirculation both specifically and non-
specifically. For example, antigenic stimulation can affect lymphocyte 
homing in a variety of ways. Firstly, by increasing local blood flow 
which indirectly increases lymphocyte traffic through an area (Hay et 
al., 1980). Secondly, it causes a transient delay in lymphocyte exit 
from a stimulated lymph node which thereby increases the number of 
lymphocytes in that area (Cahill et al., 1976; Hall and Morris, 1965) 
and finally it selectively recruits antigen specific cells (Butcher, 1986). 
Another example is hormonal influences such as estrogen levels (Roux 
et al., 1977; Weisz-Carrington et al., 1978) which may influence 
lymphocyte migration. 
1.4 SITE SPECIFIC MIGRATION OF LYMPHOCYTES 
Although lymphocytes have the potential for universal migration they 
often display non-random, selective migration to certain lymphoid 
tissues (Butcher et al., 1980; Chin and Hay, 1984; Stevens et al., 1982) 
and sites within these tissues (De Sousa, 1981 ). 
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Since the classical study of Gowans and Knight ( 1964) where 
radiolabelled lymphoblasts selectively localised within mesenteric 
lymph node (MLN) and walls of the small intestine, a vast body of 
data has accumulated demonstrating selective lymphocyte homing 
and a number of extensive reviews have been published on the 
subject (Berg et al., 1989; Butcher, 1986; Duijvestijn and Hamann, 
1989; Hamann and Thiele, 1989; Jalkanen et al., 1986b; Pals et al., 
1989; Woodruff and Clarke, 1987; Yednock and Rosen, 1989). The 
majority of these in vivo studies were performed using the adoptive 
transfer method with radiolabelled cells and it was not until 1976 that 
an in vitro method for measuring lymphocyte-HEY binding was 
developed by Stamper and Woodruff (summarised in Section 1.4.2). 
1.4.1 IN VIVO STUDIES SHOWING LYMPHOCYTE BINDING 
SPECIFICITIES 
The first in vivo line of evidence suggesting site specific migration of 
lymphocytes comes from the selective migration of lymphoblasts 
demonstrated in studies by Gowans and Knight (1964). In agreement 
with these early results was the work of many researchers (Chin and 
Hay, 1980; Griscelli et al., 1969; Pierce and Cray, 1982; Rose et al., 
1976; Scollay et al., 1976) and from. this data developed the important 
concept of separate peripheral and mucosa! immune systems where 
lymphocytes express receptors for either peripheral lymph nodes 
(PLN) or mucosa! associated lymphoid organs. 
For example, Scollay et al. (1976) showed that PLN or intestinal 
radiolabelled lymphoid cells from sheep showed preferences for PLN 
or gut lymphoid tissue, respectively and this was later confirmed by 
Chin and Hay ( 1980) Similar results were also obtained in mice using 
radiolabelled MLN or peripheral T blast cells (Rose et al., 1976). 
Further specificity was shown when IgA-containing plasma cells were 
found to home to specific locations within the gut from which they 
were isolated (Pierce and Cray, 1982). 
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Additional studies have shown that lymphocytes may show specificity 
in migration for other tissues such as inflamed synovia, as indicated 
by the specific migration patterns of . lymphocytes to inflammatory 
sites (Chin and Hay, 1980; Issekutz et al., 1986; Rose et al., 1976). 
A number of reports have also indicated unique binding specificities 
for lung-associated lymphoid tissue. McDermott and Bienenstock 
( 1979) have shown that lymphoblasts isolated from lung-associated 
lymphoid tissue selectively migrate back to that tissue. Furthermore, 
the early studies of Spencer et al. (1983) in the sheep were confirmed 
by Spencer and Hall (1984) who showed that rat, radiolabelled 
immunoblasts isolated from intrathoracic lymph nodes localised after 
intravenous injection preferentially to the lungs rather than the gut. 
1.4.2 IN VITRO. STUDIES SHOWING LYMPHOCYTE BINDING 
SPECIFICITIES 
The study of lymphocyte binding specificities was greatly aided by 
the development of an in vitro assay technique which could quantify 
the attachment of lymphocytes to HEY (Stamper and Woodruff, 1976). 
In this assay viable lymphocytes were layered onto cryostat sections 
of lymphoid tissue and their degree of binding determined by various 
methods (Butcher et al., 1979a; Rosen et al., 1985; Stamper and 
Woodruff, 1976). In vitro results were seen to closely parallel in vzvo 
results (Butcher et al., 1979b; Gallatin et al., 1983; Woodruff and 
Clarke, 1987) demonstrating that specific HEY-lymphocyte 
interactions occurred in vivo. This assay has been widely used to 
compare different binding specificities between lymphocytes and 
lymphoid tissues and in the production of mAbs to lymphocyte 
receptors for HEY (Section 1.6). 
As was the case with in vivo studies, specificity of lymphocyte/HEY 
interactions was demonstrated by the separate binding specificities of 
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lymphocytes for PLN and PP HEY. Butcher et al. (1980) showed i n 
vitro (and in vivo) that about 1.4 times as many PP as lymph node 
lymphocytes bound to PP HEY and conversely, twice as many lymph 
node cells interacted with HEY in nonmesenteric lymph nodes. Even 
greater specificity was demonstrated with lymphoma cell lines that 
selectively bound to either PP or PLN HEY. MLN were found to be 
unique in that they bound lymphocytes with either PP or lymph node 
specificity. These findings led Butcher et al. ( 1980) to propose a 
generalised model for lymphocyte/HEY interactions (Section 1.5). 
Another example of lymphocyte specificity is that demonstrated with 
the preferential binding of T cells to PLN HEY and B cells to PP HEY. 
Thus Stevens et al. (1982) showed that B cells from any source bound 
preferentially to PP HEY (twofold to threefold higher) and T cells of 
any type to PLN HEY (1.5 fold higher). Results of in vivo studies of 
PLN and PP selective homing were found to resemble closely those of 
in vitro HEY-binding preferences (Kraal et al., 1983; Stevens et al., 
1982). Furthermore in situ, PLN contain a greater. proportion of T 
cells than B cells with the opposite being true for PP (Y ednock and 
Rosen, 1989). These results indicated that specific receptors for PLN 
and PP were present on each cell type with one receptor being 
present to a higher degree than the other (Yednock and Rosen, 1989). 
This led Stevens et al. ( 1982) to suggest that lymphocyte/HEY binding 
specificity would regulate lymphocyte localisation within a tissue and 
hence the type of immune response generated within that organ. Also 
differences were seen between the ability of the CD4+ and ens+ T cell 
subsets to bind to PLN HEY (Kraal et al., 1983). 
Although the specificity of homing of T and B cells was seen to differ, 
it has been suggested that this may reflect the presence of memory 
cells in the population and not unprimed cells which may exhibit 
several homing receptors that are then selected for by antigen 
stimulation (Butcher, 1986; Yednock and Rosen, 1989). This theory 1s 
supported by a number of lines of evidence. Firstly, Hall et al. ( 1977) 
showed that lymphoblasts isolated from adults homed specifically 
I , 
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when injected into foetal animals, whereas foetal T cells were not seen 
to home (Cahill et al., 1979). Secondly, lymphocytes obtained from 
lymph node and spleen (recirculating cells) specifically adhered to 
frozen sections of HEY (Stamper and Woodruff, 1976) whereas 
lymphocytes obtained from bone marrow and thymus (non-
recirculating cells, immature cells) could not. This apparent specificity 
difference between T and B cells adhering to HEY is not the result of 
differing affinities for HEY as both affinity and rate of binding are of 
similar magnitude (Kuttner and Woodruff, 1979) nor is this specificity 
absolute, for a small subpopulation of thymocytes has been shown to 
have homing abilities in vivo (Zatz and Lance, 1970) and similarly in 
vitro (Butcher et al., 1979a). 
Generally therefore, most immature lymphocytes from bone marrow 
and thymus do not have homing receptors, while mature lymphocytes, 
not yet primed from spleen or lymph node do, and can bind to both 
mucosa! and peripheral lymphoid tissue. Antigen-specific memory 
cells however, show very selective migratory behaviour moving to 
those tissues originally involved in antigen exposure and activation. 
For example, isolated intraepithelial lymphocytes of the gut home 
exclusively to gut and gut associated lymphoid tissue (GALT) such as 
PP (Schmitz et al., 1988). 
As was discussed previously, lymphocytes have been shown to have 
specificity for inflamed synovia in vivo (Chin and Hay, 1980; Issekutz 
et al., 1986; Rose et al., 1976). This has been also shown in vitro by 
J alkanen et al. ( 1986c) who demonstrated that lymphocytes bound 
specifically to inflamed synovia HEY, an interaction which was not 
inhibited by antibodies against the receptors on lymphocytes specific 
for either PLN REV or GALT HEY. Furthermore, lymphoblastoid cell 
lines which bound to either PLN or GALT were unable to bind to 
synovial HEY, which suggested a separate HEY receptor in 
inflammatory sites (J alkanen et al., 1986c ). 
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Geoffroy et al. (in preparation, quoted by Yednock and Rosen, 1989) 
confirmed that lung specificity was separate from that of PLN and PP, 
in a series of experiments where treatments that selectively inhibited 
PLN or PP HEY attachment were applied to lung-associated lymphoid 
tissue. No inhibition of lymphocyte binding to lung HEY was seen, 
confirming that this specificity is unique. 
1.5 MOLECULAR MODELS OF LYMPHOCYTE HOMING 
As has been previously stated lymphocytes migrate and localise 
selectively to particular lymphoid organs, leaving the blood by means 
of specialised HEY. The specificity of migration has long been thought 
to be due to specific receptors on the lymphocyte surface which bind 
to complementary structures on the HEY surf ace. 
Based on these concepts a model for lymphocyte specificity was 
developed initially by Butcher et al. ( 1980), and then modified by 
Stevens et al. (1982). The latter proposed that at least three 
complementary lymphocyte-HEY receptor sets exist namely, a set 
involved in PLN entry, a set associated with PP and appendix entry, 
and finally a set involved in lymphocyte entry into inflamed 
synovium. It would appear that a lung-associated specificity also 
exists (Geoffroy et al., in preparation; McDermott and Bienenstock, 
1979; Spencer and Hall, 1984) and other possible tissue specificities 
are still being investigated. Also some lyn1phoid organs such as MLN, 
exhibit a mixture of entry specificities which, in the case of MLN 1s 
consistent with receptors for both PLN and PP HEY entry. 
A simple molecular model depicting this mechanism of lymphocyte 
homing with different receptor specificities is proposed in Figure 1.3 
(modified from Yednock and Rosen, 1989). However, this model does 
have some drawbacks in that it does not take into account the role of 
PLN-specific immunoblast PP-specific immll'lOoost Lung node-specific immunoblast 
! T 
PN HEV PPHEV LJ.ng node HEV 
Virgin lymphocyte Memory lymphocytes 
00 0 
.. ---- ··--------·--=---
Mesenteric ly~ node HEV Paratracheal lymph node HEV 
Figure 1.3 Model for Organ-Specific Lymphocyte 
Attachment to HEV 
(Yednock and Rosen, 1989) 
) 
1 6 
soluble enhancers of in vitro lymphocyte binding found in lymph , 
such as adherence enhancing factor (Carey et al., 1981 ) and high 
endothelial binding factors for PP (HEBFpp, lB.2) and PLN (HEBFLN , 
A.11 antigen)(Chin et al., 1986; Rasmussen et al., 1985; Woodruff and 
Clarke, 1987). Furthermore, additional receptor-ligand interactions 
which may augment organ-specific binding, such as the LFA-1 /ICAM-
1 interaction (Dustin and Springer, 1988; Section 1.6.2) are not 
considered. 
1.6 CELL SURFACE MOLECULES IMPLICATED IN 
LYMPHOCYTE HOMING 
The identification of defined cell surface molecules involved in 
lymphocyte homing was facilitated by the development of an in vitro 
technique for measuring the binding of lymphocytes to HEY (Stamper 
and Woodruff, 1976) which was described earlier (Section 1.4.2). This 
in vitro technique combined with mAb technology, has led to the 
identification of a range of lymphocyte cell surface molecules involved 
in lymphocyte homing. 
Broadly cell adhesion molecules can be divided into four maJor 
structural superf amilies depicted in Table 1.1. These are the lectin 
associated family, the integrin family, the immunoglobulin (lg) 
superfamily and the link protein associated family. 
The lectin associated family is characterised by a lectin-like 
domain at their amino-terminal end followed by an epidermal growth 
factor (EGF) -like domain and short repeating protein units. Members 
of this family include MEL-14 (Section 1.6.1 ), LAMI (leukocyte 
adhesion molecule 1), GMP-140 (human granule-membrane protein) 
expressed by activated platelets and endothelial cells (Johnston et al., 
1989) and ELAM-I (endothelial leukocyte adhesion molecule 1). 
L 
Table 1.1 Cell Adhesion Families 
Family 
Lectin associated 
lntegrins 
Molecule involved in adhesion 
MEL-14 antigen (mLHR} 
LAMI 
ELAM-1 
GMP-140 (CD62} 
Ca-dependent lectins 
LFA-1 (CD11 a/18, Ly15} 
LPAM-1 (VLA-4} 
CR3 (CD11 b/18, Mac1, Mo 1, OKM1, Leu15} 
p150,95 (CD11 c/18) 
GPllb (GPllla} 
lmmunoglobulins ICAM-1 (CD54, 7F7-antigen} 
ICAM-2 
CO2 (T11, LFA-2, SRBC rosette receptor) 
CD4 (T4, Leu3, L3T4} 
CD8 (TB, Leu2, Ly2) 
Link protein associated CD44 (HCAM, Hermes antigens, Pgp-1, gp90Hermes, 
CR/ECMRIII, ln(Lu)-related p80, Hutch1, Ly24) 
Distribution 
Murine lymphocytes 
Human leukocytes 
Human endothelium of immune/inflammatory lesions 
Human activated platelets and endothelium 
Human and rodent lymphocytes and malignant lymphoid lines 
Human and murine leukocytes 
Human and murine lymphocytes and malignant lines 
Human and murine leukocytes 
Human leukocytes 
Platelet plasma membrane 
Human endothelium, epithelium and fibroblasts 
Human endothelium and lymphoblastoid cell lines 
Human T cells 
Human and murine T cells restricted to class 11 MHC 
Human and murine T cells restricted to class I MHC 
Human and non-human primates and murine haematopoietic, 
epithelial and mesenchymal cells and related lines. 
1--4 
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LAMl, which is expressed on human lymphocytes, may be involved 1n 
lymphocyte extravasation into lymphoid organs or sites of acute 
inflammation (Tedder et al., 1990). The LAMl amino acid sequence 1s 
highly homologous with that of the MEL-14 antigen suggesting that 
they may share a common function (Tedder et al., 1989). 
Furthermore, the LAMl molecule reacts with the TQ 1 and Leu-8 
mAbs. 
ELAM-1 which has recently been cloned (Bevilacqua et al., 1989) is 
expressed by activated human endothelial cells and mediates the 
adhesion of neutrophils to the lining of blood vessels stimulated by 
inflammatory lymphokines. 
The integrin family of cell surface receptors is characterised by two 
noncovalently associated transmembrane polypeptides, termed 
subunits a and p. It contains several adhesion molecules ( chicken 
integrin complex, fibronectin (FN) receptor, vitronectin (VN) receptor 
. 
and glycoprotein lib/Illa) involved in recognition of extracellular 
matrix (ECM) proteins such as FN, VN, fibrinogen (FB) and von 
Willebrand factor (VWF). Many of these are identified by their ability 
to bind these ligands at sites encompassing the tripeptide sequence 
arginine-glycine-aspartic acid (RGD; Hynes, 1987; Ruoslahti and 
Pierschbacher, 1987). Based on structural and sequence homology a 
number of leukocyte cell surf ace antigens are also included in this 
family. 
In terms of the immune system two sets of integrin receptors are of 
particular interest. The first is restricted to leukocytes and consists of 
LFA-1 (lymphocyte function-associated antigen-I), Mac-1, and 
p150/95 (reviewed by Anderson and Springer, 1987). LFA-1, which 
will be discussed further in Section 1.6.2, has an accessory function in 
the adhesion of lymphocytes to HEY (Harder and Heinz-Gunther, 
1988). Mac-1 and p 150/95 mediate monocyte and granulocyte 
adhesion to endothelial cells and other substrata. 
... 
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The second is the VLA (very late antigens; VLA-1, -2, -3, -4 and -5 ) 
series of antigens which are expressed on a variety of human cell 
types such as lymphocytes, and include receptors for ECM proteins 
such as FN, laminin and collagen (Hemler, 1988; Takada et al., 1987, 
1988). Each VLA antigen is composed of unique a-subunits in 
association with a common 13,000 molecular weight (MW) ~ subunit. 
LPAM-1 (lymphocyte PP HEV adhesion molecule-I) which showed 
similarities to VLA-4 (Holzmann et al., 1989), is involved in the 
adhesion of murine lymphocytes to PP HEY. 
The lg superfamily contains a very broad range of functionally 
diverse molecules including lg, TcR, MHC class I and II, CDl, CD2, CD3 , 
CD4, CD8, LFA-3, Thy-1, NCAM (neural cell adhesion molecule), ICAM-
1 (intercellular adhesion molecule-I) and ICAM-2 (Anderson et al., 
1988; Calabi, 1987). These are grouped together in the superfamily 
on the basis of structural homology between disulfide-bonded protein 
domains rather than DNA sequence. lg domains show related but 
distinct folding patterns in their variable (V) and constant (C) regions. 
In both V and C domains two ~ -sheets stabilised by the disulfide 
bond, form the lg fold, however the V -domain fold has an extra loop 
in the middle forming the second hypervariable region in antibodies 
(Williams, 1987). Sequence homology can be common to both V and C 
domains or specific to either the V or C domain types. 
The Igs which are typical examples of this family consist of . two light 
and four heavy chain domains containing V and C regions and, like 
many members of the superf amily, they may possess multiple 
domains (Calabi, 1987). 
Members of the lg superfamily such as ICAM-1 and ICAM-2 have 
been implicated as secondary adhesion molecules involved in 
lymphocyte migration (Section 1.6.2). Also it has been suggested that 
members of the lg superfamily are involved with sulfated 
polysaccharides (SPS). For example, CD4 binds to dextran sulfate and 
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heparin (Lederman et al., 1989) and Class II MHC 1s a chondroitin 
sulfate proteoglycan (Sant et al., 1985). 
Finally, there is the link protein associated family of which the 
only known cell adhesion molecule is CD44 (Section 1.6.1). Cloning 
data (Goldstein et al., 1989; Stamenkovic et al., 1989) has shown CD44 
to be a member of this family where the amino-terminal, extracellular 
domain sequence showed structural homology with cartilage link 
proteins and a related segment of proteoglycan core protein. 
Relevant members of these superfamilies which are involved 1n 
lymphocyte homing will be discussed in more detail below (see also 
Table 1.2). 
1.6.1 SPECIFIC ADHESION MOLECULES 
MEL-14 As previously mentioned, lymphoma cell lines which 
exhibit specific adherence for HEY (Table 1.2) have been used to 
study lymphocyte homing at the molecular level. The identification of 
the MEL-14 antigen is one of the first examples of this approach 
where a rat mAb was raised against the mouse lymphocyte adherence 
receptor for PLN HEY. 
In this case the PLN specific B cell lymphoma cell line, 38C-13 
(Bergman and Haimovich, 1977; Haran-Ghera and Peled, 1973), was 
used to immunise Fischer rats and the immune rat spleen cells were 
then fused with the SP20 mouse myeloma to generate hybridomas 
(Gallatin et al., 1983 ). Supernatants taken from these hybridomas 
were tested by immunofluorescence for their reactivity with the 
surface of 38C-13 cells and normal lymphocytes, and for the absence 
of reactivity with two non-binding lymphoma cell lines (Rawl 12 and 
EL-4). Antibodies from one hybridoma termed MEL-14, were found 
to react with lymphoma cell lines that were capable of binding to PLN 
HEV (Table 1.2). 
r 
Table 1.2 Lymphocyte Adhesion Molecules 
Molecule Endothelial adhesion site Size (kDa) Ligand 
MEL-14 PLN HEV and MLN HEV 80-90, 180 M6P 
Ca-dependent lectins PLN HEV and MLN HEV 90?, 180 M6P, F1 P, PPME, tucoidin, 
sialyloligosaccharide on H EV 
A.11 antigen (HEBFLN) PLN HEV and MLN HEV 40, 60,135 Unknown 
LPAM-1 (VLA-4) PP HEV and MLN HEV 160, 130 Extracellular matrix ?, MECA-367 
antigen ? 
1 B.2 antigen (HEBFpp) PP HEV and MLN HEV 80 Unknown 
CD44 (HCAM, Hermes antigens, Multiple tissue endothelia 80-95, 160, 180-200 Extracellular matrix ? 
Pgp-1, gp90Hermes, CR/ECMR111, 
ln(Lu)-related p80, Hutch1, Ly24) 
LFA-1 (CD11 a/18, Ly15) Multiple tissue endothelia 95,180 ICAM-1, other HUVE ligand(s) 
ICAM-1 Multiple tissue endothelia 90 LFA-1 
ICAM-2 Multiple tissue endothelia 46 LFA-1 
M6P = mannose-6-phosphate, F1 P = fructose-1-phosphate, PPME = phosphomannan ester, HUVE = human umbilical vein endothelium 
Table modified from Stoolrnan (1989) 
l'-.) 
~ 
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Furthermore when 38C-13 cells that were previously incubated with 
the MEL-14 mAb were tested for binding to PLN HEV it was found 
that binding was almost completely inhibited. MLN lymphocytes, 
which bind to both PLN and PP HEV, were then pretreated with NIEL-
14 and incubated on sections of PLN and PP HEV. It was found that 
binding of lymphocytes to PLN but not PP HEV was blocked by MEL-
14 pretreatment. This is in agreement with the model proposed by 
Stevens et al. ( 1982) where MLN HEV carries separate lymphocyte 
binding receptors for both PLN and PP HEV (Figure 1.3). Similar 
results were obtained in vivo, which supported the view that the 
MEL-14 antigen is necessary for homing of lymphocytes to the PLN in 
mouse. 
These results were further confirmed by experiments where 
intraperitoneal injection of MEL-14 greatly reduced (by 10-20 fold) 
the size of enlarged PLN observed in MLR-lpr/lpr mice, presumably 
by blocking the homing of cells to the PLN (Mountz et al., 1988). 
Characterisation of the MEL-14 antigen showed that it is a 
glycoprotein varying in MW from 80,000 on lymphocytes to 92,000 on 
the lymphoma cell line gp9oMEL-14 (Gallatin et al., 1983) and 
100,000 on neutrophils (Lewinsohn et al., 1987). Its pl range is from 
4.0-4.5 and it contains intrachain disulfide bonds (Siegelman et al., 
1986). The molecule is heavily glycosylated as shown by 
endoglycosidase F digestion (Siegelman et al., 1986). An important 
property of the MEL-14 antigen is that it is a lectin (Stooln1an et al., 
1984) recognising carbohydrate moieties on the surf ace of PLN HEV 
(Yednock et al., 1987b). This aspect will be more fully discussed in 
Section 1. 7 .3. 
The MEL-14 antigen has recently been cloned and sequenced (Lasky 
et al., 1989; Siegelman et al., 1989) and was found to be an integral 
membrane protein with the amino-terminal amino acid sequence 
having sequence homology with the carbohydrate domain of some 
Ca 2+ dependent lectins (Drickamer, 1988 ). This is fallowed by an EGF-
' I 
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like domain of 33 amino acids and two identical 62 amino acid repeats 
(Figure 1.4). 
The MEL-14 antigen has a high amino acid sequence homology with 
that of another member of the lectin associated family, the LAMl 
molecule (Tedder et al., 1989, 1990). 
MEL-14 antigen expression changes during lymphocyte development. 
Reichert et al. ( 1984, 1986) found that only 3-6 % of thymocytes, 
mostly mature, have high MEL-14 levels and similarly, only mature B 
and T cells in other lymphoid organs and the blood express high levels 
of MEL-14 antigen. Antigen-activated lymphocytes, which lose their 
lymph node homing ability, were found to have much lower surface 
expression of MEL-14 (Dailey et al., 1985). Thus the MEL-14 antigen 
is associated with mature, recirculating, unstimulated lymphocytes. 
Screening of bacteriophage )..gtl 1 cDNA libraries (constructed using 
38C-13 cell line mRNA; St. John et al., 1986) for MEL-14 antigen 
expression, resulted in the isolation of cDNA clones encoding the 
ubiquitin sequence. This result suggested that ubiquitin may be part 
of the MEL-14 antigen. Ubiquitin is an evolutionarily highly 
conserved (Gavilanes et al., 1982) polypeptide of MW 8451 first 
isolated from bovine thymus (Goldstein et al., 1975). Its suggested 
functions have included control of gene transcription and organisation 
of chromatin structure, regulation of intracellular protein degradation, 
and control of mitosis (Siegelman et al., 1986). Partial amino acid 
sequencing of the MEL-14 antigen revealed the presence of two amino 
termini, one of which corresponded exactly to the amino terminus of 
ubiquitin (Siegelman et al., 1986). This was the first demonstration of 
a ubiquitinated cell surface protein. The functional significance of this 
observation is unclear. However, it has been suggested that 
ubiquitination may signal rapid degradation of the MEL-14 antigen, 
possibly when the molecule is internalised by the cell following ligand 
binding. 
COOH 
Figure 1.4 MEL-14 Antigen 
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C D44 CD44 has been previously known under a variety of alternative 
names which have caused confusion e.g. in the human, In(Lu)-related 
p80, ECMRlll ( extracellular matrix receptor 111), Hermes antigens, 
HCAM and gp90 Hermes; in the macque Hutch 1; and in the mouse, 
Pgp-1 0r Ly-24. All of these have been shown by antibody and other 
studies to be essentially the same molecule (Gallatin et al., 1989; 
Hughes et al., 1983; MacKay et al., 1988; Omary et al., 1988; Picker et 
al., 1989; Stefanova et al., 1989; Trowbridge et al., 1982). 
Furthermore, the relationship of CD44 to MEL-14 was at one stage 
confused when CD44 was incorrectly inferred to be the human 
equivalent of MEL-14 (J alkanen et al., 1986c ). In 1987 at the Third 
International Workshop on Leukocyte Differentiation Antigens the 
nomenclature of human antigens was standardised and the molecule 
was renamed CD44 (Cobbold et al., 1987). 
The human CD44 molecule was originally described by Dalchau et al. 
( 1980) as a human molecule identified by mAb Fl 0-44-2. It 1s an 
acidic, sulfated protein containing both 0- and N-linked 
oligosaccharide sidechains (J alkanen et al., 1987), multiple 
phosphoserine residues and several intrachain disulfide bonds. 
Although CD44 has a restricted tissue distribution it is found on a 
large variety of cell types including T lymphocytes, smooth muscle 
cells, some secretory glands and skin epithelial cells (Flanagan et al., 
1989). 
Cloning data (Goldstein et al., 1989; Idzerda et al., 1989; Stamenkovic 
et al., 1989) has shown that CD44 contains a C-terminal cytoplasmic 
tail, a hydrophobic transmembrane domain of 23 amino acids and a N-
terminal extracellular region of 248 amino acids shown in Figure 1.5 
(Coombe and Rider, 1989). The 150 amino acid proximal extracellular 
domain contains two putative N-glycosylation sites and five putative 
0-glycosylation sites and is the region thought to contain four sites for 
chondroitin sulfate linkage through serine-glycine motifs. The 90 
amino acid distal region of CD44 contains the majority of potential N-
glycosylation sites and cysteines and exhibits homology to the 
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cartilage link protein and proteoglycan core proteins (as mentioned 
previously) which are involved in protein-hyaluronic acid interactions 
( Goetinck et al., 1987). This data suggests that the amino-terminal 
domain on CD44 may be a receptor for an anionic polysaccharide 
ligand, possibly similar to the mannose-6-phosphate (M6P) ligand of 
MEL-14 (Section 1. 7 .3). This would also agree with data indicating 
SPS involvement in lymphocyte migration (Section 1.7.3). An 
attractive hypothesis proposed by Coombe and Rider ( 1989) is that 
the presentation of glycoconjugate structures on CD44, such as the 
chondroitin sulfate sidechains (J alkanen et al., 1988), may be 
recognised as ligands by carbohydrate-binding receptors on the 
surface of endothelial cells. The demonstration that SPS probably 
inhibit lymphocyte-HEY binding in vivo by reacting with SPS 
receptors on HEV (Brenan and Parish, 1986) supports this view. 
The functional aspects of CD44 can be divided into four main areas. 
Firstly, CD44 is involved in lymphocyte binding to HEV (Table 1.2). 
The Hermes series of antibodies, Hermes 1, 2 and 3 described by 
J alkanen et al. (1986a), are involved in the binding of lymphocytes to 
mucosal, peripheral and synovial HEV (Jalkanen et al., 1987). Hermes 
3 inhibited lymphocyte interactions exclusively with mucosal HEV, 
whereas a polyclonal antisera against CD44 did not show this 
distinction and inhibited binding to all HEV (Jalkanen et al., 1987). 
This implied a possible CD44 mediated tissue specific homing 
mechanism. However, this mechanism has since been disregarded due 
to the structural similarity between CD44/Hermes antigens in 
different lymphoid lines (Stoolman, 1989). Instead, a generalised 
hypothesis has been proposed by Holzmann et al. (1989) that the 
organ specific component of the lymphocyte/HEY interaction is 
mediated by multiple adhesion molecules, where several adhesion 
molecules may have to operate in conjunction to allow lymphocyte 
recognition and entry into an organ. 
Secondly, CD44 may act as a link between extracellular matrix 
components and the cytoskeleton of cells. ECMRIII was described by 
I 
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Carter (1982), as a 90 kDa surface molecule of human fibroblasts. It 
was proposed to link the fibroblast cytoskeleton with the ECM through 
binding both collagen type I and VI and FN (Carter & Wayner, 1988). 
Thirdly, CD44 may regulate cell adhesion systems in vivo via the 
CD2/LFA-3 interaction. LFA-3 on sheep and human erythrocytes 
interacts with CD2 on T cells resulting in E-rosette formation. 
Antibodies to CD44 inhibit this interaction by binding to erythrocytes 
and modifying the ability of LFA-3 to interact with CD2 (Shimizu et al., 
1989). Such observations suggested that CD44 may be in close 
proximity to LFA-3 on the erythrocyte surface or binding of 
antibodies to CD44 may in some way induce a conformational change 
in LFA-3 (Haynes et al., 1989). 
Fourthly, CD44 molecules on the surface of T lymphocytes may 
regulate the CD2/LFA-3 interaction and thereby be involved in 
regulation of T cell activation. Huet et al. ( 1989) and Shimizu et al. 
(1989) both observed that mAb to CD44 dramatically augmented T 
cell proliferation and IL-2 synthesis induced by CD3 and CD2 receptor 
mediated activation. 
Vascular Addressins Vascular addressins are the complementary 
receptor glycoproteins on the surface of HEY that provide a target 
structure for lymphocyte receptors (Streeter et al., 1988a). Tissue 
specific mAbs to these addressins have been produced. For example, 
MECA-367 and MECA-89 are specific for vascular addressins on 
murine PP HEY whereas MECA-79 is specific for a vascular addressin 
on murine PLN HEY (Streeter et al., 1988a, b). MECA-367 
immunoprecipitates a 58-66 kDa protein, that contains disulfide 
bonds, possesses a heterogeneous pl of 6.7, 6.8 and 6.9 and is N- and 
0-glycanase resistant. In contrast, MECA-79 recognises a 92 kDa 
molecule, unchanged by reduction, with a pl of 6.2 and which is N-
glycanase sensitive (Berg et al., 1989). Currently the nature of the cell 
surface receptors on lymphocytes for these vascular addressins has 
I 
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not been established, although strong candidates are MEL-14 (human 
LAMl) and CD44. 
1.6.2 SECONDARY ADHESION MOLECULES 
LF A-1 LFA-1 (CD1 la/CD18) is a member of the integrin family (see 
Table 1.1 ), found exclusively on leukocytes (Hynes, 1987). It has an a 
and P chain of MW 180,000 and 95,000 respectively, arranged in a 
heterodimer complex. Studies by Hamann et al. (1988) have revealed 
that antibodies to LF A-1 inhibit lymphocyte attachment to HEY in 
vitro and in vivo where the migration of normal lymphocytes into 
lymph nodes and PP was decreased by 40-60%. Localisation to the 
lung was also impaired. Cells that contained high levels of the MEL-14 
antigen were less susceptible to inhibition by anti-LF A-1 than those 
with low levels, which supports the function of LFA-1 as an accessory 
molecule supporting weak interactions between cells (Harder and 
Heinz-Gi.inther, 1988). There is also some evidence that LFA-1 
expression is required for metastasis to occur in certain lymphoma 
cell lines (Roossien et al., 1989). This secondary function of LF A-1 is 
supported by its role in stabilising cell adhesion in many other forms 
of leukocyte adhesion (Springer et al., 1987). 
ICAM-1/ICAM-2 ICAM-1 (CD54) was identified as a B cell 
activation marker (Clark et al., 1986) and a putative ligand for LFA-1 
(Table 1.2) expressed on B-lymphoblastoid cells (Rothlein et al., 1986), 
an observation subsequently confirmed by Simmons et al. (1988). It 
is a single chain glycoprotein of MW 90,000, constitutively expressed 
on some tissues and induced on others in inflammation (Boyd et al., 
1988; Dustin et al., 1988; Dustin and Springer, 1988; Marlin and 
Springer, 1987). Another ligand to LFA-1 which has been cloned 
recently by Staunton et al. (1989) is ICAM-2. Both ICAM-1 and 
ICAM-2 are members of the lg supergene family (see Table 1.1) 
(Wawryk et al., 1989). 
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LPAM-1 Lymphocyte adhesion to PP but not PLN HEY can be 
inhibited by a mAb recognising the LPAM-1 antigen (Holzmann et al., 
1989; Holzmann and Weissman, 1989). The structure of the a 
subunits of LPAM-1 and VLA-4 are almost identical (Holzman et al., 
1989) suggesting LPAM-1 is VLA-4 and a member of the integrin 
family of cell adhesion molecules (Table 1.1 ). The ~ chain of the 
LP AM-1 molecule appears to be antigenically distinct from other 
known ~ chains and forms a heterodimer with the a-subunit, a 
process which is Ca2+ dependent (Holzmann and Weissman, 1989). 
1.7 EVIDENCE FOR CARBOHYDRATE RECOGNITION IN 
LYMPHOCYTE HOMING 
Carbohydrate recognition systems, particularly involving SPS and 
glycosaminoglycans (GAGs), and their complementary lectins have 
been identified in many systems hence interest has grown in the role 
that they may play in lymphocyte migration. Some examples of this 
are the binding of bacteria or viruses to host cell (Ofek et al., 1977; 
Sharon, 1987) including influenza virus recognition of cell-surface 
sialic acids (Wiley and Skehel, 1987) and the symbiosis between 
p~ants and nitrogen-fixing bacteria (Ho et al., 1986). 
Carbohydrate binding systems have been implicated 1n recognition 
between yeasts (Pierce and Ballou, 1983 ), slime mould aggregation 
(Ziska and Henderson, 1988), and reaggregation of marine sponges 
(Coombe et al., 1987a; Coombe and Parish, 1988). Also sperm-egg 
adhesion (Ahuja, 1982; Bolwell et al., 1980; Glabe et al., 1982) and 
embryogenesis (Tucker, 1986; Wenzl and Sumper, 1981; Yamaguchi 
and Kinoshita, 1985) appear to involve SPS recognition. Adhesion of 
neural retina cells from embryonic chickens has also been shown to 
involve the heparin-binding domain of NCAM (Cole et al., 1986; Cole 
and Glaser, 1986) and carbohydrates are involved in neuron-glial and 
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glial-glial adhesion (Ktinnenmunde et al., 1988). Finally, smooth 
muscle cell growth and migration can be inhibited by heparin and 
heparin-like molecules (Castellot et al., 1981; Majack and Clowes, 
1984). 
Carbohydrate involvement in lymphocyte homing has been indicated 
by three major areas of research. Firstly, the effect of modifiers of 
carbohydrate structure on lymphocyte migration. Secondly, the 
effects of lectins on lymphocyte homing and thirdly, direct inhibition 
of lymphocyte homing by carbohydrates. 
1.7.1 EFFECT OF MODIFIERS OF CARBOHYDRATE STRUCTURE 
ON LYMPHOCYTE MIGRATION 
A number of treatments which specifically alter carbohydrate 
structure on the cell surf ace have been used to demonstrate the direct 
involvement of carbohydrates in lymphocyte homing. These include 
treatments of cells with glycosidases, and glycosylation inhibitors ( e.g. 
swainsonine) and period ate. 
Glycosidases Gesner and Ginsburg (1964) found that thoracic duct 
lymphocytes which were incubated in vitro with glycosidases showed 
altered migration patterns in vivo. This effect was specifically 
blocked by inclusion of either L-fucose or N-acetyl-galactosamine 
respectively, during the glycosidase treatment. They therefore 
postulated that lymphocyte migration patterns were dependent upon 
the recognition of cell surface sugar molecules. 
Similar results were obtained with neuraminidase (sialidase) 
treatment. Neuraminidase is a N-acetylneuraminylhydrolase, which 
cleaves the 2,3 and 2,6 glycosidic linkages between N-
acetylneuraminic acids and subterminal sugars on carbohydrate 
sidechains. Treatment of lymphocytes with neuraminidase was found 
to alter their migration behaviour (Gesner et al., 1969; Woodruff and 
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Gesner, 1969). Gesner et al. ( 1969) performed studies where 
radiolabelled thoracic duct lymphocytes were incubated with 
neuraminidase and injected intravenously into recipient rats and the 
resultant radioactivity in various organs measured. It was found that 
there was a decrease in the number of lymphocytes in the spleen and 
lymph nodes with a corresponding increase in the liver at 30 min and 
2 h post injection, an affect which was not seen at 24 h post injection. 
Other studies -with more highly purified preparations of 
neuraminidase have shown similar results (Kolb and Kolb-Bachofen, 
1978; Kolb-Bachofen and Kolb, 1979). These results suggest that 
carbohydrate structures on the cell surface which were altered by 
neuraminidase treatment were essential for correct lymphocyte 
migration. However, these early studies with glycosidases have been 
severely criticised, as it has been suggested that inhibition of entry 
into lymphoid organs is a secondary effect resulting from 
sequestration of glycosidase treated lymphocytes in non-lymphoid 
organs due to recognition of altered cell surf ace carbohydrates. 
The neuraminidase experiments were particularly questionable as 
neuraminidase treatment often resulted in exposure of subterminal 
galactose residues which could be recognised by a galactose-binding 
lectin in the liver (Ashwell and Kawasaki, 1978). In fact, the 
sequestration of treated lymphocytes in the liver is almost certainly 
due to these liver lectins. Nevertheless, more recent experiments 
have implicated sialic acid residues in lymphocyte HEV binding. Thus 
treatment of frozen sections of HEV from mouse or rat with sialidases 
specifically inhibited lymphocyte attachment to PLN but not PP HEY 
while MLN HEV showed a partial response (Rosen et al., 1985). This 
confirmed previous ideas that MLN HEY contained receptors for both 
PLN and PP HEV (Stevens et al., 1982). Similar results were obtained 
in vivo where injected sialidases selectively prevented subsequent l n 
vitro attachment of lymphocytes to PLN HEV and also short term 
accumulation of lymphocytes in PLNs (Rosen et al., 1989). 
Furthermore, the use of linkage-specific sialidases has indicated that 
... 
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either a2,3 or a2,8 (but probably not a2,6) sialic acid is involved in 
attachments of ligands to PLN HEY (Yednock and Rosen, 1989). 
Rosen et al. (1989) therefore suggested that sialic acid \Vas either a 
direct recognition determinant of the ligand on PLN HEY or had an 
indirect modulatory role in HEY adherence. Differentiation between 
these two models may ultimately require the isolation and 
characterisation of the actual HEY ligands involved. 
Interestingly, sialic acid may also be involved in the pathogenesis of 
certain bacterial and parasitic infections. Many microorganisms 
release sialidases into the serum possibly as a means of perturbing 
lymphocyte homing and thus modifying immune responsiveness 
(Schauer, 1985; Yednock and Rosen, 1989). 
Glycosylation Inhibitors Another line of evidence which 
suggested direct involvement of carbohydrates in lymphocyte 
attachment to HEY is that afforded by treatment with the 
glycosylation inhibitor, swainsonine. Swainsonine treatment of 
lymphocytes affected lymphocyte migration to lymph nodes and the 
spleen (Hooghe et al., 1984 ). Swainsonine is a potent inhibitor of 
mannosidase II and causes the formation of hybrid types, rather than 
complex types, of oligosaccharides having an oligomannosyl core 
characteristic of neutral oligosaccharides and one or several sequences 
characteristic of complex chains (reviewed by Elbein, 1987). 
Periodate Sodium periodate is an oxidising agent which in dilute 
solution removes the terminal two carbon atoms from sialic acid and 
converts the alcohol group of carbon seven to the aldehyde form (van 
Lenten and Ashwell, 1971), it also oxidises vicinal hydroxyl groups on 
other carbohydrates. Zatz et al. (1972) demonstrated that treatment 
of lymphocytes with potassium periodate, under conditions selective 
for the oxidation of cell surf ace carbohydrates, inhibited the migration 
of lymphocytes to lymph nodes and to a lesser extent the spleen. 
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1.7.2 EFFECTS OF LECTINS ON LYMPHOCYTE MIGRATION 
Traditionally a lectin (from Latin legere: to choose) is defined as a 
sugar-binding protein or glycoprotein of non-immune origin which 
agglutinates cells and/or precipitates glycoconjugates (Goldstein et al., 
1980). Lectins have been used extensively as molecular tools in 
biology (reviewed by Barondes, 1981; Lis and Sharon, 1986; Sharon 
and Lis, 1989) and have been used to determine the involvement of 
carbohydrates in lymphocyte migration. 
In experiments performed by Schlesinger and Israel ( 197 4) a range of 
lectins were tested for their ability to affect lymphocyte migration. 
Radiolabelled murine lymphocytes were exposed to concanavalin A 
(Con A), phytohaemagglutinin (PHA), a fucose binding protein or 
wheat germ agglutinin and then injected intravenously into syngeneic 
recipient mice. It was found that Con A inhibited lymphocyte 
migration to lymph node to a greater degree than entry into the 
spleen whereas PHA inhibited migration to each of these organs to a 
similar degree. Neither fucose binding protein or wheat germ 
agglutinin affected lymphocyte migration. The effect of Con A on 
lymphocyte migration was overcome by incubation of the Con A 
treated lymphocytes with a-methyl-mannopyranoside prior to 
injection which indicated that Con A affected lymphocyte migration by 
specifically binding to cell surface carbohydrates. However, as with 
the glycosidase studies, these experiments were criticised on the basis 
that lectins bound to the surf ace of lymphocytes, due to their 
multivalent nature and could modify lymphocyte migration by 
binding non-specifically to other cells and tissues in vivo. 
Further studies, reviewed by Yednock and Rosen ( 1989) examined the 
effect on lymphocyte/HEY interaction of treating cryostat sections of 
endothelia with lectins. It was found that L imax agglutinin (a sialic 
acid-specific lectin) blocked attachment to both PP and PLN HEY 
whereas other lectins (Con A, wheat germ agglutinin, Dolichus biflorus 
agglutinin, Limulus polyhem.us agglutinin, Ricinus communis 
,, 
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agglutinin and Ulex europeus I) had no effect. This effect was 
considered specific because addition of a sialylated lectin inhibitor to 
Limax agglutinin (bovine submaxillary mucin) blocked its inhibitory 
potential. This again demonstrated the involvement of carbohydrate 
structures particularly sialic acid, in lymphocyte/HEY interactions. It 
is interesting to note that although sialidase treatment did not affect 
lymphocyte binding to PP HEY (Section 1.7 .1), binding was inhibited 
by the sialic acid-specific lectin. This could be due to sialidase-
resistant forms of sialic acid (Schauer, 1982) present on PP HEY. 
1.7.3 INHIBITION OF LYMPHOCYTE MIGRATION BY 
CARBOHYDRATES 
Monosaccharides Direct evidence for the involvement of 
carbohydrates in lymphocyte/HEY interactions comes from the work 
of Stoolman and Rosen (1983). Using the in vitro assay (Section 1.4.2) 
developed by Stamper and Woodruff ( 1976), they tested the ability of 
neutral monosaccharides to inhibit the attachment of lymphocytes to 
rat PLN HEY. They demonstrated that L-fucose and D-mannose 
selectively inhibited lymphocyte/PLN HEY interactions when 
compared to other neutral monosaccharides. However, their results 
were not entirely satisfactory due to the high concentrations (75-150 
mM) of monosaccharide needed to induce inhibition. 
In further experiments, Stoolman et al. (1984 ), discovered more 
potent monosaccharide inhibitors of the lymphocyte/HEY interaction. 
M6P and fructose-I-phosphate (Fl P) inhibited lymphocyte/PLN HEY 
binding by 80-90% at a concentration of 10 mM, which indicated that 
in terms of inhibitory activity M6P was 25-50 fold more inhibitory 
than D-mannose. In contrast, mannose-1-phosphate, fructose-6-
phosphate, galactose-1- and 6-phosphates, glucose-I- and -6-
phosphates showed little or no inhibition at 10 mM (see also Table 
1.3 ). 
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Table 1.3 Inhibition of Lymphocyte Binding to 
High Endothelial Venules 
Carbohydrate 
Galactose-1 P 
Glucose-6P 
Glucose-1 P 
Galactose-6P 
Fructose-6P 
Mannose-1 P 
Fructose-1 P 
Mannose-6P 
PPME 
Fucoidan 
Concentration of carbohydrate 
for 50°/o inhibition (mM)a 
>10 
>10 
>10 
>10 
>10 
>10 
2-3 
2-3 
1 o-5 
<10-4 
a Concentration of carbohydrate necessary for one half maximal inhibition of 
lymphocyte binding to HEV (in vitro). 
PPME = mannose 6-phosphate-rich core mannan 
Modified from Rosen and Yednock (1986); Stoolman et al. (1984) 
To determine if M6P moieties expressed by HEV were essential for 
lymphocyte biJJ.ding, sections of mouse PP and PLN were incubated 
with high concentrations of alkaline phosphatase and a-mannosidase. 
No subsequent inhibition of lymphocyte attachment was observed 
which led to the conclusion that M6P may be a structural mimic of the 
actual ligand O!} PLN HEV (Yednock and Rosen, 1989). 
Phosphomannan Ester (PPME) Following these investigations 
another more potent inhibitor of lymphocyte attachment was 
discovered, the polysaccharide PPME. PPME is a M6P-rich core 
mannan derived from the yeast Hansenula holstii. It has a MW of 2.5 
x 106 and consists exclusively of mannose residues with one in every 
six sugar residues being phosphorylated in the carbon-six position. 
Fifty percent inhibition of lymphocyte/PLN HEV binding was achieved 
in the rat at a concentration of 1 o-8 M (Table 1.3; Spamgrude et al, 
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1984 ). Similar inhibitory effects are seen with PPME in the mouse 
(Yednock et al., 1987a) and human in vitro HEY assay (Stoolman et al., 
1987). 
PPME is therefore thought to m1m1c a ligand for the PLN homing 
receptor and although it may be postulated that a carbohydrate is 
probably involved in the PP binding system, as yet none has been 
identified (Yednock and Rosen, 1989). However, PPME was found to 
inhibit lymphocyte attachment to lung lymph node HEY (Geoffroy et 
al., in preparation). 
To determine whether the receptor for PPME was located on the 
lymphocyte or the REV surface, simple preincubation experiments 
were employed (Stoolman et al., 1984; Stoolman and Rosen, 1983). It 
was found that incubation of lymphocytes but not REV with PPME 
inhibited REV binding, suggesting that PPME bound to the lymphocyte 
surface. 
In order to demonstrate this directly, fluorescent beads were 
covalently coupled with PPME (Yednock et al., 1987a) and then bound 
to lymphocytes with bead binding being quantified by flow 
cytometry. PPME beads bound avidly to mouse, rat and human 
peripheral lymphocytes with this interaction being selectively 
inhibited by M6P, FlP, PPME and fucoidan (Stoolman et al., 1987; 
Yednock et al., 1987 a). Similarly Brandley et al. ( 1987) have 
employed PPME immobilised on an inert polyacrylamide surface to 
demonstrate that subpopulations 
for M6P and related structures. 
(Yednock et al., 1987a, b) have 
of rat lymphocytes carry receptors 
These experiments and others 
indicated that binding of peripheral 
lymphocytes to PPME beads mimics the in vitro interaction of 
lymphocytes with PLN HEV seen in the Stamper and Woodruff assay 
( 1976). Experiments were then carried out to identify the 
"carbohydrate-binding receptor" (Rosen and Yednock, 1986) and its 
relationship to other known cell surface antigens, a prime candidate 
being MEL-14 antigen. A series of experiments have demonstrated, in 
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fact, that MEL-14 is either very closely associated with or identical to 
the PPME receptor on lymphocytes (Yednock et al., 1987b). Evidence 
includes the observation that the binding of PPME beads to 
lymphocytes was specifically blocked by MEL-14 and not by other 
antibodies to cell surface molecules. Also there was a high correlation 
between expression of PPME receptor activity and the cell-surface 
expression of the MEL-14 antigen on lymphoma cell lines. 
Sulfated Polysaccharides (SPS) Aside from indirect evidence for 
the involvement of SPS in lymphocyte recirculation, such as the 
presence of receptors for SPS on many cell types, there is a wide body 
of data suggesting that SPS and their receptors may play a direct role 
in lymphocyte homing. 
Receptors for SPS are present on a wide variety of cell types including 
lymphocytes (Bradbury and Parish, 1989; Parish et al., 1984, 1988; 
Parish and Snowden, 1985; Thurn and Underhill, 1986), macrophages 
(Bleiberg et al., 1983; Chong and Parish, 1986), endothelial cells (Glabe 
et al., 1983b; Glimelius et al., 1978), rat neurones (Vidovic et al., 
1986), mammary adenocarcinoma cells (Coombe et al., 1987b ), rat 
liver cells (Kjellen et al., 1977), calf brain membranes (Miller and 
Waechter, 1984 ). Furthermore, there is evidence that known 
lymphocyte cell surface antigens such as Thy-1, Ly-5 (T-200), CD4 
and CD2 interact with sulfated carbohydrates (Lederman et al., 1989; 
Parish et al., 1988a, b ). 
Direct evidence that SPS recognition plays a role in lymphocyte 
migration comes from the finding that certain SPS, such as dextran 
sulfate and heparin, cause leucocytosis and inhibit lymphocyte 
recirculation when injected into animals (Bradfield and Born, 197 4; 
Jansen et al., 1962; Sasaki and Suchi, 1967). Also, fucoidan, a sulfated 
polymer of L-fucose, was found to be a potent inhibitor ( of similar 
magnitude to PPME) of lymphocyte adhesion to HEY in vitro 
(Stoolman et al., 1987; Stoolman and Rosen, 1983). Furthermore, HEY 
can rapidly incorporate radiolabelled sulfate into a glycolipid which is 
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secreted and causes lymphocytes to localise at intradermal sites of 
injection (Andrews et al., 1982, 1983 ). 
Another very interesting line of evidence for carbohydrate 
involvement in lymphocyte migration is the fact that the lymphocyte 
homing receptors MEL-14 and CD44 may participate in carbohydrate-
protein interactions (Coombe and Rider, 1989). A protein sequence in 
MEL-14 resembles the carbohydrate binding domain found in a 
number of lectins with Ca2+-dependent, carbohydrate-binding activity 
(Lasky et al., 1989). Furthermore, CD44, as previously mentioned 
(Section 1.6.1) contains not only a carbohydrate binding domain but 
also extensive glycoconjugate structures, including putative 
chondroitin sulfate sidechains which may be recognised by 
carbohydrate-binding receptors on HEY. 
The most conclusive in vivo evidence for SPS involvement in 
lymphocyte recirculation comes from the work of Brenan and Parish 
( 1986) where they demonstrated the selective effects of SPS on entry, 
displacement and furthermore positioning of lymphocytes within 
lymphoid organs. In the case of lymphocyte entry, SPS appeared to 
be blocking SPS receptors on the surface of endothelial cells. For 
example, A.-carrageenan and K-carrageenan decreased lymphocyte 
entry into the spleen to 20% and 83 % that of control values 
respectively, although they have the same polysaccharide backbone 
and differ only in their degree of sulfation. Also some SPS such as 
fucoidan and dextran sulfate, displaced lymphocytes from their 
normal positions in the red and white pulp of the spleen. 
1.8 PROPOSED \'VORK 
Lymphocyte migration 1s therefore seen as an extremely complex 
process involving specific interactions between ligands and receptor 
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molecules on the cell surface. Certain lines of evidence, such as the 
involvement of carbohydrates in many cell adhesion systems (Section 
1.7) and the direct role they have already been seen to play in 
lymphocyte homing ( Section 1. 7 .3 ), suggest that carbohydrates may 
play an intrinsic role in the process of lymphocyte recirculation. 
Although the MEL-14 antigen, which is a carbohydrate-binding 
receptor (Section 1.6.1 ), has been implicated in lymph node/HEY 
binding, as yet molecules have not been identified on the lymphocyte 
surface, which are involved in splenic entry. However, evidence 
strongly suggests the involvement of SPS in this process (Brenan and 
Parish, 1986; Section 1. 7 .3 ). Furthermore nothing is known about the 
molecular control of lymphocyte positioning within lymphoid organs, a 
process which appears to be disrupted by SPS. 
This study therefore focuses on the interactions between SPS ligands, 
initially isolated from splenic tissue, and lymphocyte receptors for 
these and other SPS. An attempt has then been made to isolate and 
characterise lymphocyte receptors and determine in part, their role 1n 
lymphocyte recirculation in vivo. It is hoped that this will provide 
some basis for future vvork on the role of SPS in lymphocyte 
recirculation. 
CHAPTER 2 : MATERIALS AND METHODS 
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2.1 MICE 
All mice were bred at the John Curtin School of Medical Research. 
C57BL/6 mice of either sex were used for experiments involving 
splenic GAGs whereas in all other experiments female mice were used 
from 6-20 weeks of age. C57BL/6, BALB/c and CBA mice were used 
for in vivo migration studies and BALB/c mice for maintaining cell 
lines. 
2.2 POLYSACCHARIDES 
All polysaccharides were obtained from Sigma Chemical Co. (St. Louis, 
MO) with the exception of dextran sulfate (MW 500,000) which was 
purchased from Pharmacia Fine Chemicals (Uppsala, Sweden). 
Structural features of the polysaccharides are shown in Table 3 .2. The 
separation of bovine lung heparin into fractions with high and low 
affinity for antithrombin III was performed using an antithrombin III 
coupled Sepharose column, according to the method of Parish et al. 
(1987). The polysaccharides were dissolved in 0.15 M NaCl at stock 
concentrations of 20 mg/mL, or in the case of hyaluronic acid and the 
carrageenans (because of their viscosity in solution) at 10 and 2 
mg/mL respectively, and stored at -2ooc. They were boiled for 1 min 
before use in binding specificity experiments. 
2.3 ANTIBODIES 
The mAbs used and their mode of immobilisation for 
immunoprecipitation experiments is listed in Table 2.1, the antibodies 
Table 2.1 Monoclonal Antibodies 
Antibodies Species Source Antigenic determinant lmmunoprecipitation method Origin 
recognised 
Sheep anti Protein A Protein G Sephar-
rat lg beads beads ose 48 
beads beads 
MEL-14 rat cs MEL-14 + R. Ceredig 
53.6.7 rat cs Ly-2 + R. Ceredig +:>a 
2.4G2 rat cs FcR + R. Ceredig 0 
C363 rat cs CD3 + R. Ceredig 
53-9.2.8 rat ascites ThB + I. McKenzie 
ASH 1788 mouse ascites Ly-5.1 (T200) + I. McKenzie 
8-6.2 mouse ascites Ly-15.2(LFA-1) + I. McKenzie 
IM7.8.1 rat ascites Pgp-1 + F. Lynch 
ASH 1848 rat ascites Thy-1.2 + I. McKenzie 
A1 mouse ascites EL-4 43kDa protein + 0. Kanagawaa 
a Nagasawa et al., 1987 
cs = culture supernatant 
.... 
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being immobilised on one of four substrata. Purified anti-Ly-15 .2 and 
anti-Pgp-1 antibodies were covalently coupled to CNBr-activated 
Sepharose-4B beads (Pharmacia) (Parish et al., 1988a). A number of 
rat mAbs (MEL-14, anti-Ly-2, anti-FcR and anti-CD3) were adsorbed 
to sheep anti-rat lg-coupled Sepharose 4B beads (Silenus laboratories, 
Hawthorn, Australia). The remaining antibodies were bound to either 
protein A-coupled Sepharose CL-4B beads (Pharmacia)(anti-ThB and 
anti-Ly-5.1) or recombinant protein G-coupled agarose (Genzyme 
Corp, Boston, MA) (anti-Thyl .2 and Al). 
2.4 CELL LINES 
The cell lines RDlOs (gift from K. Walker, Sydney) and BCL.1 (Slavin 
and Strober, 1978)(Table 2.2) were passaged continuously in BALB/c 
mice by injecting 106 RDlOs cells intravenously and 2 x 106 cells 
BCL.1 cells intraperitoneally. Splenic tumours were removed from 
RD 1 Os and BCL.1 injected mice, 14 days and 16 days post injection, 
respectively. Organs were gently teased through a fine wire mesh 
and single cell suspensions were prepared (Section 2.5) for reinjection. 
All other lymphoma lines (Table 2.2) were cultured in vitro in Eagle's 
minimum essential medium (Fl 5; Gibco, Grand Island, NY)/ 
supplemented with 2.2 g/L sodium bicarbonate, 5-10% foetal calf 
serum (FCS) and antibiotics (penicillin 120 mg/L, streptomycin 200 
mg/L, neomycin 200 mg/L). 
Table 2.2 Tumour Cell Lines 
Cell Line Origin Mouse strain Mode of induction Propagation Recipient mouse straina 
BCL.I B BALB/c spontaneous In VIVO BALB/c 
RD10s B BALB/c hybridoma in vivo BALB/c 
EL-4 T C57BU6 benzopyrene in vitro C57BL/6 
RI+ T C58 spontaneous in vitro CBA 
RI- T C58 spontaneous in vitro CBA 
BUVL3 T C57BL/Ka Rad LV in vitro C57BL/6 
MBL-2 T C57BU6 Moloney LV in vitro C57BL/6 
C6VL/1 T C57BL/Ka Rad LV in vitro C57BL/6 
LSTRA T BALB/c Moloney LV in vitro BALB/c ~ N 
CL2-FT2 T C57BU6xBALB/c Moloney LV in vitro C57BL/6 
RK4.7 pre-T C57BU6 Abelson-Rad L V complex in vitro C57BL/6 
P815 mast DBA/2J methylcholanthrene in vitro BALB/c 
LV=leukemia virus Rad=radiation 
a Recipient mouse strain used for in vivo migration studies. 
~ 
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2.5 PREPARATION OF CELL SUSPENSIONS 
Single cell suspensions from C57BL/6 spleen were prepared in 
phosphate-buffered saline (PBS) containing 0.1 % (w/v) bovine serum 
albumin (BSA) (Fraction V, Armour Pharmaceuticals, Eastbourne, 
England) as described by Parish et al. (197 4 ). Suspensions were 
depleted of red and dead cells by Isopaque-Ficoll separation 
(Davidson and Parish, 1975). 
Blood was collected from sheep 1n Alsever's solution and the red cells 
washed four times in 20 volumes of 0.15 M NaCl by centrifugation 
( 600g, 5 min, 200C) just before use. 
2.6 COUPLING OF POLYSACCHARIDES TO 
ERYTHROCYfES 
For rosetting assays, polysaccharides were coupled to sheep red blood 
cells (SRBC) via CrCl3 using a method described in detail by Parish and 
Snowden (1985). Briefly, to 0.9 mL of 0.15 M NaCl was added 0.05 
mL of packed SRBC and 0.4 mg of polysaccharide dissolved in 0.15 M 
NaCl. After mixing, 0.1 mL of 0.1 % CrCl3 in 0.15 M NaCl was added 
with constant shaking. The mixture was left to react at room 
temperature (RT) for 5 min and the reaction was stopped by addition 
of 4.0 mL of PBS. The coupled SRBC were pelleted by centrifugation 
(400g, 5 min, 2QOC) and washed with 5.0 mL of PBS. The final SRBC 
pellet was resuspended in 5.0 mL PBS/0.1% BSA/0.1% NaN3 and 
stored at 40c. PS-coupled (polysaccharide-coupled) SRBC were used 
within 2 days of coupling. 
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2.7 ROSETTING ASSAYS 
The rosetting of mur1ne lymphocytes (splenocytes and thymocytes) 
with PS-coupled SRBC was carried out in 96-well, round-bottomed 
microplates (Linbro Chemical Co., New Haven, Conn.) as described 
previously (Parish and Snowden, 1985). To 25 µL/well of 
lymphocytes (4 x 106/mL in ice-cold PBS/0.1 % BSA) was added an 
equal volume of 1 % (v/v) PS-coupled SRBC in the same medium. The 
cells were mixed by gentle vortexing of the microplate and pelleted 
by centrifugation (200g, 1 min, 40C). The pellet was then incubated 
on ice for at least 30 min before being gently resuspended with a 
Pasteur pipette. Methyl violet staining solution, 0.05% (w/v) in PBS, 
was prepared immediately prior to use by dilution of a stock solution 
of 1 % (w/v) methyl violet in double distilled water (DDW). Then 50 
µL of the staining solution was added to each well. Each sample was 
transferred to a haemocytometer slide for counting and the 
percentage of rosette-forming cells assessed by scanning 100 
lymphocytes. Any lymphocyte that bound four or more red cells was 
classified as a rosette. 
2.8 RADIOLABELLING OF CELL SURF ACES AND 
PREPARATION OF CELL LYSATES 
Lymphocytes and lymphoma cell lines were cell surface labelled with 
125 I using the lactoperoxidase catalyzed method (Parish et al., 1978) 
and a detergent lysate prepared by resuspending the labelled cells to 
a concentration of 4 x 107 /mL in 0.15 M NaCl, 0.05 M Tris-HCI pH 8.0, 
0.5% Triton X-100 (TTS) containing 300 KIU/mL of aprotinin (Sigma). 
After incubation (30 min, 40C) cell debris and nuclei were pelleted by 
centrifugation (28 ,OOOg, 20min, 40c). 
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2.9 COUPLING POLYSACCHARIDES TO 
CARBOXYMETHYLCELLULOSE 
Polysaccharides were coupled to carboxymethyl cellulose (CMC) based 
on a method reported earlier (Parish et al., 1988a). Precycled fibrous 
CMC (CM-23, Whatman) was poured into a 10 mL Econo-Column (Bio-
Rad, Richmond, CA) until approximately 3 mL of packed fibres was 
obtained. The column was equilibrated with 20 mL of 0.15 M NaCl 
and then 10 mL of 1 % (w/v) CrCl3, prepared in 0.15 M NaCl (Parish 
and McKenzie, 1978) was run into the column. The CrCl3 was left to 
react with the CMC for 1 h at RT and then unreacted CrCl3 was 
removed by washing with 20 mL of 0.15 M NaCl. A solution 
containing polysaccharides at 5 mg/mL in 0.15 M NaCl was run into 
the column (4 mL/column) and left to react for 16-18 h at RT. The 
column was then washed with 10 mL of 0.15 M NaCl and 20 mL of 
PBS, fibres removed from the column and stored at 40c containing 
0.1 % NaN3 for up to 12 months. It has been estimated that approx. 1 
mg of polysaccharide was bound per mL of packed CMC fibres (Parish 
et al., 1988a). 
2.10 BINDING OF LYSATES TO AFFINITY COLUMNS 
For binding of lymphocyte lysates to PS-coupled CMC fibres , 50 µL of 
packed fibres were transferred to 1.5 mL eppendorf test tubes, 
washed (three times) by centrifugation with 1.0 mL TTS and reacted 
with 0.2 mL of 1251-Iabelled lymphocyte lysate (107 cell equivalents) 
for 1 h at 40c on a rotator (Parish et al., 1988 a, b). The fibres were 
then washed five times with TTS and the final sixth wash with 0.15 M 
NaCl, 0.05 M Tris-HCl pH 8.0 (TS). For sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis, samples were 
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resuspended in 50 µL of either reduced or non-reduced sample buffer 
and boiled in a water bath for 5 min prior to analysis. 
In some experiments, following washing the fibres six times with TTS, 
bound material was eluted from the fibres with 2 M NaCl, 0.05 M 
Tris-HCl pH 8.0, 0.5% Triton X-100. The eluate was desalted by 
passage through a PD-10 column (Pharmacia) equilibrated with TTS 
and the resultant 125 I-labelled fractions containing polysaccharide-
binding proteins were pooled. 
For isolation of Con A, gelatin or lentil lectin binding material, 125 I-
labelled splenocyte lysates (prepared as described above) were 
reacted with 50 µL of packed, TIS equilibrated, Con A-Sepharose 4B 
(Pharmacia), gelatin-Sepharose 4B (Pharmacia) or lentil lectin-
Sepharose 4B beads (Pharmacia), for 1 h at 40c on a rotator. The 
beads were then washed in TTS as for the CMC fibres in TTS and 
analysed by SDS-PAGE (Section 2.21) or isoelectric focussing (Section 
2.22). 
2.11 RELEASE OF HEPARIN-BINDING MOLECULES 
FROM CELLS 
In order to release certain heparin-binding molecules from 
lymphocytes 125I-labelled lymphocytes (107 cells) were resuspended 
at 40c in 0.25 mL of solutions of PBS containing 2.5% Tween 40, 2.5 
mM iodoacetamide, 1 % (w/v) aprotinin (Standring and Williams, 
1978) for 1 h; 2.5 M KCl for 5 min; 1 mg/mL RGDS (Arg-Gly-Asp-Ser; 
Peptide Technology Ltd., Sydney) for 30 min or 10 mM inositol 
hexaphosphate (phytic acid, Sigma) (Ishihara et al., 1987) for 30 min. 
The cells were then pelleted by centrifugation (300g, 5 min, 4°C) and 
solubilised as described earlier with TTS and aprotinin (Section 2.8). 
S upernatants were desalted by passage through a PD-10 column 
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equilibrated with TTS and the resultant 125 I-labelled fractions which 
contained the released cell-surface proteins pooled. 
Lysates of cell pellets and cell supernatants were bound to heparin-
CMC fibres (Section 2.10) and bound material analysed by SDS-PAGE. 
Alternatively, inositol hexaphosphate released proteins were acetone 
precipitated directly and then analysed by SDS-PAGE (Section 2.21 ) 
1251-splenocytes were also treated with solutions of PBS containing 
0.31-10 mM inositol hexaphosphate; 5 mM DL-myo-inositol 1-
monophosphate ( 1-MP; Sigma); 5 mM myo-inosi tol 2-monophosphate 
(2-MP; Sigma); and 5 mM myo-inositol hexasulfate (HS; Sigma); and 
PBS alone by a modified method of Ishihara et al. ( 1987). Released 
proteins were analysed by SDS-PAGE. 
2.12 REASSOCIATION OF HEPARIN-BINDING 
MOLECULES WITH LYMPHOCYTES 
In some experiments 125 I-labelled heparin-binding molecules 
released from lymphocytes by 5 mM inositol hexaphosphate 
treatment were allowed to reassociate with lymphocytes. The inositol 
hexaphosphate eluted molecules in PBS (107 cell equivalents in 1 mL) 
were allowed to bind to splenocytes (107 cells; lh, 40C) pretreated 
with 5 mM inositol hexaphosphate. 
In order to detect low affinity binding of labelled molecules to cells, 
the cell eluate mixture ( 1 mL) was layered on 0.3 mL dibutyl 
phthalate (Selby, Sydney) in an eppendorf tube and centrifuged 
(28,000g, 30 min). The supernatant and oil were removed and the 
cell pellet resuspended in 50 µL of reduced sample buffer for SDS-
PAGE analysis. 
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In inhibition of reassociation experiments, 125 I-labelled, inositol 
hexaphosphate released molecules were incubated with inositol 
hexaphosphate pretreated lymphocytes as described above in the 
presence of 0.63-10.0 mM inositol hexaphosphate, 5 mM 1-MP, 5 mM 
2-MP or 5 mM HS. Following washing of cells by centrifugation 
through oil as described above, the cell-bound 125 I was counted and 
the percent of the control binding calculated, where control (PBS) 
binding in absence of inhibitor was taken as 100%. 
2.13 ISOLATION OF SPLENIC-GAGS 
The major steps 1n the isolation of murine splenic GAGs from munne 
spleen are depicted in Figure 2.1. 
Murine C57BL/6 spleens (about 600-1200) were collected and stored 
frozen in PBS. Initially spleens were defrosted and drained of PBS 
and the packed volume measured. Half a volume of ice cold DDW was 
added and the mixture blended on ice in an Ato-n1ix blender (MSE, 
London, England) on the maximum setting for 1 min. Blended spleens 
were added gradually to 10 volumes of ice cold acetone with vigorous 
stirring, the precipitate allowed to settle on ice for 15 min and the 
acetone decanted. Another 3 volumes of ice cold acetone was added, 
the mixture stirred vigorously for 5 min, and the precipitate allowed 
to settle for 15 min. The final acetone wash was repeated and the 
acetone removed by filtration using a large Buchner funnel, under 
suction. The precipitate was then transferred to a glass tray and 
spread out to dry overnight (with occasional stirring) at RT in a fume 
hood. The dried precipitate was weighed and ground with a mortar 
and pestle to a fine powder. The powder was suspended in 0.05 M 
Tris-HCl buffer, pH 7.5, containing 0.1 % NaN3 (10 mL buffer/g of 
powder), pronase (15 mg/g powder, protease from Streptomyces 
Mouse spleens ( 600-1200) 
I 
T 
Delipidate by acetone extraction 
I 
T 
Pronase digest acetone powder for 3 days at 370c 
I 
T 
Adjust to 0.5M NaCl and CPC precipitate GAGs 
I 
T 
Remove CPC by ethanol precipitation 
I 
T 
Precipitate contaminating DNA and peptides with TCA and dialyse 
supernatant against distilled water 
I 
... 
Precipitate GAGs from supernatant with CPC and remove CPC by 
ethanol precipitation 
I 
T 
'Crude' splenic-GAG preparation. 
Figure 2.1 Procedure for Isolating I\Jlurine 
Splenic-GAGs from Murine Spleen 
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grzseus , Sigma) added and the mixture incubated at 370c for 3 days 
with occasional shaking. 
Following pronase treatment undigested material was pelleted by 
centrifugation (2500g, 10 min), the supernatant harvested and 
adjusted to 0.5 M NaCl by addition of 2 M NaCl and GAGs isolated by 
5% (w/v) cetylpyridinium chloride (CPC; Stansens, Kingsgrove, 
Australia) and ethanol precipitation as previously described (Roden et 
al., 1972). The ethanol precipitated material was redissolved in DDW 
and contaminating DNA and peptides precipitated overnight at 40c by 
the addition of 0.2 volumes of ice cold 50% (w/v) trichloroacetic acid 
(TCA). 
The precipitate was pelleted by centrifugation (16000 g, 15 min, 40c) 
and the supernatant dialysed for 2 h against DDW, the dialysate being 
changed every 30 min. The dialysed solution was adjusted to 0.05 M 
Tris-HCl buffer, pH 8.0, and 0.15 M NaCl and the GAGs reprecipitated 
by CPC and ethanol (Roden et al., 1972). The final GAG precipitate 
was dissolved in DDW and the amount of SPS present determined by 
the dimethylmethylene blue assay (Farndale et al., 1986) using 
chondroitin-4-sulfate as a standard. The protein content of the GAG 
preparation was determined by the Coomassie Blue procedure (Rylatt 
and Parish, 1982) and the DNA/RNA content assessed by absorbance 
at 260/280 nm using a DMS 100 Varian spectrophotometer. 
2.14 ENZYMATIC DIGESTION OF GAGS 
For chondroitinase digestions, GAGs were dissolved in 0.1 mL of 0.05 
M sodium acetate, 0.05 M Tris-HCI buffer, pH 8.0, containing 1.25 
U/mL of either chondroitinase ABC (from Proteus vulgaris, Sigma) or 
chondroitinase AC (from Arthrobacter aurescens, Sigma), 0.1 % (w/v) 
sodium azide added and the solutions incubated overnight at 370c. In 
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the case of RNase and DNase, GAGs were digested with 20-25,000 
U/mL of enzyme for 30 min at 37°C in PBS or 0.1 M NaCl, O.lM MgCl2 
and O.OlM Tris-HCl buffer, pH 7.5 respectively. For binding 
experiments solutions were then boiled for 5 min to destroy the 
enzyme. Control digests did not contain the enzyme. For nitrous acid 
cleavage of radiolabelled GA Gs 9 volumes of 0.24 M N aN02 in 1.8 M 
acetic acid was added and the mixture incubated overnight at RT 
(Lindahl et al., 1973 ). The mixture was then either dialysed against 
DDW (2 h, RT, with 30 min changes in DDW), lyophilised and 
redissolved in SDS-PAGE sample buffer (Laemmli, 1970) or dialysed 
against PBS if the preparation was radiolabelled and was to be used 
for subsequent splenocyte binding assays. 
Chondroitinase digestion of unlabelled GAGs was monitored by a 
previously described dimethylmethylene blue assay (Farndale et al., 
1986), although decrease in absorbance at 600 nm was used to 
quantify GAGs rather than increase in absorbance at 525 nm as 
reported earlier. The method was automated and miniaturised by 
perf arming the assays in 96-well, flat bottom microtitre plates 
(Nunclon Delta, Roskilde, Denmark) and reading absorbance values on 
a Dynatech MR600 microplate reader (Dynatech Labs, Alexandria, Va). 
Digestion of the 125I-labelled GAG preparation by chondroitinases 
was monitored by passage of the digested sample through a PD10 
column and measuring 125 I-labelled undigested material in the 
excluded peak. This elution profile was compared with that obtained 
with an untreated sample of labelled GAGs. 
2.15 PREPARATION OF RADIOLABELLED GAGS 
GA Gs were fluoresceinated and radiolabelled with 125 I as described 
by Glabe et al. (1983a). Briefly, the procedure entailed CNBr 
activation of the GAGs, coupling the activated GAGs with 
fluoresceinamine and subsequent 125I-labelling of the attached 
L__ 
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fluorescein moieties. Unincorporated 125 I was removed by dialysing 
the radiolabelled preparations for 2 h at RT against PBS. 
2.16 BINDING OF RADIOLABELLED GAGS TO CELLS 
Binding assays were performed in either 1.0 x 7 .6 cm plastic 
centrifuge tubes (3DT tubes, Disposable Products, Adelaide, Australia) 
or in the case of larger experiments and where timing was critical, 96-
well, round bottom microplates were used. The reaction mixture 
consisted of 100 µL of 1251-splenic-GAGs in PBS containing 0.1% BSA 
to which 100 µL ( 4 x 106) of splenocytes was added and the cells left 
to react on ice for 60 min with occasional shaking. Tube assay 
samples were washed three times by centrifugation (300 g, 5 min, 
40C) with 1 mL/tube of ice cold PBS/0.1 % BSA whereas in the 
microplate assay, cells were washed with PBS/0.1 % BSA using a 
Titertek cell harvester (Flow Laboratories Ltd., Irvine, Scotland). Air 
dried filter paper discs were collected and cell bound 125 I counted. 
To correct for nonspecific binding, control binding assays were 
performed in the presence of a 50-150 fold excess of unlabelled 
heparin (shown to inhibit binding of labelled splenic-GAGs). In 
binding-inhibition experiments 50 µL aliquots of inhibitor (6.25-800 
µg/mL) were placed in microplates, a constant amount of 1251-splenic 
GAGs (50 µL, 20 µg/mL) added followed by 4 x 106 splenocytes in 
100 µL and the standard binding assay performed. 
2.17 ION EXCHANGE FRACTIONATION OF GAGS 
C57BL/6 splenic-GAGs were prepared, iodinated (Section 2.8) and 
dialysed 2.5 h against either 0.25 M NaCl, 0.01 M Tris-HCl buffer, pH 
7 .0 (ready for ion exchange fractionation) or chondroitinase treatment 
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buffer (see above). The latter sample was chondroitinase ABC 
digested overnight at 37°C and degradation products removed by 
passage of the sample through a PD 10 column equilibrated with 0.25 
M NaCl, 0.01 M Tris-HCl buffer, pH 7.0. 
A DEAE Sepharose CL6B column ( 41.5 x 1.8 cm, Pharmacia) was 
equilibrated with 0.25 M NaCl, 0.01 M Tris-HCl buffer, pH 7.0, the 
sample applied and the column washed with 50 mL of equilibration 
buffer prior to elution of material from the column with a 200 mL 
linear 0.25-1.0 M NaCl gradient, buffered with 0.01 M Tris-HCl, pH 
7 .0. The column flow rate was 10.2 mL/h and 2 mL fractions were 
collected and assayed for Na Cl content by refractometry and counted 
for radioactivity. Groups of fractions (20 per group) were pooled 
(Pools I-VII), dialysed overnight against DDW, lyophilised and 
redissolved in 2 mL PBS/0.1 % BSA. 
2.18 BIOTINYLATION OF GAGS 
Splenic-GAGs (2 mg in 1.0 mL DDW) were CNBr activated by the 
addition of 0.2 mL of CNBr (50 mg/mL in DDW) and the mixture left to 
react for 5 min at RT, the pH being maintained at 11.0 by the addition 
of 1 M NaOH. Unreacted CNBr was removed by passage of the splenic-
GAGs through a PD-10 desalting column equilibrated with 0.2 M 
borate buffer, pH 8.0. The excluded peak was collected (2.0 mL), 4 mg 
of biocytin (N-E-biotinyl-L-lysine) added and the mixture left to react 
at RT overnight. Biotinylated GAGs were separated from free biocytin 
by passage through another PD-10 column and collection of the 
excluded peak (3.0 mL). Based on a MW of 20 kDa, each GAG 
molecule was conjugated with 4-5 biotin molecules. 
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2.19 IMMUNOFLUORESCENT FLOW CYTOMETRY 
Binding of biotinylated splenic-GAGs to mur1ne splenocytes was 
quantified by flow microfluorometry using an indirect 
immunofluorescence technique similar to that described by Berman 
and Basch (1980). Briefly, 50 µL of splenocytes (107 /mL) were added 
to 50 µL of biotinylated GAGs (1.6-200 µg/mL) in PBS/0.1 % BSA and 
the mixture incubated on ice for 60 min. Following washing in 
PBS/0.1 % BSA the cells were incubated with a second step avidin-
fluorescein conjugate (Becton Dickinson, Immunocytometry Systems, 
Mountain View, CA; 1 :20 dilution), a third step rabbit anti-avidin 
antiserum (Sigma; 1 :250 dilution) and a fourth step fluorescein 
conjugated sheep (Fab')2 anti-rabbit lg (Silenus; 1 :10 dilution); the 
cells were washed twice with F15/5% FCS between each incubation 
step. Labelled cells were analysed on a Becton-Dickinson FACS IV 
(Becton Dickinson) with appropriate controls for each incubation step. 
2.20 IMMUNOPRECIPIT ATIONS 
Immunoprecipitations were performed with 10-15 µL of packed 
antibody-coupled beads, different mAbs being immobilised to 
different solid supports as listed in Table 2.1. 
To reduce binding of 125 I-labelled mouse lg to sheep anti-rat beads, 
radiolabelled murine lymphocyte lysates were incubated overnight 
with uncoupled sheep anti-rat lg beads (0.25 mL lysate/10 µL beads). 
In addition, binding of radiolabelled lysate to mAb-coupled beads was 
perf armed in the presence of 1 % heat-inactivated mouse serum in TTS 
(10 µL serum/10 µL beads). 
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2.21 GEL ELECTROPHORESIS 
125 I-labelled proteins were precipitated with acetone from solutions 
for gel electrophoresis by mixing in an eppendorf tube 0.2 mL 125 I-
labelled protein solution in TIS and 5 µL PBS/0.1 % BSA (5 µg carrier 
BSA) with 1 rnL of ice cold acetone. After incubation on ice for 5 min 
the protein precipitate was pelleted by centrifugation (28,000g, 5 min, 
4 OC) and the pellet resuspended in 50 µL of reduced sample buffer for 
SDS-PAGE analysis. 
Pooled fractions of radiolabelled GAGs from ion exchange 
fractionations were analysed by one dimensional 10% and 15% SDS-
PAGE according to the method of Laemmli (1970). In all other 
experiments samples were analysed by 8-18% SDS-PAGE, the samples 
were prepared in 50 µL of either reduced or non-reduced sample 
buff er and were boiled 5 min before gel loading. Gels were stained 
with Coomassie blue, destained to localise added MW markers (Bio-
Rad Laboratories, Richmond, CA), then dried for autoradiography and 
MW markers identified with radioactive (35 S 04 2-) ink. The MW 
markers used were myosin MW 200,000; E.coli ~-galactosidase MW 
116,250; rabbit muscle phosphorylase b MW 97,400; BSA MW 66,200; 
ovalbumin MW 42,699; bovine carbonic anhydrase MW 31,000; 
soybean trypsin inhibitor MW 21,500 and hen egg white lysozyme 
MW 14,400. Dried gels were autoradiographed at -700C on Kodak 
XAR-5 film using Cronex intensifying screens and in some 
experiments scanned using a LKB UltroScan XL Laser Densitometer 
(Bromma, Sweden). 
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2.22 ISOELECTRIC FOCUSSING 
To determine the isoelectric point of the 90 kDa protein, 2 x 107 
C57BL/6 murine splenocytes were cell-surface labelled with 1251, the 
labelled cells lysed and the heparin-binding molecules in the lysate 
prepared (Section 2.8, 2.10). The 90 kDa protein was then further 
purified by binding the heparin eluate to lentil lectin-Sepharose 4B 
beads (Section 2.10), and 125 I-labelled material was eluted with 20 
µL of 0.2 M a-methyl-D-mannoside (Sigma). The isoelectric point of 
the lentil lectin eluate was determined by the Phast Gel System using 
a homogeneous polyacrylamide gel ( 43 x 50 x 0.35 mm) containing 
Pharmalyte carrier ampholytes (22 µmol/mL pH unit) which was pre-
run at 2000 volts, 3.5 W for 75 volt hours to establish a linear pH 
gradient in the range 3-9. One microlitre samples of 125I-labelled 
lysate were loaded electrophoretically from a plastic comb applicator 
at 2000 vol.ts, 3.5 W for 420 volt hours at 150c. The samples and pl 
markers were focussed at 2000 volts , 3 .5 W for 410 volt hours over a 
separation length of 37 mm. The pl markers used were 
amyloglucosidase pl 3.5; soybean trypsin inhibitor, pl 4.55; ~-
lactoglobulin A, pl 5.20; bovine carbonic anhydrase B, pl 5.85; human 
carbonic anhydrase, pl 6.55; horse myoglobin, pl 6.85 and 7 .35; lentil 
lectin, pl 8.15, 8.45 and 8.65; and trypsinogen, pl 9.30. Protein bands 
were detected by Coomassie Blue staining, and the gel was 
autoradiographed for 125J-labelled proteins. 
2.23 ANALYSIS OF IN VIVO LYMPHOCYTE MIGRATION 
For lymphocyte migration studies the method used to label 
fluorescently cells with bis-benzimide trihydrochloride, Hoechst 
33342 (H33342, Sigma) was based on the procedure described by 
Brenan and Parish (1984) and Brenan et al. (1985). H33342 was 
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prepared as a 600 µg/mL stock solution 1n DDW and stored at 40c. 
Lymphocytes or lymphoma cell lines at 5 x 1 o7 /mL in PBS \tvere 
incubated with 6 µg/mL H33342 for 15 min at 370c. Cells were 
washed twice by centrifugation (300 g, 5 min, 40C) and resuspended 
to a concentration of 4 x 107 cells/mL in PBS, 0.5 mL (2 x 107 cells) of 
cells being injected intravenously into recipient mice of the 
appropriate strain (Table 2.2). 
Spleen and lymphoid organs were removed 2 h post injection and cell 
suspensions prepared from whole organs by processing the cells 
through a fine wire mesh. The suspension was then declumped, 
resuspended in a fixed volume of media, and H33342-labelled cells 
counted in a haemocytometer chamber using an Olympus microscope 
(Model BHT) with a HBO (100 W) mercury vapour lamp· for epi-
illumination and appropriate barrier and filter combinations for 
H33342 (364 nm excitation and >435 nm emission). The percentage 
of cells entering an organ was calculated relative to splenocyte entry 
which was taken as 100%. 
Alternatively, for positioning studies spleens were placed directly into 
4% paraformaldehyde in PBS for overnight fixation. Topographical 
localisation of fluorescent cells was visualised by a modification of the 
method of Brenan and Parish (1986). Fixed murine spleens were 
sectioned approximately in half, placed on nonfluorescent silicone 
rubber (Silastic, Dow Corning; Midland, MI) and viewed and 
photographed under a Olympus microscope. 
CHAPTER 3 : ISOLATION AND CHARACTERISATION 
OF ENDOGENOUS SPLENIC-GLYCOSAMINOGL YCANS 
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3.1 INTRODUCTION 
The molecular and cellular basis of lymphocyte migration and 
subsequent positioning within lymphoid tissues is not well 
understood. Lymphocytes exhibit defined migration patterns, 
showing preferences for certain lymphoid tissues (Butcher et al., 1980; 
Chin and Hay, 1984; Stevens et al., 1982) and sites within these 
tissues (De Sousa, 1981 ). Specific cellular interactions have been 
implicated in this phenomenon, the most notable being the binding of 
lymphocytes to HEY in lymph nodes (Butcher et al., 1979, 1980; Chin 
et al., 1982; Gallatin et al., 1983; Woodruff and Clarke, 1987), the 
reaction of lymphocytes with macrophages in the marginal zones of 
the spleen (Humphrey, 1980) and the interaction of lymphocytes with 
interdigitating cells in the T-dependent regions of lymphoid organs 
(Inaba and Steinman, 1986). 
Recent studies in a range of biological systems have suggested that 
SPS recognition plays a key role in a range of cell-adhesion systems 
(Section 1.7) such as sponge cell aggregation (Coombe et al ., 1987a), 
neuronal cell-cell adhesion (Cole et al., 1986), sperm-egg adhesion 
(Ahuja, 1982; Bolwell et al., 1980; Glabe et al., 1982) and 
embryogenesis (Tucker, 1986; Wenzl and Sumper, 1981; Yamaguchi 
and Kinoshita, 1985). Furthermore, receptors for SPS are present on 
many cell types (Section 1.7.3) including macrophages (Bleiberg et al., 
1983; Chong and Parish, 1986), endothelial cells (Glabe et al., 1983b; 
Glimelius et al., 1978), mammary adenocarcinoma cells (Coombe et al., 
1987b), and lymphocytes (Parish et al., 1984, 1988; Parish and 
Snowden, 1985; Thurn and Underhill, 1986). Thus it seems possible 
that SPS recognition may play a role in the migration and positioning 
of lymphocytes within lymphoid tissues. 
Some experimental data, in fact, supports this view (Section 1.7 .3 ), 
such as the inhibition of lymphocyte recirculation and leukocytosis 
caused by injection of certain SPS (Bradfield and Born, 197 4; Jansen et 
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al., 1962; Sasaki and Suchi, 1967) and inhibition of lymphocyte 
binding to HEY in vitro by fucoidan (Stoolman and Rosen, 1983). 
Different SPS can also selectively modify entry and positioning of 
lymphocyte subpopulations within lymphoid organs (Brenan and 
Parish, 1986), possibly by blocking receptors on lymphocytes for SPS. 
If SPS recognition plays such a key role in lymphocyte migration and 
positioning, one would predict that endogenous SPS isolated from 
lymphoid tissue should bind to lymphocytes and in some way effect 
their recirculation behaviour. This chapter describes attempts to 
isolate and characterise the endogenous sulfated GAGs present in 
murine spleen and determine whether murine splenic lymphocytes 
carry cell surface receptors for any of these GAGs. 
3.2 RESULTS 
3.2.1 ISOLATION OF SPLENIC-GAGS 
Earlier studies have shown that murine lymphocytes carry cell surface 
receptors for SPS (Parish et al., 1984; 1988; Parish and Snowden, 
1985; Thurn and Underhill, 1986). To determine if there are 
endogenous SPS in murine spleen that bind to murine splenic 
lymphocytes, GAGs were first isolated from murine spleens (Section 
2.13; Figure 2.1 ). Briefly, homogenised spleens were delipidated by 
acetone extraction, deproteinised and GAG sidechains released by 
pronase digestion and then sulfated-GAGs precipitated by CPC. A high 
NaCl concentration (0.5M) was used during CPC precipitation to ensure 
that only sulfated GAGs were precipitated (i.e. no hyaluronic acid 
contaminated the preparation) and to minimise DNA contamination. 
TCA precipitation was then used to remove residual contaminating 
DNA and peptides and finally, the 'crude' splenic-GAGs were 
precipitated with CPC and ethanol (Roden et al., 1972). With C57BL/6 
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mice, 1000 spleens produced 21 g of acetone extracted powder \vhich 
yielded 6.5 mg of 'crude' splenic-GAGs. Based on protein and 
DNA/RNA assays, the GAG preparation contained no detectable protein 
and contained less than 1 % RN A and DNA. 
The GAG composition of the 'crude' splenic-GAG preparation was 
assessed by chondroitinase ABC and AC digestion and nitrous acid 
treatment (Section 2.14 ). It was found that 84.5 + 16% of the 
preparation was chondroitinase ABC sensitive and 60.9 + 22% 
chondroitinase AC sensitive (Table 3 .1 ). Nitrous acid treatment, which 
selectively degrades heparan sulfate/heparin chains, destroyed <15% 
of the 'crude' splenic-GAG preparation. Since fluoresceinated and 
1251-labelled splenic-GAGs were used in subsequent binding studies 
(Section 3.2.2; 3.2.3) it was important to determine the composition of 
the labelled GAG preparation. It was found (Table 3 .1) that the 
majority of the labelled GAGs were chondroitinase ABC sensitive 
although substantially less was chondroitinase AC sensitive when 
compared with the unlabelled material. This suggests that dermatan 
sulfate in the preparation may have been more efficiently 
fluoresceinated than the chondroitin sulfates. Similarly, there 
appeared to be a somewhat higher proportion of nitrous acid sensitive 
GAGs in the labelled preparation. 
3.2.2 BINDING OF SPLENIC-GAGS TO SPLENOCYTES 
The isolated splenic-GAGs were radiolabelled with 125 I (Section 2.15) 
and their binding to C57BL/6 splenocytes assessed (Section 2.16). 
Figure 3.1 depicts a typical binding curve which is indicative of 
saturable binding. The data presented was corrected for non-specific 
binding by the inclusion of a 50-f old excess of unlabelled heparin as 
binding-inhibition experiments (Section 3.2.3) showed that heparin 
was a potent inhibitor of splenic-GAG binding. At all concentrations 
non-specific binding represented less than 15% of specific binding. 
The data when applied to a Scatchard plot (Figure 3.1 b) approached 
I,. 
Table 3.1 Effect of Different Degradative Procedures on Binding of 
Splenic-GAGs to Splenic Lymphocytes 
Degradation (0/o) 
Treatment Unlabelled Labelled Binding of labelled GAGs 
GAGsa GAGsb to splenocytes (0/o) c 
Nil - - 100±3.0 
Chondroitinase ABC 84.5 ± 16 60.3 130 + 4.3 
Chondroitinase AC 60.9 + 22 18.4 96 + 3.7 
Nitrous acid <15 30.9 56 + 3.7 
a Degradation of unlabelled GAGs monitored by a dimethylmethylene blue assay. Each data point is the mean of three replicates± standard errors. 
b Represents 1251-label associated with undegraded GAGs. Each data point represents a single determination. 
c Mean of three to six data points ± standard errors using 10 µg/ml of labelled GAGs. 
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Figure 3.1 Analysis of Binding of Radiolabelled 
Morine Splenic-GAGs to Murine Splenocytes. 
(a) Concentration dependence of binding of 125 I-splenic GAGs to 
splenocytes. The data shown have been corrected for nonspecific 
binding as defined by the amount of radioactivity associated with 
the splenocytes in the presence of a 50-fold excess of unlabelled 
heparin. Washing of cells was performed by centrifugation. The 
data shown are the mean of five replicates + standard errors of 
means. (b) Scatchard analysis of splenic-GAG binding data 
(correlation coefficient = 0.96) 
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linearity (correlation coefficient 0.96) with 139 + 15 ng of splenic-GAGs 
bound/106 cell. Subsequent kinetic studies demonstrated that the 
majority of binding occurred very rapidly ( < 5 min incubation) and 
most binding had occurred after 15 min of incubation (Figure 3.2a). 
Furthermore, bound GAGs were rapidly and effectively displaced by a 
150-fold excess of unlabelled heparin (Figure 3 .2b ). 
At this stage it was important to determine whether all splenocytes, 
or a distinct subpopulation were involved in splenic-GAG binding. In 
order to resolve this issue, splenocytes were reacted with 
biotinylated-GAGs (Section 2.18) and bound GAGs detected by 
immunofluorescent flow cytometry (Section 2.19) using an 
amplification procedure involving fluoresceinated avidin, rabbit anti-
avidin antibodies and fluoresceinated sheep anti-rabbit lg. Typical 
flow cytometry profiles are depicted in Figure 3 .3 and it is evident 
that, when compared with control binding, the majority of spleen cells 
bound the splenic-GAGs, although there may be a very small 
subpopulation of cells ( <2%) which exhibit high density binding. Flow 
cytometry profiles (not shown) revealed splenic-GAG binding at 
concentrations ranging from 0.8-100 µg/mL, data consistent with the 
binding assay depicted in Figure 3 .1 a. 
3.2.3 POLYSACCHARIDE SPECIFICITY OF SPLENIC-GAG 
BINDING 
A range of different polysaccharides were tested for their ability to 
inhibit the binding of 125 I-splenic GA Gs to spleen cells (Section 2.16). 
The inhibitory activity of these different polysaccharides and their 
relevant structural features are presented in Table 3.2. Splenic-GAG 
binding was almost completely inhibited (approx. 80%) by heparin, 
pentosan sulfate, fucoidan, dextran sulfate, "A- and t-carrageenan and 
partially inhibited (approx. 50%) by ic-carrageenan. Hyaluronic acid, 
chondroitin-4- and -6-sulf ate, dermatan sulfate, keratan sulfate and 
heparan sulfate (bovine kidney) had little or no effect on GAG binding. 
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Figure 3.2 Analysis of Binding of Radiolabelled 
Murine Splenic-GAGs to Splenocytes. 
(a) Time course of binding of 1251-splenic GAGs to splenocytes . 
Data was corrected for nonspecific binding as in Figure 3.1 and 
each data point is the mean of two replicates. (b) Reversibility of 
binding of 125 I-splenic GA Gs to splenocytes in the presence of 
either no competitor ( ) or a 150-f old excess of unlabelled 
heparin ( ). Each data point is the mean of three replicates ·+ 
standard error of means. All washing of cells was performed on 
the cell harvester . 
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Figure 3.3 . Ability of Biotinylated Splenic-GAGs 
to Bind to Murine Splenocytes as Quantified by 
Flow Microfluorometry. 
Biotinylated splenic-GAGs at 100 µg/mL (-); control profile (- -) 
representative of cell preincubated with second, third and fourth 
stage reagents. 
Table 3.2 Polysaccharide Inhibition of Binding 
of C57BL/6 Splenic-GAGs to C57BL/6 Splenic Lymphocytes 
Polysaccharide Major monosaccharides Moles/Disaccharide Mean percentage 
Carboxyl group Sulfate groups control binding 
Nil - - - 100 ± 5.4 
Hyaluronic acid GlcUA GlcNAc 1.0 0 84.1 ± 1.9 
Chondroitin-4-sulfate GlcUA GalNAc 1.0 1.0 97.9 + 2.2 
Chondroitin-6-sulfate GlcUA GalNAc 1.0 1.0 101 + 1.0 
Dermatan sulfate GlcUA GalNAc ldUA 1.0 1.0-2.0 96.0 + 1.5 
Keratan sulfate Gal GlcNAc 0 1.0-2.0 89.7 + 4.7 
Heparan sulfate GlcUA GlcNAc ldUA 1.0 1.0-2.0 82.1 ± 6.1 
Fucoidan L-Fuc 0 2.0 12.7 ± 1.0 
0\ 
N 
Pentosan sulfate 0-Xyl 0 4.0 12.1 + 1.0 
Dextran sulfate 0-Glc 0 4.6 18.0 + 0.8 
1e-carrag ee nan 0-Gal 0 1.0 46.7 + 1.9 
A-carrageen an 0-Gal 0 3.0 18.9 + 0.5 
1-carrageenan D-Gal 0 2.0 28.0 + 1.0 
Heparin GlcUA GlcNAc ldUA 1.0 2.0-3.0 17.9 ±1.3 
Heparin, high affinitya GlcUA GlcNAc ldUA 1.0 2.0-3.0 16.0 + 1.4 
Heparin, low affinitya GlcUA GlcNAc ldUA 1.0 2.0-3.0 19.3 + 0.9 
Each percentage is the mean of three data points ± standard errors. 
a Heparin separated into fractions with high and low affinity for antithrombin Ill. 
• 11,.. 
63 
Figure 3 .4 depicts the ability of hyaluronic acid, chondroitin-4-sulfate, 
K-carrageenan and heparin at a range of concentrations ( 1.6-200 
µg/mL) to inhibit splenic-GAG binding. Heparin was a potent inhibitor 
of GAG binding, inhibiting binding by 85-90% at high concentrations. 
Furthermore, heparin fractions with either high or low affinity for 
antithrombin III were equally effective at inhibiting GAG binding. In 
contrast, hyaluronic acid and chondroitin-4-sulfate had little effect on 
GAG binding even at the highest concentrations tested whereas K-
carrageenan exhibited an intermediate inhibition profile, partially 
inhibiting (50-60%) GAG binding to murine spleen cells. 
3.2.4 CHARACTERISATION OF SPLENIC-GAGS WHICH BIND 
TO SPLENOCYTES 
Chondroitinase digestion of the splenic-GAG preparation demonstrated 
that the majority of the GAGs belonged to the chondroitin sulfate 
family (Section 3.2.1; Table 3.1). It was important, therefore, to 
determine whether chondroitinase ABC and AC digestion had any 
effect on the binding of splenic-GAGs to murine splenocytes. It was 
found (Table 3 .1) that chondroitinase AC digestion had no effect on 
GAG binding (i.e. 96 + 3.7% of control binding following enzyme 
treatment) whereas chondroitinase ABC digestion actually resulted in 
a significant increase in binding (i.e. 130 + 4.3 % of control binding 
following digestion). Similarly RNase and DNase digestion of the GAGs 
had no effect on binding (data not shown). In contrast, nitrous acid 
treatment resulted in a substantial reduction in GAG binding (i.e .. 56 + 
3.7% of control binding following treatment). These data indicate that 
a subpopulation of splenic-GAGs interacts with murine spleen cells 
and the relevant GAGs were not chondroitin sulfates but probably 
belong to the heparan sulfate/heparin family. 
To further characterise the chondroitinase ABC resistant GAGs the 
radiolabelled splenic-GAG preparation was chondroitinase ABC 
digested prior to application and fractionation on a DEAE-Sepharose 
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Figure 3.4 Inhibition of Binding of 12 5 I-Sp I en i c 
GAGs to Splenocytes using Unlabelled GAGs. 
Unlabelled GA Gs used were hyaluronic acid ( * ), chondroitin-4-
sulfate (• ), K-carrageenan (..i.) and heparin (a). Results are 
expressed as the percentage of splenic-GAGs binding in the 
absence of inhibitor. Washing of cells was performed on the cell 
harvester. Each data point is the mean of two replicates. 
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column (Section 2.17). The fractionation profile was compared with 
that obtained for undigested splenic-GAGs (Figure 3.5). With the 
undigested GAG preparation the bulk of the radioactivity was eluted 
at >0.6 M NaCl. As was previously observed a large proportion of the 
splenic-GAG preparation was destroyed by chondroitinase ABC 
digestion (Figure 3.5b). However, the remaining radioactivity was 
eluted from the DEAE-Sepharose column over a wide range of NaCl 
concentration. Column fractions were then screened for their content 
of GAGs which bound to splenocytes (Figure 3.5c). In order to 
expedite the screening procedure column fractions were collected into 
seven pools (Pools I-VII) each containing 20 fraction. Pools I-IV from 
both column runs contained little or no splenic-GAGs which bound to 
splenocytes. In contrast, Pools V, VI and VII contained material 
(eluted at >0.6 M NaCl) which bound to murine splenocytes, Pool VII 
(>0.9 M NaCl) containing the most activity and enrichment of binding 
activity occurring in pools from the chondroitinase ABC digested 
preparation. 
To characterise further the splenic-GAGs present in the eluted 
material, Pools I-VII of both untreated and chondroitinase ABC 
treated samples were analysed by SDS-PAGE (Section 2.21 ). In Pools 
V-VII from both untreated and chondroitinase treated samples, 
radiolabelled material was detected throughout the gel, a pattern 
characteristic of the polydispersed nature of GAGs (Figure 3.6a and b). 
Nevertheless, chondroitinase digestion tended to destroy the high MW 
material (>200 kDa) and enriched for low MW GAG sidechains close to 
the dye front, particularly in Pools VI and VII. Subsequent nitrous 
acid treatment (Figure 3 .6c) resulted in total elimination of the 
chondroitinase resistant material in Pools IV-VII indicating that the 
residual GAGs were heparan sulfate/heparin in nature. Additional 
SDS-PAGE runs on 15% gels revealed that the mean MW of 
chondroitinase ABC resistant GAGs in Pools VI and VII was 
approximately 50 kDa (range 10-50 kDa) (data not shown). It should 
be emphasised that this estimate is somewhat arbitrary due to the use 
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Ion Exchange Chromatography of an 
GAG Preparation. 
An 1251-Splenic GAG preparation either untreated or digested 
with chondroitinase ABC, was applied to a DEAE Sepharose CL6B 
column and eluted with a 0.25-1.0 M NaCl gradient in 10 mM 
Tris-HCl buffer, pH 7.0. (a) Salt gradient generated during 
column run. (b) Radioactivity detected in different column 
fractions with untreated (--) or chondroitinase ABC digested 
(- -) splenic-GAGs. Fractions were collected into Pools I-VII as 
indicated. (c) Ability of radioactive material in Pools I-VII to 
bind to murine splenocytes. The percent bound for untreated 
( [Zl ) and chondroitinase ABC treated ( ~ ) splenic-GAGs 1s given. 
Washing of cells was performed by centrifugation. 
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Figure 3.6 SDS-PAGE Analysis of 125I-Splenic 
GAG Pools Isolated by Ion Exchange 
Chromatography. 
(a) Pools I-VII from untreated splenic-GAGs. Exposure time 24 h. 
(b) Pools I-VII from chondroitinase ABC treated splenic-GAGs. 
Exposure time, 7 days. (c) Pools IV-VII from chondroitinase ABC 
treated splenic-GAG which were either nitrous acid digested ( +) or 
untreated (-). Exposure time, 7 days. The position of molecular 
weight markers is indicated in kDa. 
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of protein rather than defined polysaccharide standards when 
determining the GAG molecular weights. 
3.3 DISCUSSION 
This chapter describes attempts to isolate and characterise sulfated-
GAGs from murine spleen which could be involved in controlling the 
migration and positioning of murine splenic lymphocytes. A 
procedure was devised for isolating sulfated-GAGs from murine 
== ---= 
spleen in good yield and high purity (Figure 2.1; Section 2.13) and the 
resultant GAG preparation was used in subsequent binding studies. It 
was found that isolated splenic-GAGs bound to murine splenocytes 1n 
a saturable (Figure 3 .1 a), rapid (Figure 3 .2a) and reversible (Figure 
3 .2b) manner, characteristics consistent with a cell surface receptor of 
high affinity and specificity. Further analysis of the splenic-G AG 
preparation revealed that a small subpopulation of the GAG molecules 
bound to spleen cells. The reactive GAGs were chondroitinase ABC 
resistant and nitrous acid sensitive, properties consistent with 
polysaccharides belonging to the heparan sulfate/heparin family. 
Furthermore, immunofluorescent flow cytometry studies 
demonstrated that the majority of murine splenic lymphocytes 
express binding sites for the relevant splenic-GAGs. 
It should be noted that nitrous acid treatment of the 'crude' splenic-
GAG preparation reduced binding to spleen cells by only 44% (Table 
3.1). However, subsequent studies revealed that GAGs present in 
DEAE column fractions highly enriched for binding activity were 
entirely nitrous acid sensitive as judged by SDS-PAGE analysis (Figure 
3.6). This discrepancy may be due to nitrous acid producing small 
fragments (for example tetra/pentasaccharides) which are not 
detected by SDS-PAGE but still retain some binding activity. 
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Based on the data presented an estimate can be made of the binding 
affinity of the lymphocyte receptors for splenic-GAGs. Since probably 
only 15% of the splenic-GAG preparation was involved in binding and 
assuming a mean MW of the GAGs of 50 kDa, the binding sites on 
spleen cells have an apparent affinity constant of 5 x 10-8 M. This 
affinity is 50-fold higher than the affinity of the interaction between 
heparin and antithrombin III (Lindahl and Hook, 1978). 
Some interesting features of the splenocyte/splenic-GAG interaction 
were revealed by the binding inhibition studies (Table 3.2, Figure 3.4). 
Firstly, out of 13 polysaccharides tested, only seven (heparin, 
fucoidan, pentosan sulfate, dextran sulfate, ic-, A- and t-carrageenan ) 
inhibited binding (Table 3.2). Charge density alone cannot account for 
the binding inhibition observed as chondroitin-4- and -6-sulfate and 
dermatan sulfate have a higher charge density than ic-carrageenan 
and yet only the latter polysaccharide inhibited binding. Similarly t-
carrageenan and fucoidan inhibited binding, whilst the chondroitin 
sulfates (of similar charge density) did not. Secondly, minor changes 
in the sulfation pattern of the polysaccharides had substantial effects 
on inhibitory activity as ic- and t-carrageenan, which differ only in the 
number of sulfates per disaccharide ( one and two, respectively), 
showed significant differences in their ability to inhibit GAG binding. 
Thirdly, the observation that ic-carrageenan only partially inhibited 
splenic-GAG binding suggests that splenocytes may contain more than 
one type of binding site on their cell surface, one site not reacting with 
ic-carrageenan and the other site reacting with all seven inhibitory 
polysaccharides. Similarly, diversity of binding sites for SPS has been 
detected on murine thymocytes (Parish et al., 1988). Fourthly, 
heparin fractions with either high or low affinity for antithrombin III 
exhibited similar inhibitory activity indicating that the antithrombin 
III binding site on heparin plays little or no role in splenocyte 
binding. 
Although the splenic-GAGs which bind to lymphocytes appear to 
belong to the heparan sulfate/heparin family it is interesting to note 
--
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that heparan sulfate isolated from bovine kidney did not inhibit 
splenic-GAG binding. This observation is not particularly surprising as 
heparan sulfates exhibit great structural diversity, earlier studies 
suggesting that theoretically 1o36 types of heparan sulfate could 
occur in animal tissues (Dietrich et al., 1983 ). Presumably therefore , 
bovine kidney heparan sulfate, which is less sulfated than heparin , 
does not contain the correct positioning of sulfates for binding to 
occur. In this context, cell surface receptors which can distinguish 
subtle changes in the structure of SPS have been detected on a range 
of cell types such as lymphocytes (Parish et al., 1988; Parish and 
Snowden, 1985), macrophages (Chong and Parish, 1986), endothelial 
cells (Glabe et al., 1983b) and neurones (Vidovic et al., 1986). 
3.4 SUMMARY 
Previous studies have shown that lymphocytes carry cell surface 
receptors for SPS and SPS recognition may play a role in lymphocyte 
migration and positioning in vivo. This chapter describes attempts to 
isolate and characterise the endogenous GAGs of murine spleen and 
determine whether splenic lymphocytes carry cell surface receptors 
for these GAGs. 
A procedure was devised for isolating GAGs from mur1ne spleen 1n 
good yield and high purity and the GAG preparation was then 
radiolabelled for subsequent binding studies. It was found that the 
splenic-GAGs bound to murine splenocytes in a saturable, rapid and 
reversible manner with only a small subpopulation of the splenic-GAG 
preparation being involved in binding. This reactive species was 
chondroitinase ABC resistant and nitrous acid sensitive, indicative of a 
heparan sulfate/heparin-like molecule. Furthermore, using 
immunofluorescent flow cytometry studies it was demonstrated that 
the majority of spleen cells have receptors for these GAGs. 
.. 
'I 
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Subsequent ion exchange fractionation and SDS-PAGE analysis of 
chondroitinase ABC resistant GAGs confirmed that the splenic-GAG 
recognised by splenocytes was a heparan sulfate/heparin molecule of 
approx. 50 kDa with a binding affinity to splenocytes of approx. 5 x 
1 o-8 M. 
Additional binding inhibition studies indicated two possible binding 
sites for splenic-GAGs on the splenocyte surface, one being fully 
inhibited by a range of SPS such as heparin (both coagulant and 
anticoagulant forms), pentosan sulfate, fucoidan, dextran sulfate, "A-
and 1-carrageenan, and the second being partially inhibited by K-
carrageenan. 
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4.1 INTRODUCTION 
A vast amount of literature has been published recently on the 
identification and characterisation of cell surface antigens on 
lymphocytes particularly those involved in cellular adhesion events 
and lymphocyte recognition processes (Table 1.1, 1.2). Some of these 
molecules, such as MEL-14 and CD44, have been implicated in 
lymphocyte migration and in particular, appear to play a role in the 
interaction of lymphocytes with HEV (Section 1.6.1 ). However, despite 
such findings, the endogenous ligands for many of these molecules are 
unknown. In this context, a large body of data suggests that 
carbohydrate recognition systems may play a role in many forms of 
cell adhesion and lymphocyte migration (Section 1.7). Evidence for 
this includes the modification of lymphocyte migration by 
carbohydrate modifiers such as glycosidases, periodate and 
swainsonine ( Section 1. 7 .1); by lectins ( Section 1. 7 .2) and 
polysaccharides (Section 1. 7 .3 ). 
Following the demonstration that splenocytes interact with 
endogenous splenic-GAGs in a highly avid and specific manner 
(Chapter 3), this chapter describes attempts to identify and 
characterise defined molecules on the lymphocyte surface which 
interact with these GAGs. Of particular interest was whether well 
characterised cell surface molecules, particularly those implicated 1n 
lymphocyte migration, bind GAGs. 
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4.2 RESULTS 
4.2.1 IDENTIFICATION OF GAG-BINDING PROTEINS ON THE 
SURFACE OF LYMPHOCYTES 
Initially three approaches were used to detect receptors for GAGs on 
the surf ace of lymphocytes. Firstly, binding studies such as those 
described in Chapter 3, were performed where 1251-labelled GAGs 
were bound to murine lymphocytes and the binding data assessed. 
This approach gave a gross indication of whether GAG-binding 
molecules were present on the lymphocyte surface. Secondly, GAG-
coupled erythrocytes were examined for their ability to form rosettes 
with murine lymphocytes. As with the binding studies using 
radiolabelled GAGs, this approach only gave a gross assessment of the 
presence or absence of cell surface receptors for GAGs. Nevertheless, 
rosetting assays have the advantage that, due to multipoint binding of 
erythrocytes, they are much more sensitive than binding assays using 
radiolabelled GAGs. Furthermore, with a rosetting procedure the 
percentage of lymphocytes carrying receptors for a particular GAG can 
be assessed. Thirdly, the molecular nature of cell surface receptors 
for GAGs was determined by binding 1251-cell surface labelled lysates 
of lymphocytes to immobilised GAGs and characterising bound 
molecules by SDS-PAGE. This approach could be used to identify 
specific cell surf ace receptors for GAGs on splenocytes and 
thymocytes. 
A range of polysaccharides, namely, hyaluronic acid, chondroitin-4-
sulfate, chondroitin-6-sulf ate, dermatan sulfate, keratan sulfate, 
heparin and heparan sulfate were radiolabelled with 125 I (Section 
2.15) and their binding to splenocytes assessed (Section 2.16). The 
data presented in Figure 4.1 depicts the binding of 1251-labelled 
heparin and 1251-labelled chondroitin-4-sulfate to splenocytes and 
was corrected for non-specific binding by the presence of a 50-fold 
excess of unlabelled heparin or chondroitin-4-sulfate, respectively. 
GI 
' I 
600 
500 
-O> 
C: 400 
-
-0 
C: 
:J 
0 
co 300 
-C: 
:J 
0 
E 200 < 
100 
0 
0 5 1 0 15 20 25 30 35 40 45 50 
Concentration of GAGs (}Jg/ml) 
Figure 4.1 Analysis of Binding of 1251 Labelled 
GAGs to Morine Splenocytes 
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Concentration dependence of binding of 125 I labelled chondroitin-
4-sulf ate (.6.) and heparin (•) to murine splenocytes. The data 
shown have been corrected · for nonspecific binding by subtracting 
the amount of radioactivity bound in the presence of a 50-fold 
excess of unlabelled GAG. Each data point is the mean of three 
replicates + standard error. 
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The binding of heparin to splenocytes shows a typical binding curve 
indicative of saturable binding and is similar to that observed for the 
binding of endogenous splenic-GAGs to splenocytes (Figure 3.la). A 
Scatchard plot of data (not shown) indicated that the line approached 
linearity ( correlation coefficient 0.81) with approx. 9 .1 x 106 
molecules of heparin bound to the surf ace of each splenocyte ( 151 ng 
heparin/106 cells) with a binding affinity of approx. 1.1 x 10-6 M 
(assuming a MW of 104 for heparin). Non-specific binding of heparin 
(where a 50 fold excess of unlabelled heparin was included in the 
incubation mixture) was found to be <15% of specific binding. 
In contrast, there was much less binding of 125 I-labelled chondroitin-
4-sulf ate to splenocytes and specific binding was too low for Scatchard 
analysis. It should be emphasised however, that the binding assay 
was found to be relatively insensitive due to the high non-specific 
binding of radiolabelled polysaccharides. This non-specific component 
of the binding reaction was determined by the inclusion of a 50 fold 
excess of unlabelled polysaccharide in the incubation mixture. For 
example, in the case of chondroitin-4-sulfate it was calculated that 
maximum non-specific binding at 50 µg/mL was 3.4 x 105 
molecules/cell and similar non-specific binding was observed with 
hyaluronic acid, chondroitin-6-sulfate, dermatan sulfate, keratan 
sulfate and heparan sulfate. This implied that to calculate accurately 
the binding affinities of GAGs to lymphocytes, under saturating 
conditions much greater than 3.4 x 105 molecules of 125I-labelled 
GAGs would need to be bound to each cell. Obviously in the case of 
heparin and endogenous splenic-GAGs, where large numbers of 
molecules bound to the splenocyte surf ace ( 4.2 x 106 and 9 .1 x 106 
molecules respectively), this assay is feasible. However, when <3.4 x 
10 5 polysaccharide molecules bound to the surf ace of each cell 
another method needed to be employed to detect GAG receptors. Thus 
in order to detect relatively low numbers of GAG receptors on 
lymphocytes the rosetting approach was used. 
411 
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The rosetting of murine lymphocytes to PS-coupled SRBC was carried 
out as described in Section 2.7. Results of this assay presented in 
Table 4.1 indicate that between 20% and 90% of lymphocytes express 
receptors for GAGs. Both splenocytes and thymocytes carried 
receptors for hyaluronic acid, chondroitin-4-sulfate, chondroitin-6-
sulfate and heparin although differences were seen between the 
percent rosetting for thymocytes and splenocytes with different GAGs. 
For example, only 21 % of thymocytes expressed receptors for 
hyaluronic acid whereas 62% of splenocytes expressed receptors for 
this non-sulfated GAG (Table 4.1). In contrast, a high proportion (82-
90%) of both splenocytes and thymocytes rosetted with heparin-
coupled erythrocytes. Thus, the rosetting studies indicate that 
lymphocytes express receptors for all classes of GAGs, although 
binding studies with radiolabelled heparin imply that there are 
substantially more binding sites on the lymphocyte surf ace for 
heparin than for the other GAGs. 
Table 4.1 Rosetting of Lymphocytes from 
Thymus and Spleen with GAG-Coupled Sheep 
Erythrocytes 
GAG 
Hyaluronic acid 
Chondroiti n-4-su If ate 
Chondroitin-6-sulfate 
Heparin 
Spleen 
62.3 + 2.9 
62.7 ± 1.9 
72.3 + 4.2 
82.0± 1.7 
Each value is the mean of three replicates± standard errors. 
Rosettes (0/o) 
Thymus 
21.0 + 1.5 
54.3 ± 3.2 
64.3 + 1.2 
90.3 + 0.3 
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In an attempt to characterise GAG binding molecules on the surface of 
lymphocytes 125 I-labelled cell surface molecules were bound to a 
variety of GAGs (hyaluronic acid, chondroitin-4-sulfate, chondroitin-6-
sulfate, dermatan sulfate, heparan sulfate, endogenous splenic-GAGs 
and heparin) immobilised on CMC fibres (Section 2.9, 2.10) and the 
bound molecules characterised by SDS-PAGE. The results of such an 
analysis are shown in Figure 4.2 and indicate that a number of 
molecules on the surface of splenocytes and thymocytes bind to GAGs. 
Murine splenocytes were seen to express at least 10 distinct GAG-
binding molecules with a wide range of molecular masses (i.e. , approx. 
10-20, 33, 40, 60, 90 and 100 kDa). However, each GAG bound to a 
unique profile of cell surface molecules (Figure 4.2; Table 4.2). For 
example, chondroitin-4-sulf ate bound predominantly to molecules 
with molecular masses of 10-20, 33 and 90 kDa whereas chondroitin-
6-sulfate bound additional molecules of 40 and 60 kDa. The reactivity 
of particular molecules also varied between GAGs, for example a 90 
kDa protein on splenocytes reacting strongly with chondroitin-4-
sulfate and chondroitin-6-sulfate, moderately with dermatan sulfa te 
and weakly with hyaluronic acid and heparan sulfate (Table 4.2). 
Furthermore, differences were seen between the splenocyte and 
thymocyte receptor profiles, the latter expressing a similar pattern of 
cell surface molecules which bound to each GAG but with additional 
molecules at 190 and 250 kDa when compared with spleen . The very 
prominent 90 kDa GAG-binding molecule which was detected on the 
thymocyte and splenocyte surf ace will be characterised in detail in 
Chapter 5. However, the binding data presented in Figure 4.2 suggests 
that the 90 kDa GAG-binding protein differs in its GAG specificity 
between thymus and spleen. 
Finally, the molecules which bound to endogenous splenic-GAGs 
include all the major GAG-binding proteins, namely molecules with 
molecular masses of approx. 10-20, 33, 40, 60, 90 and 100 kDa on 
splenocytes and additional molecules of 190 and 250 kDa on 
thymocytes. 
Figure 4.2 Analysis of 125I-Labelled 
Cell Surf ace Molecules Which Bind to 
GAGs 
Splenocyte 
Immobilised 
Bound molecules were run on a 8-18% gradient SDS-PAGE gel and 
gels were autoradiographed for two days except in the case of 
heparin-binding molecules where gels were exposed for one day. 
Molecular weight markers are indicated in kDa. 
HA=hyaluronic acid, Ch4S=chondroitin-4-sulfate, Ch6S=chondroitin-
6-sulfate, DermS=dermatan sulfate, HepS=heparan sulfate, 
GAG=endogenous splenic-GAGs, Hep=heparin. 
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Table 4.2 Summary of GAG-Binding Molecules 
on the Surface of Murine Splenocytes 
GAG GAG-binding molecule (kDa) 
10-20 33 40 60 90 
Hyaluronic acid + + tr 
Chondroitin-4-sulfate + + ++ 
Chondroiti n-6-sulfate + + + + ++ 
Dermatan sulfate + + tr + 
Heparan sulfate + + tr tr 
Splenic-GAGs + + ++ ++ ++ 
Heparin + + ++ ++ ++ 
- = no detectable binding, tr= trace binding, + = binding, ++ = strong binding 
4.2.2 CHARACTERISATION OF GAG RECEPTORS ON 
SPLENOCYTES 
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To determine if any of the cell surface molecules which bound to GAGs 
corresponded to known lymphocyte cell surf ace antigens and 
especially those involved in cell adhesion events, immunoprecipitation 
studies were performed on heparin-binding molecules isolated from 
1251-labelled splenocyte lysates (Section 2.20). Heparin-binding 
molecules were obtained by binding 125 I-labelled splenocyte lysates 
to heparin immobilised on CMC fibres and eluting bound molecules 
with 2 M NaCl (Section 2.9, 2.10). Preparations of heparin-binding 
molecules were used as they contained all GAG-binding molecules 
detected (Table 4.2; Figure 4.2). 
The mAbs tested are listed in Table 2.1 and some typical 
immunoprecipitation results are depicted in Figure 4.3. The MEL-14 , 
Ly-2, FcR, CD3, ThB, Ly-5, Ly-15, Pgp-1 and Thy-1 cell surface 
antigens were all immunoprecipitated from 1251-Iabelled splenocyte 
lysates with corresponding molecular masses of approx. 95 (MEL-14 ), 
36 and 38 (Ly-2), 48-68 (FcR), 41 (CD3), 12-20 (ThB), 190-210 (Ly-5), 
Figure 4.3 Ability of Different Splenocyte Cell 
Surface Antigens to Bind to Immobilised Heparin 
Each mAb was used to monitor the presence of radiolabelled 
antigen in either an unfractionated splenocyte lysate or 125 I-
labelled splenocyte molecules eluted from heparin-CMC fibres. 
Monoclonal antibodies were bound to sheep anti-rat coupled (a and 
b), protein A coupled (c and d) or protein G coupled (e) Sepharose 
4B. Exposure times varied from 7, 22, 1, 4 and 6 days for a, b, c, d 
and e respectively. Molecular weight markers are indicated in kDa. 
200-
116-
93-
66-
45-
31-
22-
14-
200-
45-
31-
22-
14-
Lysate 
Lysate a) 
c) Hep-Binding 
Hep-Binding 
d) 
200-
11~-9 -
66-
45-
31-
22-
14-
b) 
Thy-1 
0 
? 
uo "~ 
e) 
75 
100 and 182 (Ly-15), 96 (Pgp-1) and 27 kDa (Thy-1). These values 
correspond reasonably well with previously published values. 
The mAbs against MEL-14, Ly-2, FcR and CD3 cell surface antigens 
were rat lgs and therefore, immunoprecipitations were performed 
with sheep anti-rat lg beads. Although extensive preincubation steps 
were perf armed (Section 2.20) to reduce the binding of radio labelled 
mouse lg to the sheep anti-rat lg beads, due to residual cross 
reactivity of these beads, some binding of mouse lg still occurred, i.e., 
two heavy chain bands of approx. 66 and 80 kDa and one light chain 
band of approx. 29 kDa were observed in all immunoprecipitations 
involving sheep anti-rat lg beads (Figure 4.3a). Nevertheless, the 
mouse lg bands did not interfere with the interpretation of the 
immunoprecipitation results and, furthermore, these experiments 
revealed that the surf ace lg on murine splenocytes does not bind to 
heparin. In the case of the immunoprecipitations performed with 
Protein A and Protein G beads, non-specific binding of labelled 
material was not a problem. There was however, a small amount of 
non-specific binding of the 90 kDa molecule to Ly-15 mAb-coupled 
beads. 
Results depicted in Figure 4.3 show that the 1251-labelled GAG-
binding molecules did not correspond to any of the cell surf ace 
antigens tested, with the exception of the Ly-2 antigen which weakly 
bound to heparin fibres, i.e. in order to clearly discern the Ly-2 
immunoprecipitated from the heparin eluate, the autoradiograph had 
to be exposed three times longer than the control (lysate) 
i m 1n u no pre c i pit ate. 
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4.3 DISCUSSION 
This chapter describes attempts to isolate and characterise receptors 
for GAG molecules on the splenocyte and thymocyte surface. 
Studies reported in this chapter using radiolabelled GAGs 
demonstrated that the binding of heparin to splenocytes showed a 
typical saturable binding curve (Figure 4.1) with a large number of 
binding sites for heparin (9.1 x 106 heparin molecules bound/cell) 
estimated to be present on the splenocyte surface. However these 
binding studies were not sensitive enough to determine the binding 
characteristics of other GAG molecules to the splenocyte surface. The 
binding affinity for heparin was calculated to be 1.1 x 1 o-6 M, 
(assuming a MW of 104 for heparin) which indicates a less avid 
interaction than that demonstrated previously for endogenous 
splenic-GAGs to splenocytes (5 x 10-8 M; Section 3.2.2). In this 
context it should be noted that heparin-like molecules in the splenic-
GAG preparation were the major binding species (Section 3.2.4). Thus, 
it appears that the heparin-like GAGs in murine spleen have unique 
structural features which result in more avid recognition by murine 
splenocytes, a property not unexpected for an endogenous ligand. 
Both rosetting studies (Table 4.1) and receptor profiles (Figure 4.2) 
provided more sensitive assays for assessing GAG-binding and these 
demonstrated that splenocytes and thymocytes have receptors for all 
GAGs tested. Rosetting studies showed that between 20% and 90% of 
lymphocytes express receptors for GAGs. Splenocytes were found to 
possess a unique family of cell surface molecules which reacted with 
each GAG (hyaluronic acid, chondroitin-4-sulfate, chondroitin-6-
sulfate, dermatan sulfate, heparan sulfate, heparin and endogenous 
splenic-GAGs), an observation which was much less evident with 
thymocytes. For example, a 33 kDa splenocyte molecule did not bind 
to dermatan sulfate and heparan sulfate but bound all other GAG 
species. Similarly, a 60 kDa molecule bound to all species of GAGs 
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except chondroitin-4-sulfate and hyaluronic acid. Furthermore, 
differences were seen in the intensity of the reaction of certain 
splenocyte molecules with different GAGs (Figure 4.2; Table 4.2). This 
indicates that the interaction between particular GAGs and their 
receptors on the lymphocyte surf ace is very precise. 
An interesting feature of the reactivity profile of GAG receptor 
molecules is the differences seen between GAG receptors on 
thymocytes and splenocytes. Thymocytes displayed a similar pattern 
of cell surface molecules which bound to each GAG when compared to 
that seen for splenocytes. This would be as expected, for thymocytes 
constitute a relatively homogeneous population of T cells which have 
not yet begun the process of migration to the peripheral lymphoid 
organs (Section 1.2). Splenocytes, on the other hand, are a 
heterogeneous population of cells including migrating and non-
migrating T and B lymphocytes and a small subpopulation of non-
lymphoid cells (Section 1.2.2) and so would be expected to express a 
variety of GAG receptors some of which are possibly involved in 
lymphocyte migration processes. 
Another interesting feature of thymocytes is the presence of GAG-
binding molecules of approx. 190 and 250 kDa which reacted with all 
GAG species tested. These GAG-binding molecules were not detected 
on the surface of splenocytes. The 190 kDa thymocyte molecule is 
probably the cell surface antigen T200 or Ly-5, which has been shown 
previously to bind SPS (Parish et al., 1988a) whereas the identity of 
the 250 kDa molecule is unknown. 
Endogenous splenic-GAGs isolated from murine spleen which bound 
avidly and specifically to splenocytes (Section 3 .2.2, 3 .2.3 ), bound a 
similar profile of GAG-binding molecules (Figure 4.2) to that observed 
for heparin and heparan sulfate (although the latter expressed a 
weaker binding pattern). This is in agreement with previous results 
(Section 3.2.4) where endogenous splenic-GAGs which bound to 
murine splenocytes were characterised as belonging to the 
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heparin/heparan sulfate family of GAGs and would therefore be 
expected to bind to similar cell surf ace molecules as heparin and 
heparan sulfate. 
Immunoprecipitation studies with a limited number of mAbs were 
used to try and identify the GAG-binding molecules on splenocytes. It 
was found that with one exception the heparin-binding molecules did 
not correspond to any of the cell surface antigens tested and, in 
particular, molecules associated with cell adhesion such as MEL-14, 
Ly-15 and Pgp-1 (Table 1.1 ). The exception was a heparin-binding 
molecule of approx. 40 kDa which was identified as possibly Ly-2. Of 
particular interest was the finding that the very prominent 90 kDa 
molecule did not correspond to MEL-14, Ly-15 ~-chain or Pgp-1, all of 
which had been considered as possible candidates due to their 
molecular masses being approx. 90 kDa. 
Interestingly, splenocyte Ly-5 did not bind heparin although as 
mentioned previously, the thymocyte form binds to a range of SPS 
including fucoidan, dextran sulfate and heparin (Parish et al., 1988). 
This is probably due to the presence of different structural types of 
Ly-5 produced on different cell types, obviously only some of which 
can bind GAGs. 
The Ly-5 family (also called CD45, T200, B220 and leukocyte common 
antigen family) is a group of glycoproteins expressed on the surface of 
all mammalian lymphoid and myeloid cells. Members of this family 
differ in their polypeptide and carbohydrate structures which are 
expressed differently according to cell type. Variations in N-terminal 
peptide sequence are coded for by up to three alternately transcribed 
exons, designated Ex-4, 5, and 6 potentially giving rise to eight distinct 
forms of mRNA containing O to 3 of these exons (Chang et al., 1989), 
six of which have been isolated so far (Thomas, 1989). For example, 
thymocytes express the lowest molecular mass form of 180 kDa ( do 
not contain Ex-4, 5 or 6), B cells the highest 220 kDa form (containing 
Ex-4, 5 and 6) and mature T cells multiple forms (Thomas, 1989; Tung 
I 
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et al., 1984). Also differences exist in Ly-5 structure due to the state 
of activation of the T cell. Therefore differences in the heparin-
binding capacity of the Ly-5 molecules on splenocytes and thymocytes 
is not surprising for these lymphocytes carry different forms of Ly-5 
on their surf ace. In fact, it appears that the 180 kDa form on 
thymocytes which lacks the three N-terminal exons is the heparin-
binding species. 
It was also demonstrated that the Thy-1 antigen on mur1ne 
splenocytes did not bind to any of the GAGs tested (Section 4.2.2). 
However, there is evidence that this molecule does in fact bind to 
some other SPS such as dextran sulfate and fucoidan (Parish et al., 
1988a), which were not tested. Obviously, the endogenous sulfated 
ligand for this molecule remains to be identified. 
Finally, the detection of the very prominent 90 kDa GAG-binding 
protein on both thymocytes and splenocytes (Figure 4.2) posed an 
interesting problem, for prior studies performed by Parish et al. 
(1988a), where thymocyte 125 I-labelled GAG-binding molecules were 
examined, did not identify this molecule. This anomaly led to the 
studies performed in Chapter 5 where attempts were made to 
characterise further this molecule and thereby resolve the issue~ 
4.4 SUMMARY 
This chapter describes attempts to isolate and characterise GAG-
binding molecules on the lymphocyte surface. Initial binding studies 
with radiolabelled GAGs demonstrated that bovine lung heparin has a 
binding affinity to splenocytes of approximately 1.1 x 1 o-6 M. 
However, due to the large amount of non-specific binding incurred in 
this assay the binding affinities for other GAG molecules could not be 
calculated. 
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Rosetting studies with GAG-coupled red cells demonstrated that 
between 20% and 90% of lymphocytes express receptors for all the 
GAGs tested. Analysis of the binding of solubilised radiolabelled cell 
surface molecules to immobilised GAGs revealed that murine 
splenocytes express at least 10 distinct cell surf ace receptors for GA Gs 
(i.e., hyaluronic acid, chondroitin-4-sulfate, chondroitin-6-sulfate , 
dermatan sulfate, heparan sulfate, endogenous splenic-GAGs and 
heparin) with a wide range of molecular m.asses (approx. 10-20, 33 , 
40, 60, 90 and 100 kDa). Thymocytes express similar receptors for 
GAGs with additional receptor molecules of 190 and 250 kDa. Each 
GAG bound to a unique profile of cell surface molecules although 
splenocytes exhibited a much more heterogeneous binding pattern 
than thymocytes. Immunoprecipitation studies demonstrated that the 
GAG-binding molecules on splenocytes did not correspond to any of 
the cell surface antigens tested, namely MEL-14, FcR, CD3, ThB, Ly-5 , 
Ly-15, Pgp-1 and Thy-1, although some data suggested that Ly-2 may 
bind weakly to heparin. 
CHAPTER 5 : CHARACTERISATION OF A 
90 KDA GAG-BINDING MOLECULE ON MURINE 
LYMPHOCYTES : EVIDENCE FOR ASSOCIATION WITH 
THE LYMPHOCYTE SURFACE VIA AN 
INOSITOL PHOSPHATE RECEPTOR 
... 
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5.1 INTRODUCTION 
Earlier studies have demonstrated that GAGs can bind to the surface 
of lymphocytes (Parish et al., 1984, 1988; Parish and Snowden, 1985; 
Thum and Underhill, 1986), endothelial cells (Glabe et al., 1983b; 
Glimelius et al., 1978) and macrophages (Bleiberg et al., 1983; Chong 
and Parish, 1986) in a specific and saturable manner. However, very 
few studies have attempted to identify and characterise GAG-binding 
molecules on the cell surf ace. An exception was the detection and 
characterisation of a 56-70 kDa hyaluronic acid-binding protein 
expressed on the surf ace of heart fibroblasts (Turley, 1982; Turley et 
al., 1985). Similar studies by Parish et al. (1988) demonstrated that 
the T200 (Ly-5) antigen displayed on the surface of murine 
thymocytes is a heparin-binding protein. Additional experiments 
with a range of SPS revealed that the Thy-1 antigen on murine 
thymocytes interacts with sulfated carbohydrate structures such. as 
dextran sulfate (Parish et al., 1988), the dextran sulfate possibly 
mimicking the structure of an endogenous sulfated ligand recognised 
by Thy-1. Chapter 4 described detailed attempts to detect and 
identify GAG-binding molecules on the surface of murine 
lymphocytes. In the course of these studies, a 90 kDa GAG-binding 
protein was detected on the lymphocyte surf ace, this molecule being 
particularly prominent on thymocytes. Interestingly, this 90 kDa 
GAG-binding species was not detected in membrane preparations of 
murine thymocytes (Parish et al., 1988), an observation which 
suggested that the molecule is weakly bound to the lymphocyte 
membrane and was displaced during the membrane isolation 
procedure used. 
These observations led to the studies performed in this chapter, 
where attempts were made to further characterise the 90 kDa 
molecule with particular emphasis being placed on the mode of 
attachment and release of the molecule from the lymphocyte surf ace. 
... 
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5.2 RESULTS 
5.2.1 GENERAL PROPERTIES OF THE 90 KDA GAG-B INDING 
MOLECULE 
Studies described 1n Chapter 4 demonstrated that a 90 kDa molecule 
was one of the prominent cell surface proteins which interacted with 
GAGs. Before determining the mode of attachment of this molecule to 
the lymphocyte membrane, some general physicochemical properties 
of the protein were determined. 
Initially, the glycoprotein nature of the 90 kDa molecule was assessed 
by examining the reactivity of the protein with lectin affinity columns, 
i.e., Con A and lentil lectin Sepharose. Furthermore, since the 90 kDa 
molecule was a heparin-binding protein it could be related to FN and 
thus the ability of the molecule to bind to immobilised gelatin 
(gelatin-Sepharose) was determined. 
In these experiments two 1251-cell surface labelled splenocyte lysates 
which contained the 90 kDa protein were examined, namely 
radiolabelled molecules which bound and were eluted from either 
chondroitin-6-sulfate or heparin-coupled fibres. These molecules 
were reacted with Con A, lentil lectin or gelatin affinity columns 
(Section 2.10) and the resultant binding material analysed by SD S-
p AGE. The results of such a study (Figure 5 .1) showed that the 90 kDa 
GAG-binding molecule is a glycoprotein containing glucose and/or 
mannose residues, demonstrated by binding to Con A and lentil lectin, 
but it was not FN-like as it did not bind to gelatin. Furthermore, other 
heparin-binding proteins also bound to lentil lectin and especially Con 
A, although these were not generally seen as discrete bands on the 
gel. The exception is a heparin-binding molecule of approx. 200 kDa 
which bound to Con A Sepharose, the identity of which may be the 
T200 (Ly-5) antigen. Although this molecule was not seen previously 
in splenocyte lysates, its presence may relate to the activation state of 
.... 
Figure 5.1 Ability of GAG-Binding Proteins on the 
Surface of Murine Splenocytes to Bind to 
Immobilised Lectins and Gelatin 
Chondroitin-6-sulfate (Chond6S) or heparin-binding molecules 
(Heparin) isolated from 125 I-labelled murine splenocytes were 
bound to either Concanavalin A (Con A), lentil lectin (L Leet) or 
gelatin Sepharose 4B beads and bound material analysed by SDS-
P AGE and autoradiography. Exposure time was 5 days. The 
position of molecular weight markers is indicated in kDa. 
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lymphocytes in the spleen of the donor animals used in this 
experiment. 
The selective binding of the 90 kDa protein to lentil lectin was used as 
a purification procedure for subsequent isoelectric focussing studies. 
Isoelectric focussing (Section 2.22) of the 90 kDa GAG-binding protein 
produced a single band with a pl of 6.16 (Figure 5 .2 ). The ref ore, 
although the molecule interacts with polyanions such as chondroitin -
6-sulfate and heparin, it has an overall slightly negative charge at 
neutral pH. Thus, there may be regions of the protein rich in 
positively charged amino acids which facilitate heparin binding. 
5.2.2 MODE OF ASSOCIATION OF THE 90 KDA GAG-
BINDING MOLECULE WITH THE LYMPHOCYTE SURFACE 
Previous sections of this thesis have described the identification 
(Section 4.2.1) and partial characterisation (Section 4.2.2, 5.2.1) of the 
90 kDa GAG-binding molecule on the surface of lymphocytes. 
Interestingly, this molecule which was present on the thymocyte 
surface (Section 4.2.1 ), was not detected in membrane preparations of 
murine thymocytes (Parish et al., 1988), possibly due to the loss of the 
molecule during preparation of the thymocyte membranes. This 
suggested that the molecule may be weakly bound to the cell surface 
occurring as a peripheral rather than integral membrane protein. 
Experiments were therefore undertaken to investigate the mode of 
attachment of this molecule to the cell surf ace. 
Initially, 125 I labelled splenocytes and thymocytes were treated with 
the detergent Tween 40 as this detergent was used as the first step in 
the preparation of the thymocyte membranes used in earlier studies 
(Parish et al., 1988). Furthermore, to determine if the molecule was 
weakly attached to the cell surf ace via a peripheral linkage system 
such as an integrin-binding sequence, an ionic interaction and/or a 
phosphatidylinositol (PI) receptor, 125 I labelled lymphocytes were 
Figure 5.2 Isoelectric Focussing of the 90 kDa GAG-
Binding Protein 
The 90kDa protein was purified from an 125 I-labelled splenocyte 
lysate by binding and elution from heparin-coupled fibres followed 
by lentil lectin affinity chromatography. The isoelectric point was 
determined as 6.16 by the Phast Gel System when compared with 
pl standards as indicated. 
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84 
treated with RGDS, high salt concentrations or inositol hexaphosphate 
(phytic acid) respectively (Section 2.11 ). Previous studies have shown 
that inositol hexaphosphate releases peripheral cell surface molecules 
which are probably attached to the cell surf ace via a PI receptor 
(Carey and Evans, 1989). 
It was found that the 90 kDa GAG-binding molecule was released from 
the thymocyte (data not shown) and splenocyte surface by treatment 
of lymphocytes with high salt (2 M KCl) and the detergents Tween 40 
and Triton X-100 (Figure 5.3). Release of the molecule from the cell 
surface by Tween 40 treatment implies that lymphocyte membranes 
prepared using the Tween 40 procedure (Standring and Williams, 
1978) would be depleted of the 90 kDa GAG-binding protein. 
Furthermore, displacement of the 90 kDa protein by 2 M KCl indicates 
that the molecule is ionically attached to the cell surf ace. 
Further experiments confirmed the peripheral linkage of the protein. 
Although the 90 kDa GAG-binding molecule could not be displaced 
from the cell surface by the integrin-binding sequence RGDS ( 1 
mg/mL), it could be released from the splenocyte (Figure 5.3) and 
thymocyte (Figure 5 .4) surface with inositol hexaphosphate ( 10 mM). 
Therefore, the 90 kDa GAG-binding protein appeared to be attached to 
the lymphocyte surf ace by a PI receptor. Furthermore, it is evident 
that the 90 kDa GAG-binding protein is continually being released 
from the cell surf ace at a slow rate in PBS alone ( control tract; Figure 
5 .3) as would be expected with a loosely bound molecule. 
Following these findings, experiments were performed to further 
investigate the specificity of interaction between the putative PI 
receptor and the 90 kDa GAG-binding protein. Initially other possible 
PI receptor-bound proteins present on the splenocyte surface were 
identified by examining all proteins displaced from splenocytes by 
inositol hexaphosphate treatment. Preliminary data depicted in 
Figure 5 .5, showed that splenocytes have a number of proteins which 
are displaced from the cell surf ace by inositol hexaphosphate. These 
Figure 5.3 Release of 90 kDa GAG-Binding Protein 
from Splenocytes by Various Treatments 
Murine splenocytes were labelled with 125 I. and cell surface 
proteins were released by treatment with solutions containing 1 
mg/mL RGDS (.A.rg-Gly-Asp-Ser), 10 mM inositol hexaphosphate 
(phytic acid; PA), 2.5 M KCl, 2.5% Tween 40, 0.5% Triton X-100 or 
PBS (Cont). The released proteins were bound to heparin fibres 
prior to SDS-PAGE analysis. Exposure time of autoradiographs was 
4 days. Molecular weight markers are indicated in kDa. 
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Figure 5.4 Release of 90 kDa GAG-Binding Protein 
from Morine Thymocytes by Inositol 
Hexaphosphate Treatment 
NI urine thymocytes were labelled with 125 I and cell surface 
proteins were released by treatment with either 5 mM inositol 
hexaphosphate (phytic acid; PA) in PBS or PBS alone (Cont) and 
then released material bound to heparin fibres prior to analysis by 
SDS-PAGE. Exposure time of autoradiographs was 7 days. 
Molecular weight markers are indicated in kDa. 
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Figure 5.5 Analysis of Cell Surface Proteins 
Released from Splenocytes by Inositol 
Hexaphosphate Treatment 
Murine splenocytes were labelled with 125 I and cell surface 
proteins were released by treatment with either 5 mM inositol 
hexaphosphate (phytic acid; +PA) in PBS or PBS alone (-PA). The 
released proteins (Tot) and those proteins which bound to heparin 
fibres (Hep) were then analysed by SDS-PAGE. Exposure time of 
autoradiographs was 6 days. Molecular weight markers are 
indicated in kDa. 
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include an approximately 50 kDa protein and two high MW proteins of 
around 200 kDa. Two protein bands migrating at around 90 kDa were 
detected. These bands are probably an artifact as the carrier protein 
(BSA) used for acetone precipitation of radiolabelled molecules 
(Section 2.21) migrates in this region of the SDS-PAGE gel and appears 
to interfere with the migration of the 90 kDa band. This experiment 
needs to be repeated with other protein carriers in order to resolve 
this problem. Nevertheless, when inositol hexaphosphate released 
material was bound to heparin fibres the 90 kDa band was found to 
bind (Figure 5.5). 
Release of the 90 kDa GAG-binding protein from the cell surface by 
inositol hexaphosphate treatment was found to be very selective. A 
range of concentrations of inositol hexaphosphate were tested -for 
their ability to release the 90 kDa molecule from the splenocyte 
surface. It was found that at concentrations as low as 0.31 mM, 
inositol hexaphosphate released more than twice the amount of 90 
kDa protein (222% release of control) than PBS alone (Figure 5.6). 
Furthermore, inositol derivatives such as inositol hexasulf ate, inositol-
1-monophosphate and inositol-2-monophosphate at a concentration of 
5 mM displaced a much smaller amount of the 90 kDa GAG-binding 
molecules (187%, 199% and 98%, respectively of PBS control) when 
compared with inositol hexaphosphate release (724%; Figure 5.7). In 
fact, when compared with the PBS control, inositol-2-monophosphate 
did not significantly displace the 90 kDa molecule from the 
lymphocyte surface. 
5.2.3 REASSOCIATION OF THE 90 KDA GAG-B INDING 
MOLECULE WITH SPLENOCYTES 
Assuming that the 90 kDa GAG-binding molecule is attached to the 
lymphocyte surface by a PI receptor (an interaction which can be 
selectively displaced by inositol hexaphosphate) one would predict 
that the 90 kDa molecule could reassociate with splenocytes via this 
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Figure 5.6 Release of 90 kDa GAG-Binding Protein 
from Splenocytes by Inositol Hexaphosphate 
Murine splenocytes were cell surface labelled with 125 I and 
treated with different concentrations of inositol hexaphosphate 
(0.31, 1.25 and 10.0 mM PA) in PBS or PBS alone. Labelled 
molecules present in the cell supernatant were then resolved on 
SDS-PAGE and the amount of 90 kDa protein released, quantified 
by microdensitometry. The amount of 125 I labelled 90 kDa 
protein released by treatment of the cells with PBS alone was taken 
as 100%. 
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Figure 5.7 Release of 90 kDa GAG-Binding Protein 
from Splenocytes by Different Inositol Derivatives 
Murine splenocytes were cell surf ace labelled with 125 I and cell 
surface proteins were released by treatment with solutions of PBS 
containing 5 mM myo-inositol-hexasulfate (HS), DL-myo-inositol-1-
monophosphate (1-MP), myo-inositol-2-monophosphate (2-MP), 
inositol hexaphosphate (phytic acid; PA) or PBS alone ( control). The 
released proteins were bound to heparin fibres prior to SDS-PAGE 
and percent release of the 90 kDa protein was calculated by 
microdensitometry of autoradiographs. The amount of 125 I 
labelled 90 kDa protein released by treatment of the cells with PBS 
alone was taken as 100%. 
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receptor. In order to max1m1se this interaction, spleen cells were 
pretreated with inositol hexaphosphate to free the PI receptor of 
endogenous ligands. The 125 I-labelled 90 kDa GAG-binding protein 
released from the splenocyte surface by 5 mM inositol hexaphosphate, 
was allowed to interact with inositol hexaphosphate pretreated 
murine splenocytes. This interaction was performed in the presence 
and absence of 5 mM inositol hexaphosphate and resultant labelled 
material which bound to splenocytes was examined by SDS-PAGE. It 
was found that the 90 kDa protein reassociated with splenocytes (-PA 
track, Figure 5 .8) but, this reassociation would be inhibited by the 
presence of 5 mM inositol hexaphosphate ( +PA track, Figure 5 .8). 
Such a result is in agreement with the hypothesis that the 90 kDa 
molecule is bound to the lymphocyte surf ace by a specific PI receptor. 
Furthermore, it was demonstrated that reassociation of the 90 kDa 
protein to splenocytes was inhibited specifically by inositol 
hexaphosphate, but to a much lesser extent by other inositol 
derivatives (Figure 5 .9). Thus inositol hexaphosphate at all 
concentrations tested (0.63-10.0 mM) was found to inhibit 
reassociation by greater than 50%, with 10 mM inositol hexaphosphate 
inhibiting reassociation by 96%. In contrast, 5 mM inositol 
hexasulfate, inositol-1-monophosphate and inositol-2-monophosphate 
inhibited reassociation by only 42, 12 and 45% respectively, further 
demonstrating the specificity of interaction between the 90 kD a 
molecule and its receptor. The reason for the reversal of the effects 
seen with inositol-1-monophosphate and inositol-2-monophosphate 
between this experiment and earlier displacement experiments 
(Figure 5.7 and 5.9) is unknown. 
Figure 5.8 Reassociation of the 90 kDa GAG-
Binding Protein with Splenocytes 
Murine splenocytes were labelled with 125 I and the 90 kDa 
protein was released by treatment with 5 mM myo-inositol 
hexaphosphate (phytic acid) in PBS. The released proteins were 
then allowed to reassociate with unlabelled, phytic acid-depleted 
splenocytes in the absence (-PA) or presence ( +PA), of 5 mM phytic 
acid and the resultant splenocyte lysates analysed by SDS-P AGE. 
Exposure time was 16 days. Molecular weight markers are 
indicated in kDa. 
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Figure 5.9 Ability of Inositol Derivatives to 
Inhibit Reassociation of the 90 kDa GAG-Binding 
Protein with Splenocytes 
Radiolabelled 90 kDa protein was semi-purified from 125 I cell 
surface labelled splenocytes by inositol hexaphosphate treatment 
and heparin affinity chromatography of the supernatant. The 90 
kDa protein was then allowed to reassociate with splenocytes 
(inositol hexaphosphate pretreated) in the presence of 0.63-10 .0 
mM inositol hexaphosphate, 5 mM myo-inositol-hexasulfate (HS), 5 
mM DL-myo-inositol-1-monophosphate (1-MP) or 5 m1-'I myo-
inositol-2-monophosphate (2-MP) and the percent inhibition of 
reassociation calculated based on cpm bound, using cpm bound in 
the absence of inhibitor as the control. 
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5.3 DISCUSSION 
This chapter describes attempts to further characterise the mur1ne 
lymphocyte 90 kDa GAG-binding molecule and its mode of attachment 
to the splenocyte and thymocyte surface. 
Detection of the very prominent 90 kDa GAG-binding molecule on the 
lymphocyte surface (Chapter 4) was intriguing, for in similar studies 
performed by Parish et al. (1988), where GAG-binding molecules were 
isolated from the murine thymocyte surf ace, this molecule was not 
seen. The studies reported in this chapter indicate that the reason for 
this discrepancy is that Parish et al. (1988) examined GAG-binding 
molecules in isolated thymocyte membranes whereas the experiments 
described in Chapter 4 were performed on intact cells. It appears that 
the Tween 40 procedure used to permeabilise cells prior to 
homogenisation and release of membrane vesicles (Standring and 
Williams, 1978) solubilises many membrane molecules, particularly 
peripheral membrane proteins such as the 90 kDa GAG-binding 
molecule. This point is clearly evident in Figure 5.3 where Tween 40 
treatment of splenocytes was as effective as Triton X-100 at 
solubilising membrane proteins. The rationale behind the Tween 40 
membrane isolation procedure is that Tween 40 is a "weak" detergent 
which merely permeabilises plasma membranes so that they are more 
readily released from the cell by homogenisation. However, the 
experiments described in this chapter indicate that this assumption 
cannot be made, particularly when isolation and characterisation of 
peripheral membrane proteins is being considered. 
Since the 90 kDa GAG-binding protein appeared to be a peripheral 
membrane protein the mode of attachment of the molecule to the 
lymphocyte surf ace was investigated. It was found that the molecule 
was not FN-like (did not bind gelatin). Furthermore the protein was 
probably not related to any cell surface receptors of the integrin 
family, which interact with RGD sequences on cell adhesive proteins 
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(i.e., FB, VWF, VN, osteopontin, collagens and thrombospondin), as the 
peptide RGDS failed to release the 90 kDa molecule from the 
lymphocyte surface (Figure 5 .3 ). However, release of the molecule by 
2 M KCl suggested some form of ionic interaction between the 90 kDa 
molecule and the cell surf ace. 
Several lines of evidence suggest that the 90 kDa molecule is bound to 
the lymphocyte surface by a PI receptor. Firstly, the molecule is the 
predominant species displaced from the lymphocyte surface by 
inositol hexaphosphate treatment at concentrations as low as 0.31 mM 
(Figure 5.6) a treatment used by others to displace molecules from cell 
surface PI receptors (Ishihara et al., 1987). Secondly, displacement of 
the 90 kDa molecule from the lymphocyte surface by inositol 
hexaphosphate was highly specific as similar concentrations of other 
inositol derivatives such as inositol hexasulfate, inositol-1-
monophosphate and inositol-2-monophosphate were either much less 
effective or ineffective at displacing the molecule from the cell surface 
(Figure 5.7). Furthermore, this data suggests that the molecule was 
not displaced from the cell surf ace by ionic interactions alone, for 
inositol hexasulf ate has a similar charge density to inositol 
hexaphos·phate at pH 7. In fact, inositol hexaphosphate, which has a 
range of pKa values from 1.9 to 9.5 has at pH 7 and at a similar ionic 
strength to our experiments (0.2 M KCl) a net negative charge of 
approx. 7 .8 (Evans et al., 1982). Similarly, inositol hexasulfate, a 
derivative of the strong acid H2S O 4 would be totally ionised at pH 7 
' 
with a net negative charge of six. Therefore although both molecules 
have similar charge densities, their propensity to release the 90 kDa 
molecule is very different, a further indication that displacement 1s 
specific. It is therefore likely that steric factors may play an 
important role in this process. 
Other evidence also supports the view of a PI receptor for the 90 kDa 
GAG-binding protein. The 90 kDa GAG-binding protein released from 
lymphocytes by inositol hexaphosphate treatment could reassociate 
with splenocytes in vitro. This interaction could be virtually 
89 
completely inhibited by inositol hexaphosphate whereas, inositol 
hexasulfate, inositol-1-monophosphate and inositol-2-monophosphate 
were much less effective at inhibiting reassociation (Figure 5 .9), a 
finding which again indicates the specific nature of the association of 
the 90 kDa protein with the lymphocyte surf ace. 
Another interesting feature of anchorage of the 90 kDa protein to the 
lymphocyte surface is the observed "background" release of molecules 
into the cell supernatant under physiological conditions (Figure 5 .3, 
control tract), reinforcing the idea of a reversible interaction between 
the PI receptor and the 90 kDa molecule. 
To date only one other study has reported the association of molecules 
with the cell surface via a PI receptor (Ishihara et al., 1987). This 
study found that rat hepatocytes synthesise a heparan sulfate 
proteoglycan which appears to be bound to the plasma membrane via 
a PI receptor, an interaction which can be disrupted specifically by 
inositol hexaphosphate. There are however, many studies 
demonstrating that a wide range of cell surf ace molecules are directly 
anchored to the cell membrane via glycosyl-phosphatidylinositol (GPI) 
structures. Examples of lymphocyte cell surface antigens in this 
category are Thy-1, Qa, ThB, RT-6, Ly-6, T-cell activating protein and 
LFA-3 (reviewed by Ferguson and Williams, 1988; Low, 1989). GPI 
anchors on different proteins share a number of major structural 
features namely, the protein is linked to the GPI anchor through the 
C-terminal amino acid via a phosphoethanolamine moiety and a 
glycan ( containing mannose and glucosamine ). Variations in this 
general structure include additional sugar residues or 
phosphoethanolamines and changes in the linkage structure. 
Obviously the presence of phosphoethanolamine, ubiquitous to all GPI 
anchors, would provide an ideal method for further confirming the 
anchorage form of the 90 kDa protein to the lymphocyte surf ace. 
Experiments are planned where the incorporation of 3 H-ethanolamine 
into the 90 kDa protein will be assessed and the ability of this 
radiolabelled molecule to reassociate with splenocytes tested. 
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Additional evidence for the PI receptor could be obtained by 
attempting to displace and/or inhibit reassociation of the 90 kDa 
protein with PI-PLC (phosphatidylinositol-specific phospholipase C) 
released proteins from murine thymocytes. Such an experimental 
approach would also provide possibilities for characterising the 
endogenous GPI structure recognised by the PI receptor. 
The possible presence of a PI receptor on lymphocytes led to the 
development of a model for the attachment of the 90 kDa GAG-
binding molecule to the cell surface (Figure 5 .10), similar to that 
reported for the membrane anchoring of heparan sulfate 
proteoglycans (Ishihara et al., 1987). The 90 kDa GAG-binding protein 
is possibly linked to the cell surface initially via a GPI anchor, which is 
cleaved by endogenous phospholipase C resulting in release of the 90 
kDa protein and its subsequent reattachment to the cell surf ace via 
the PI receptor. The functional feasibility and significance of this 
process would need to be investigated further, although one possible 
explanation for this process is that it may function to internalise GPI 
linked cell surface molecules (Ishihara et al., 1987). 
5.4 SUMMARY 
Earlier studies (Chapter 4) demonstrated the presence of a prominent 
90 kDa GAG-binding protein on the surface of murine lymphocytes. 
Further characterisation of the 90 kDa GAG-binding molecule revealed 
that it is a glycoprotein with a slightly acidic pl (pl 6.16). The failure 
to detect this molecule in Tween 40 isolated membranes of murine 
thymocytes suggested that the 90 kDa molecule may be a peripheral 
rather than an integral membrane protein. Studies described in this 
chapter confirmed such a hypothesis as the 90 kDa protein was found 
to be spontaneously released from the lymphocyte surf ace at a 
significant rate and Tween 40 treatment released large quantities of 
Figure 5.10 Hypothetical Model for the Attachment 
of the 90 kDa GAG-Binding Protein to the 
Lymphocyte Surface 
The 90 kDa GAG-binding protein is anchored to the lymphocyte 
surface by means of a phosphatidylinositol anchor fatty acid chain 
which is embedded in the plasma membrane. This anchor when 
cleaved by endogenous phospholipase C releases the 90 kDa 
molecule which can then bind to the cell surf ace via a 
phosphatidylinositol receptor. Treatment of the cells with inositol 
hexaphosphate (phytic acid) selectively displaces this molecule 
from the cell surf ace. 
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the molecule from splenocytes. Furthermore, high ionic strength (2 M 
KCl) treatment released the molecule from cells although RGDS ( 1 
mg/mL) treatment did not, suggesting an integrin binding sequence 
was not involved. 
Subsequent studies suggested that the molecule is bound to the 
lymphocyte surf ace via a PI receptor. Initially, it was found that 
inositol hexaphosphate displaced the 90 kDa protein from the 
splenocyte surface with concentrations as low as 0.31 mM. 
Furthermore it was found that other inositol derivatives, namely 
inositol hexasulfate, inositol-1-monophosphate and inositol-2-
monophosphate were either ineffective or much less effective than 
inositol hexaphosphate at displacing the molecule from splenocytes. 
Further evidence for a PI specific binding of the 90 kDa protein to 
lymphocytes was obtained from reassociation experiments where the 
soluble 90 kDa protein was found to reassociate with the lymphocyte 
surf ace in a manner that could be inhibited by inositol hexaphosphate. 
Additional studies are required to demonstrate unequivocally a PI 
receptor for cell surface proteins. Such a receptor, if confirmed, has 
important implications for GPI-anchored cell surface molecules. 
CHAPTER 6 : ANALYSIS OF GAG RECEPTORS ON 
LYMPHOMA CELL LINES WITH DIFFERENT HOMING 
PROPERTIES 
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6.1 INTRODUCTION 
Previous studies have indicated that SPS recognition probably plays 
an important role in lymphocyte migration (Section 1.7). Direct 
evidence for in vivo involvement has included the finding that certain 
SPS such as dextran sulfate and heparin when injected into animals 
cause leucocytosis and inhibit lymphocyte recirculation (Bradfield and 
Born, 1974; Jansen et al., 1962; Sasaki and Suchi, 1967). Also HEY can 
rapidly incorporate radiolabelled sulfate into a glycolipid which is 
secreted and causes lymphocytes to localise at intradermal sites of 
injection (Andrews et al., 1982, 1983 ). Furthermore, fucoidan, a 
sulfated polymer of L-fucose, was found to be a potent inhibitor of 
lymphocyte adhesion to HEY in vitro (Stoolman et al., 1987; Stoolman 
and Rosen, 1983 ), being as effective as the phosphomannan polymer 
PPME. However, the most conclusive in vivo evidence for SPS 
involvement in lymphocyte recirculation comes from the work of 
Brenan and Parish (1986) which demonstrated the selective effects of 
SPS on entry, displacement and furthermore positioning of 
lymphocytes within lymphoid organs (Section 1.7 .3 ). 
Chapters 4 and 5 described detailed attempts to identify and 
characterise GAG-binding molecules on the surface of murine 
lymphocytes and in particular, describe some interesting molecular 
features of a prominent 90 kDa GAG-binding protein. In this final 
series of experiments attempts were made to determine the functional 
significance of GAG-binding molecules on lymphocytes in terms of 
lymphocyte splenic-homing in vivo. Lymphoma cell lines were chosen 
with specific migratory preference for the spleen in the hope of 
identifying ubiquitous GAG-binding molecules which may be involved 
in splenic entry and positioning. Of particular interest was the 
involvement of the 90 kDa GAG-binding protein, identified and 
partially characterised in Chapters 4 and 5, in lymphocyte migration 
to the spleen. 
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6.2 RESULTS 
6.2.1 MIGRATION BEHAVIOUR OF LYMPHOMA CELL LINES 
Initially, in order to determine possible candidate molecules which 
may be involved in splenic-homing a number of lymphomyeloid cell 
lines (Table 2.2; Section 2.4) were examined for their ability to enter 
murine spleen (Section 2.23). Eleven lymphoma cell lines and one 
mastocytoma line were labelled with the intracellular fluorescent dye 
H33342 (Section 2.23) and injected intravenously into recipient mice 
(Table 2.2). Spleens were removed 2 h post injection and cell line 
splenic entry determined by examining spleen cell suspensions and 
splenic sections for their content of fluorescent cells (Table 6.1 ). It 
was found that seven cell lines failed to enter the spleen (i.e., EL-4, 
BL/VL3, MBL-2, RK4.7, C6VL/1, P815 and LSTRA) whereas five lines 
gained access (i.e., BCL.1, RD10s, Rl +, RI- and CL2-FT2). Interestingly, 
the ability of the lines to enter the spleen was not related to either 
their cellular origin, as both T cell and B cell lines entered, or their 
mode of induction and propagation (i.e., in vivo or in vitro )(Table 2.2; 
Table 6.1). Furthermore, both Rl+ and Rl- cell lines entered the 
spleen, implying that class I MHC antigens are not involved in splenic 
entry as these two cell lines only differ in H-2 antigen expression, i.e., 
R 1 - is a variant of RI+ which has been selected for lack of cell surface 
H-2 antigens (Hyman and Stallings, 1976). 
Of the five cell lines which exhibited splenic entry, three were chosen 
for further study. These were BCL.1 and RD 1 Os, both B cell 
lymphomas maintained in vivo and Rl + a thymoma propagated in 
vitro. Both BCL.1 and RD10s grow as splenic tumours in recipient 
mice, large tumours appearing in the spleen 14-16 days after the 
injection of 2 x 106 and 106 cells respectively (Figure 6.1). EL-4, a 
thymoma maintained by in vitro culture, was used as a control cell 
line which failed to enter the spleen. 
Figure 6.1 Splenic Tumours 
Splenic tumours resulting from the injection of either (a) 2 x 106 
BCL.1 cells intraperitoneally or (b) 106 RD 1 Os cells intravenously 
14 and 16 days earlier, respectively. A normal murine spleen is 
included in each figure for comparison. 
(a) 
(b) 
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Table 6.1 Ability of Different Cell Lines to Enter 
Spleen 
Cell lines failing to enter spleen 
EL-4 (thymoma) 
8UVL3 (thymoma) 
M8L-2 (thymoma) 
RK4. 7 (pre T cell) 
C6VU1 (thymoma) 
P815 (mastocytoma) 
LSTRA (thymoma) 
Cell lines entering spleen 
8CL.1 (8 cell lymphoma) 
RD1 Os (8 cell lymphoma/hybridoma) 
RI+ (thymoma) 
RI- (thymoma) 
CL2-FT2 (thymoma) 
H33342-labelled cells (2 x 107) were injected intravenously into rec1p1ent mice 
and spleens removed 2 h post injection. Splenic entry of fluorescent cells was 
determined by fluorescence microscopy. 
As well as quantifying the entry of the four cell lines into the spleen, 
the migration of these cell lines to other organs, particularly lymphoid 
organs such as PLN, PP and MLN, was examined. Table 6.2 presents 
the results of such an analysis, each cell line being labelled with the 
fluorescent dye H33342 and 2 h following intravenous injection, the 
entry of fluorescent cells into each organ determined. In order to gain 
some measure of the efficiency of organ entry the data is presented as 
percentage of entry relative to H33342 labelled splenocytes. Results 
depicted in Table 6.2 show that the entry of RI+, BCL.1 and RDlOs into 
spleen relative to splenocytes was 9.3, 33.6 and 62.8% respectively, 
compared to negligible entry by EL-4. Entry of the cell lines into 
other lymphoid organs, namely PLN, PP and :MLN, was found to be 
unrelated to splenic entry. For example, R 1 + and RD 1 Os did not 
appreciably enter PLN but both entered spleen. Furthermore, PLN 
and PP entry did not appear to be related, as shown by the migration 
of RDlOs to PP but not to PLN. In contrast, MLN entry appeared to 
occur as a combination of both PLN and PP entry as would be 
expected from earlier specificity of migration studies (Section 1.5). 
Table 6.2 Entry of H33342 Labelled Lymphoma Cell Lines into Different Organs 
o/o Entry relative to splenocytes 
Cell line Spleen Peripheral Peyers patch Mesenteric Liver Lungs 
lymph node lymph node 
EL-4 0.5± 0.3 0 0 0 157.9 ± 22.1 66.7 ± 20.9 \D U\ 
R1+ 9.3±2.0 0 7.9±3.5 1.2 ± 1.2 321.1 ± 34.7 266.7 ± 53.3 
BCL.1 33.6 ± 5.8 6.9 ± 0.5 25.6 + 6.7 54.2 ± 6.2 215.8 ± 30.5 377.8 ± 33.3 
RD105 62.8 ±10.9 1.2 ± 0.5 174.4±11.8 45.3 ± 3.6 73.7 ± 23.2 55.6 ± 17.6 
H33342-labelled cells (2 x 10 7) were injected into recipient mice and organs removed 2 h post injection. 
Mean and standard errors were calculated from five counts taken from each of three mice (spleen) or one mouse (all other organs). 
I. 
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Entry of the lymphoma cell lines into the liver and lungs was also 
quantified to determine if trapping of cells in these organs indirectly 
affected splenic entry. Although, some lines were trapped in the liver 
and lungs more effectively than normal splenocytes this did not 
correlate with lack of splenic entry. For example, there was less 
trapping of the non-splenic homing cell line EL-4 in the liver and 
lungs than the lines R 1 + and BCL.1 which entered the spleen. 
To analyse further splenic migration in vivo, the positioning of 
fluorescently labelled cells was visualised by fluorescence microscopy 
of whole spleen sections. Figure 6.2 depicts a typical example of this 
where localisation of H33342-labelled cells in splenic sections was 
examined. It can be seen that the lymphoma cell lines R 1 +, B CL. I and 
RD 10 s and normal splenocytes entered the spleen. Also it appears 
from these photos and many others not shown, that each of these cell 
lines (Rl +, BCL.1 and RDlOs) migrates into the red pulp and marginal 
zones of the spleen and probably few cells enter the white pulp.. This 
localisation pattern contrasts with that of · normal splenocytes where 
migration of fluorescent cells into the white pulp is clearly evident 2 h 
post injection (Figure 6.2). The white pulp is easily identifiable in 
splenic sections as it autofluoresces to a greater extent than other 
splenic tissue (Figure 6.2, control). Other studies where sections were 
taken at 8 and 24 h post injection ( data not shown) indicate similar 
patterns of splenic localisation of the lymphoma cell lines, although 
the numbers of cells had decreased 24 h post injection. Finally, EL-4 
acted as a control in these experiments, this cell line failing to enter 
the spleen (Figure 6.2) as expected from earlier studies (Table 6.2). 
6.2.2 IDENTIFICATION OF GAG-BINDING MOLECULES ON 
LYMPHOMA CELL LINES 
Following the identification of lymphoma cell lines that migrated to 
the spleen, attempts were made to identify GAG-binding molecules on 
these cells which may be involved in splenic entry. 125 I-labelled cell 
Figure 6.2 Positioning of Lymphoma Cell Lines in 
Spleen 
Positioning of H33342-labelled lymphoma cell lines EL-4, Rl +, 
BCL.1 and RDlOs compared with H33342-labelled splenocytes in 
spleen at 2h after intravenous injection of 2 x 107 fluorescently 
labelled cells into syngeneic recipient mice. Control represents 
splenic section from an uninfected animal and depicts the 
autofluorescence of the white pulp of the spleen. 
Control Splenocyte 
EL-4 R1+ 
BCL.1 RD10s 
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surface molecules (Section 2.8) from different cell lines were bound to 
a variety of GA Gs ( chondroitin-4-sulfate, chondroitin-6-sulf ate, 
dermatan sulfate, heparan sulfate, endogenous splenic-GAGs and 
heparin) immobilised on CMC fibres (Section 2.10) and the bound 
molecules characterised by SDS-PAGE. The results of such an analysis 
are shown in Figure 6.3 (for all GAGs except heparin) and Figure 6.4 
(specifically for heparin-binding molecules) and indicate that a 
number of molecules on the surface of EL-4, Rl +, BCL.1 and RD10s 
bind to GAGs. 
Each cell line was seen to express distinct GAG-binding molecules with 
a wide range of molecular masses (Figure 6.3 and 6.4 ). Heparin-
binding molecules (Figure 6.4) were expressed strongly on the cell 
surface and constitute the entire range of GAG-binding molecules. 
BCL.1 expressed molecules of approx. 10-22, 35, 47, 53, 120, 172 and 
206 kDa with a very prominent GAG-binding molecule at 70-102 kDa 
which appears to be the equivalent of the 90 kDa GAG-binding protein 
previously described (Chapter 4). Rl +, on the other hand expressed a 
large range of GAG-binding molecules with molecular masses of 14-
22, 27, 30, 35, 38, 45, 53-63, 66 and 90 kDa, and higher molecular 
mass proteins of approx. 168 and 200 kDa. RD 1 Os expressed 
molecules predominantly of intermediate and high molecular masses , 
namely 58, 65, 102-124 and 150 kDa with a prominent heparin-
binding molecule of 35 kDa (Figure 6.4 ). EL-4 expressed a smaller 
number of GAG-binding molecules than seen with other cell lines, 
namely some low molecular mass proteins of 13-22 kDa. However 1n 
the heparin-binding profile additional molecules such as the 
prominent 43-52 kDa band and two bands of 77 kDa and 103 kDa 
were seen (Figure 6.4). Interestingly, the 90 kDa GAG-binding 
molecule which was seen so prominently on the surface of splenocytes 
and thymocytes (Chapter 4 and 5) was only expressed on the surface 
of the lymphoid cell lines Rl + and BCL.1. 
As an interesting side issue, attempts were made to characterise the 
prominent 43-52 kDa heparin-binding protein on EL-4. Studies have 
Figure 6.3 Analysis of 1251-Labelled 
Cell Surf ace Molecules Which Bind to 
GAGs 
Lymphoma 
Immobilised 
Bound molecules were run on a 8-18% gradient SDS-PAGE gel and 
gels were autoradiographed for 5 days. Molecular weight markers 
are indicated in kDa. Ch4S=chondroitin-4-sulfate, 
Ch6S=chondroitin-6-sulfate, DermS=dermatan sulfate, 
HepS=heparan sulfate, GAG=endogenous splenic-GAGs. 
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Figure 6.4 Analysis of 125I-Labelled Lymphoma 
Cell Surface Molecules Which Bind to Immobilised 
Heparin 
Bound molecules were run on a 8-18% gradient SDS-PAGE gel and 
gels were autoradiographed for 2 days. Molecular weight markers 
are indicated in kDa. 
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shown that a 43 kDa molecule identified by mAb A 1 is expressed on 
the surface of EL-4 and may be involved in binding to carbohydrates 
(Nagasawa et al., 1987; Yokoyama et al., 1989). This molecule was 
successfully immunoprecipitated from 125 I-labelled EL-4 lysates 
(Section 2.8, 2.20). However it was not found to bind heparin (Figure 
6.5). 
6.3 DISCUSSION 
This chapter describes attempts to determine if GAG-binding 
molecules on the surface of lymphocytes and, in particular, a 90 kDa 
GAG-binding protein are involved in lymphocyte migration to the 
spleen and other lymphoid organs. In order to do this lymphoma cell 
lines were identified which differed in their ability to enter different 
lymphoid organs and their GAG-binding molecules characterised. It 
was found that lymphoma cell lines differed markedly in their 
expression of GAG-binding molecules on their cell surfaces, an 
observation which confirms earlier receptor studies (Chapter 4) where 
differences were seen in GAG-binding molecules between splenocytes 
and thymocytes. It seems likely, therefore, that these molecules may 
be functionally significant. 
Out of 12 cell lines tested for splenic entry, only five were seen to 
enter the spleen. This may be due to a lack of correct receptors on the 
cell surface for splenic entry. Alternatively, cell lines may fail to 
enter the spleen due to physical hindrances such as becoming trapped 
in other organs including the lungs and liver. This in fact may be the 
case for some of the cell lines tested, particularly larger cells such as 
the mastocytoma P815. With this fact in mind, liver and lung entry 
was determined for each of the four lymphoid cell lines which were 
studied in detail. It was found that although some cell lines were 
Figure 6.5 Ability of the EL-4 Cell Surface Antigen 
Identified by mAb Al to Bind to Immobilised 
Heparin 
Anti-EL-4 mAb Al was used to monitor the presence of 
radiolabelled antigen in either an unfractionated EL-4 lysate (Lys) 
or for immunoprecipitation of antigen, 125 I-labelled EL-4 
molecules eluted from heparin-CMC fibres (Hep). Al mAb was 
bound to protein G coupled agarose. Molecular weight markers are 
indicated in kDa. 
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trapped in the liver and lungs this did not correlate with splenic-
homing ability. 
Based on a comparison of the GAG-binding molecules expressed by the 
different splenic-homing cell lines, the majority of these molecules can 
be eliminated as being involved in splenic entry. Interestingly, the 
very prominent 90 kDa GAG-binding protein which was discussed in 
detail in Chapters 4 and 5 was expressed by two out of four of the 
splenic-homing cell lines tested. Both BCL.1, a B cell lymphoma 
maintained in vivo, and RI+, a T cell lymphoma propagated in vitro, 
expressed the 90 kDa GAG-binding protein on the cell surface. This 
indicated that this protein is expressed on a variety of lymphoid cells 
regardless of culturing methods, an important point considering the 
molecule is not an integral membrane protein and therefore could be 
transferred between cells. However, due to the lack of expression of 
this protein on the splenic-homing cell line RD 1 Os, it is apparent that 
the 90 kDa GAG-binding protein is not required for splenic entry. 
Furthermore, homing data presented in Table 6.2 indicates that this 
protein is probably not required for PLN, PP or MLN entry. Therefore, 
although the function of this very prominent GAG-binding protein is 
unknown, an attractive hypothesis is that this molecule is involved in 
lymphocyte migration events at another level, possibly the positioning 
of lymphocytes within lymphoid organs. This point will be elaborated 
upon in Chapter 7. 
Although the 90 kDa GAG-binding molecule is not involved in splenic 
entry, an approx. 35 kDa GAG-binding protein is present on each of 
the splenic-homing cell lines tested namely, RI+, BCL.1 and RDIOs, but 
is not present on the control cell line EL-4 (Figure 6.3 and 6.4 ). 
Furthermore, it appears to be expressed by thymocytes and 
splenocytes as the approx. 33 kDa GAG-binding protein described 1n 
Chapter 4. It remains to be determined whether this protein is 
directly involved in lymphocyte migration to the spleen or other 
lymphoid organs such as PP. On the other hand, it does not appear to 
be related to PLN entry, for R 1 + expressed this protein but failed to 
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migrate to PLN. Further experimentation would be necessary to 
determine if this protein is present on other lymphoid cell lines that 
have lymphoid homing potential. 
Localisation studies of fluorescently-labelled cells in spleen were 
employed in an attempt to visualise splenic entry and positioning of 
lymphoma cell lines. Unfortunately, all three splenic-homing cell lines 
examined gave a similar localisation pattern, localising in the marginal 
zones and red pulp and failing to enter the white pulp of the spleen. 
Previous studies (Brenan and Parish, 1986) suggest that SPS 
recognition plays a particularly important role in lymphocyte 
positioning in the white pulp. Nevertheless, there may have been 
subtle differences in splenic positioning of the lymphoma cell lines 
which were not detected by the relatively. inaccurate fluorescence 
procedure used. Therefore other methods would need to be used to 
determine more accurately positioning of cells within lymphoid 
organs, in order to assess if GAG-binding molecules control positioning 
of cells within the spleen. 
6.4 SUMMARY 
This chapter describes attempts to relate the expression of GAG-
binding molecules on the surface of lymphoma cell lines to the splenic 
and lymph node homing capacity of the cell lines. 
It was found that certain cell lines failed to enter the spleen (EL-4, 
BL/VL3, MBL-2, RK4.7, C6\tL/1, P815 and LSTRA) while others gained 
access (BCL.1, RD10s , RI+, RI- and CL2-FT2). The ability to enter the 
spleen was not dependent on the cellular origin (T or B cell) or the 
mode of induction and propagation (in vivo or in vitro ) of the tumour 
cell lines. Entry of the cell lines into other lymphoid organs, namely 
PLN, PP and MLN, was found to be unrelated to splenic entry. 
'I 
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Furthermore, PLN and PP entry were not related, although MLN entry 
appeared to occur as a combination of both PLN and PP entry. Also 
entry of cells into the liver and lungs did not correlate with splenic 
entry. Positioning of fluorescently-labelled cell lines in the spleen was 
visualised by fluorescence microscopy and revealed that certain cell 
lines (RI+, BCL.1 and RDlOs) migrated into the red pulp and marginal 
zones of the spleen. 
SDS-PAGE analysis of 1251-labelled cell surface molecules indicates 
that each cell line examined (EL-4, R 1 +, BCL.1 and RD 1 Os) expressed 
distinct GAG-binding molecules with a wide range of molecular 
masses. Interestingly the 90 kDa GAG-binding molecule which was 
seen so prominently on the surf ace of splenocytes and thymocytes 
(Chapter 4 and 5) was expressed strongly by both Rl + and BCL.1 , but 
not by RD 1 Os indicating that this protein is not necessary for splenic 
entry. However, an approx. 35 kDa GAG-binding protein is present on 
all three cell lines which migrated to the spleen (R 1 +, BCL.1 and 
RD 1 Os) but is absent from EL-4, a cell line which did not enter spleen. 
Further experiments are required to prove that this molecule is 
involved in splenic-homing. 
CHAPTER 7 : DISCUSSION 
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One of the major aims of this thesis was to test the hypothesis that 
recognition of sulfated GAGs plays an important role in the migration 
and positioning of lymphocytes within the immune system. In the 
past it has been assumed that the major functional role of SPS and 
GAGs is to act as a structural component in tissues. For example, 
hyaluronic acid, the chondroitin sulfates and keratan sulfate are 
present in large quantities in connective tissues, being essential for 
their physical properties such as elasticity and compressibility 
(Obrink, 1975). Also proteoglycans and in particular heparan sulfate 
proteoglycans can bind together ECM components and mediate the 
binding of cells to the ECM (Ruoslahti, 1989; Wood et al., 1984, 1985). 
However, a vast body of data now suggests a more diverse functional 
role for GAGs which extends beyond them being purely structural 
elements. This evidence includes the observed structural diversity 
of GAGs and the ubiquitous presence of SPS recognition systems in 
many organisms. 
Structurally, GAGs are characterised by repeating disaccharide units 
consisting of alternating uronic acid (glucuronic or iduronic acid) or 
galactose and hexosamine residues (glucosamine or galactosamine) 
which in most cases are substituted with sulfate groups. The great 
variability in GAG structure is the result of variations in 
monosaccharide constituents, monosaccharide linkages, the degree 
and position of sulf ation, the sequence of disaccharide units and their 
MW. On this basis alone, heparan sulfate exhibits great structural 
diversity with an estimated 1o36 types · of heparan sulfate occurring 
in animal tissues (Dietrich et al., 1983 ), where heparan sulfate 
contains a combination of iduronic and glucuronic acid and N-acetyl 
glucosamine substituted with sulfate groups. Furthermore, not only 
are GAGs structurally diverse but a wide variety of organ and species 
specific GAGs also exist (Dietrich et al., 1977; Keller et al., 1978; 
Toledo . and Dietrich, 1977) which suggests that these molecules play 
more than a purely structural role. 
I 
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In addition to their structural diversity another important feature of 
GAGs which may indicate a functional role, is their occurrence in many 
cell-cell recognition systems (reviewed in Section 1.7). Thus, SPS and 
GAGs and their complementary lectins have been identified in several 
cell adhesion systems, such as the reaggregation of marine sponges 
(Coombe et al., 1987 a; Coombe and Parish, 1988), sperm-egg adhesion 
(Ahuja, 1982; Glabe et al., 1982), neural cell adhesion (Cole et al., 
1986; Cole and Glaser, 1986), embryogenesis (Tucker, 1986) and 
various cell-cell interactions in the immune system (see below). 
7.1 GAG RECOGNITION AND LYMPHOCYTE 
' 
RECIRCULATION 
Several lines of evidence suggest that recognition of carbohydrate 
structures particularly GAGs, is involved in lymphocyte recirculation 
(reviewed in Section 1.7). For example, the involvement of 
carbohydrates in lymphocyte homing was demonstrated by the 
effects of modifiers of carbohydrate structure (Section 1. 7 .1) and 
lectins (Section 1.7 .2) on lymphocyte migration. Also, 
lymphocyte/HEY interactions can be inhibited by a range of 
carbohydrates, including phosphosugars (M6P and PPME) and the 
SPS fucoidan (Section 1.7.3). Furthermore, SPS receptors have been 
detected on the surface of lymphocytes (Bradbury and Parish, 1989; 
Parish et al., 1984, 1988; Parish and Snowden, 1985; Thurn and 
Underhill, 1986) and certain lymphocyte cell surface antigens, 
namely Thy-1, CD2, CD4 and CD45 (Ly-5, T200) have been shown to 
interact with sulfated carbohydrates (Lederman et al., 1989; Parish 
et al., 1988a, b ). In addition, the lymphocyte homing receptors MEL-
14 and CD44 may participate in carbohydrate-protein interactions 
(Coombe and Rider, 1989; Section 1.6.1, 1.7.3). 
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Direct evidence for the involvement of GAGs in lymphocyte 
recirculation comes from the finding that certain GAGs cause 
leucocytosis and inhibit lymphocyte recirculation when injected into 
animals (Section 1. 7.3 ). However, the most conclusive in vivo 
evidence for GAG involvement in lymphocyte recirculation was the 
demonstration that GAGs and other SPS selectively effected entry, 
displacement and positioning of lymphocytes within lymphoid organs 
(Section 1.7.3; Brenan and Parish, 1986). 
In the light of these studies on the involvement of GAGs in the 
immune system, experiments were undertaken to isolate and 
characterise endogenous GAGs and lymphocyte receptors for these 
and other GAGs and determine in part, their role in lymphocyte 
recirculation in vivo. 
Several lines of experimental evidence were obtained which 
suggested that the GAGs present in murine spleen may play a role in 
lymphocyte migration and positioning. First it was found that 
endogenous splenic-GAGs isolated from murine spleen bound to 
murine splenocytes in a saturable, rapid and reversible manner 
implying the presence of specific receptors on lymphocytes for the 
endogenous GAGs in spleen (Section 3.2). Furthermore, the 
predominant endogenous GAG recognised by murine splenocytes was 
of the heparin/heparan sulfate-like class, the binding affinity for 
these molecules being very high (Km of approx. 5 x 10-8 M). 
Second, of particular interest was the observation that endogenous 
splenic heparin/heparan sulfate molecules bound to murine 
splenocytes at a much higher affinity (approx. 20 fold) than bovine 
lung heparin, suggesting substantial structural specificity in the 
recognition of this class of GA Gs by lymphocytes (Section 3 .2; 4.2). 
Third, more sensitive detection systems such as rosetting and 
binding of radiolabelled cell surface molecules to immobilised GAGs 
demonstrated the presence of cell surface receptors for most classes 
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of GAGs on at least a subpopulation of lymphocytes (Section 4.2). 
Furthermore, a great diversity of GAG-binding molecules was 
detected on the surface of lymphocytes. This diversity was evident 
from the differences between cell populations ( e.g. splenocytes and 
thymocytes) and lymphoma cell lines (e.g., EL-4, RI+, BCL.1 and 
RD 1 Os) in the profile of GAG-binding molecules they expressed 
(Section 4.2; 6.2) and, differences between GAG classes in the 
molecules they bound (particularly evident with splenocytes). 
Fourth, preliminary evidence showing the expression of a 35 kDa 
GAG-binding protein exclusively on splenic homing cell lines (Rl +, 
BCL.1 and RD 1 Os) suggested that this molecule may be involved in 
the entry of lymphocytes into the spleen (Section 6.2). However, 
' further work is required to substantiate this observation. 
Following the identification of a diverse array of GAG-binding 
molecules on the surf ace of lymphocytes, attempts were made to 
relate these molecules to known cell surface antigens. Unfortunately, 
immunoprecipitation studies demonstrated that the splenocyte GAG-
binding molecules did not correspond to any of the cell surf ace 
antigens tested, namely MEL-14, FcR, CD3, ThB, Ly-5, Ly-15, Pgp-1 
and Thy-1, although Ly-2 may bind weakly to heparin (Section 
4.2.2). The failure of MEL-14 to bind to immobilised GAGs was 
somewhat surprising as previous studies have shown that this 
molecule probably interacts with negatively charged sugars such as 
phosphosugars (M6P, PPME) and SPS (e.g. fucoidan). It could be 
argued that the incorrect SPS ligands were tested because soluble 
MEL-14 does not appear to bind to fucoidan and dextran sulfate 
(Parish, unpublished). Furthermore, evidence suggests that MEL-14 
is a calcium-dependent cell adhesion molecule (reviewed by Yednock 
and Rosen, 1989) and therefore the lack of calcium in these binding 
studies may have affected the GAG-binding ability of MEL-14. 
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7.2 IDENTIFICATION OF A NOVEL 90 KDA GAG-
BINDING MOLECULE ON LYMPHOCYTES 
In the course of these studies a particularly prominent 90 kDa GAG-
binding protein was detected on the surf ace of splenocytes and 
thymocytes (Chapter 4 and 5). Analysis of lymphoma cell lines 
which differed in their capacity to enter spleen and lymph nodes 
demonstrated that cell surf ace expression of the 90 kDa molecule did 
not correlate with entry behaviour. Thus, this molecule appears not 
to control entry of lymphocytes into lymphoid organs. 
Although immunoprecipitation studies failed to identify this 
molecule, experiments were performed to further characterise it for 
evidence suggested that it was a peripheral rather than an integral 
membrane protein. Characterisation of this molecule revealed that it 
is an acidic glycoprotein which is ionically bound to the cell surface. 
Furthermore, treatment of cells with the integrin-binding peptide, 
RGDS, failed to release this molecule from the cell surface. 
Further characterisation of the 90 kDa GAG-binding molecule 
suggested that the molecule was bound to the lymphocyte surf ace 
via a PI receptor (Section 5.2.2). This was demonstrated by 
displacement of the 90 kDa protein from the splenocyte surf ace with 
inositol hexaphosphate. Furthermore, it was found that other inositol 
derivatives (inositol hexasulf ate, inositol-1-monophosphate and 
inositol-2-monophosphate) were either ineffective or much less 
effective than inositol hexaphosphate at displacing the molecule, 
indicating that inositol hexaphosphate was specifically releasing this 
protein. The presence of a PI receptor was further confirmed in 
reassociation studies where the soluble 90 kDa protein was found to 
reassociate with splenocytes, an interaction which again could be 
selectively inhibited by inositol hexaphosphate (Section 5 .2.3 ). 
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An intriguing question 1s what is the functional significance of the 
proposed PI receptor on cells? One possibility is that it may allow 
GPI anchored cell surface proteins to deliver transmembrane signals. 
In this sense, the PI receptor may explain the ability of certain GPI-
anchored proteins (e.g., Qa-2) to deliver transmembrane signals more 
efficiently than counterparts with membrane spanning polypeptide 
components (Robinson, 1989). Another possibility is that the PI 
receptor may aid the internalisation of proteoglycans, the 
internalised GAG sidechains subsequently regulating cell growth. 
This appears to be the case with heparan sulfate proteoglycans on 
hepatocytes where a proportion of the proteoglycans are GPI-
anchored to the cell surface and can be internalised via a PI receptor 
(Ishihara et al., 1987; Ishihara and Conrad, 1989). 
Similarly, binding of soluble GAGs to the cell surface via PI-bound 
receptors (e.g., the 90 kDa protein on lymphocytes) may result in 
rapid internalisation of the GAGs and modification of cell 
proliferation. Such a process may be involved in the inhibition of 
smooth muscle cell growth and cell migration by heparin and 
heparin-like molecules (Castellot et al., 1981; Majack and Clowes, 
1984). 
7.3 FUNCTIONAL SIGNIFICANCE OF GAG-BINDING 
MOLECULES ON LYMPHOCYTES 
The question then arises, if most of the GAG-binding molecules on 
lymphocytes are not intrinsic for splenic entry, what is their 
functional role in the spleen? One line of evidence suggests that 
these molecules may be vital for cellular positioning in lymphoid 
organs. It has been found that injection of certain GAGs such as 
dextran sulfate into mice radically alters lymphocyte positioning in 
the spleen (Brenan and Parish, 1986). In fact, lymphocytes were 
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displaced from the red and white pulp. It seems possible therefore 
that GAGs may be involved in lymphocyte positioning, while other 
carbohydrates such as phosphosugars, which are involved in 
lymphocyte/HEY interactions, may be more directly involved in 
splenic entry. 
Another possible function of GAGs is that they may act in the 
regulation of cell growth. This may be achieved either directly via 
GAGs, or indirectly through aiding the action of growth factors. 
Firstly, as previously mentioned, GA Gs have been shown to directly 
regulate cell growth (reviewed by Ruoslahti, 1989) and may act, in 
the case of heparan sulfate proteoglycans, fallowing internalisation 
through a probable PI receptor (Ishihara et al., 1987; Ishihara and 
Conrad, 1989). Secondly, many growth factors have a high affinity 
for heparin (Lobb et al., 1986), an interaction which in certain cases 
can modulate growth factor activity (Imamura and Mitsui, 1987; 
Neufeld et al., 1987). It is conceivable that heparin-growth factor 
complexes can bind to GAG receptors on cells, an interaction which 
may modulate growth factor action. Furthermore, it has even been 
suggested that heparan sulfate proteoglycan may bind an autocrine 
growth· factor in the ECM and transport it via a PI receptor to the 
nucleus (Ishihara and Conrad, 1989). 
GAG-binding molecules on lymphocytes also could play a role in the 
process of chemotaxis, lymphocytes being attracted by GAGs released 
from other cells. Such a process would be important in inflammatory 
sites, e.g. the release of heparin from degranulating mast cells. 
Furthermore, GAG recognition could play a role in the entry of 
lymphocytes into sites of inflammation where GAG receptors could 
interact with heparan sulfate and chondroitin sulfate proteoglycans 
exposed on basement membranes (Hassell et al., 1986; McCarthy et 
al., 1989). 
In a more general sense GAG-binding molecules on the cell surface 
may act as "scavenger" receptors for extracellular GAGs. A possible 
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example of this is the internalisation and degradation in vitro of 
hyaluronic acid isolated from rat liver endothelial cells (Eriksson et 
al., 1983). Furthermore, radioactive hyaluronic acid injected into 
rabbits is taken up to a large extent by the non-hepatocyte cell 
fraction of liver (Fraser et al., 1981). These findings suggest that 
hyaluronic acid receptors can mediate endocytosis and subsequent 
degradation of exogenous hyaluronic acid (Orkin et al., 1982). In this 
regard, GAG-binding molecules would function in a fairly nonspecific 
manner, which may not be applicable to the highly specific 
interactions demonstrated in this study between GAGs and GAG-
binding molecules on lymphocytes. 
Furthermore, it should be emphasised that it seems unlikely that the 
GAG-binding molecules detected in this study are interacting with 
the GAGs in a purely non-specific, ionic fashion. Evidence for 
specificity includes the finding that charge density alone was not 
responsible for the inhibition of binding of GAGs to GAG-binding 
molecules, and minor changes in the sulfation pattern of the 
polysaccharides had substantial effects on their inhibitory activity· 
(Section 3 .2.3 ). 
7.4 FUTURE \tVORK 
This study is seen as the basis for future analyses of the importance 
of GAGs and GAG-binding molecules in the functioning of the immune 
system. Obviously there is scope for future research work in this 
area, as this study has only focused on a small section of the overall 
system. 
The results have indicated that, with the possible exception of a 33-
35 kDa GAG-binding protein, no correlation exists between GAG-
binding molecules expressed on the surf ace of lymphocytes and 
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splenic and lymph node entry. It remains to be determined whether 
the 33-35 kDa protein is directly involved in lymphocyte migration 
to the spleen or other lymphoid organs. Investigation of other 
lymphoma cell lines with splenic-homing ability and ultimately 
production of mAbs against this molecule may resolve this question. 
One possible function of GAG-binding molecules is that they may be 
involved in lymphocyte positioning. The area of splenocyte 
positioning in vivo and migration of lymphocytes through the spleen 
is poorly understood. Development of an in vitro assay for 
determining lymphocyte positioning in lymphoid organs, analogous 
to that developed by Stamper and Woodruff for lymphocyte/HEY 
binding ( 1976), would greatly aid experiments in this area. 
Obviously in vivo experiments showing lymphocyte positioning in 
the spleen following injection of endogenous splenic GAGs would 
provide one means of determining the role of GAGs in positioning. 
Furthermore, lymphoma cell lines with unique homing properties for 
different organs or positions within an individual organ could be 
used to identify GAG-binding molecules involved in positioning in 
v l vo. This approach has only been used in a preliminary sense in 
this thesis, lymphoma lines with different positioning behaviour in 
the spleen not being identified. Obviously the isolation of 
lymphomas from the same progenitor cell line with only minor 
differences in expression of GAG-binding molecules would be 
invaluable in determining the effect these molecules have on 
lymphocyte migration. 
Finally, there is great potential for further research into the 
intriguing anchorage via a possible PI receptor, of the 90 kDa GAG-
binding protein to the plasma membrane. The existence of the PI 
receptor needs to be demonstrated unequivocally. For example, 
confirmation could be obtained by radiolabelling the PI structure on 
the 90 kDa protein with 3 H-ethanolamine, uptake of labelled 
ethanolamine by proteins being indicative of a GPI anchor (Low 
1989). Furthermore, attempts could be made to displace the 90 kDa 
I 
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protein from cells with the purified GPI anchor of Trypanosoma 
species (Low, 1989) or by GPI-anchored proteins released from 
thymocytes by PI-PLC treatment. Also it remains to be determined 
what other molecules may be attached to the plasma membrane via 
PI receptors, and are these molecules internalised as proposed 
herein? Such studies would not only have relevance for lymphoid 
cells but would have implications for the behaviour of GPI-anchored 
proteins on all cell types. 
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